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An investigation of the mechanisms of piperaquine resistance in 
Plasmodium falciparum malaria 
 
Megan Rose Ansbro 
 
Antimalarial drug resistance is an unrelenting obstacle to malaria control programs. In Southeast 
Asia (SEA), parasites have developed some degree of resistance to nearly every malaria drug 
currently available, with the most recent emergence to artemisinin combination therapies (ACTs). 
ACTs are the recommended front-line treatments for Plasmodium falciparum malaria worldwide 
and decreased susceptibility of parasites to both artemisinin and one of the widely used partner 
drugs, piperaquine, have been reported in multiple locations in SEA. It is therefore necessary to 
have reliable methods for detecting and evaluating resistant phenotypes. The purpose of this 
study was to combine clinical data from Cambodia with findings from genomic studies to 
evaluate putative markers of piperaquine resistance. The study first developed high-throughput 
assays to reliably detect one of these markers, a copy number variation (CNV) in the plasmepsin 
2 and plasmepsin 3 (PM2-PM3) genes, in parasites likely to be PPQ-resistant. In addition to 
assay development, this study used gene overexpression techniques and CRISPR-Cas9 gene 
editing to examine the functional role of molecular markers of piperaquine resistance, including 
the PM2-3 CNV, and two gene candidates with nonsynonymous single nucleotide 
polymorphisms (SNPs): a putative exonuclease protein (exo-E415G) and a putative 
mitochondrial carrier protein (mcp-N252D). This research fills a knowledge gap in the lack of 
functional data for molecular markers of piperaquine resistance by examining the phenotypic 
relevance of the genotypes observed in contemporary isolates. To complement these functional 
studies, this doctoral work has also used a P. falciparum hypermutator parasite line to select for a 
piperaquine-resistant phenotype in vitro. Whole genome sequencing analysis (WGS) of the 
piperaquine-resistant lines obtained through these experiments has identified nonsynonymous 
SNPs in gene candidates that have been reported to play a role in antimalarial drug resistance, 
including SNPs in the chloroquine resistance transporter gene (pfcrt) and the multidrug resistant 
protein 1 (pfmdr1) transporter. SNPs in pfcrt have been reported to confer piperaquine resistance 
in the field and in vitro and our recent drug-pressure experiments provide additional evidence to 
support these findings. The WGS analysis also discovered novel SNPs in gene candidates not 
previously reported to modulate the piperaquine-resistant phenotype that will require further 
evaluation. Such work has enabled the possibility of examining whether genetic changes 
observed in patient isolates can also be investigated and observed in vitro. By combining 
functional molecular approaches with genomic analyses, this study provides new insights into the 
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How does a disease that we have known about for thousands of years–for which we have 
cures—still cause nearly half a million deaths each year? This question has driven the 
entirety of this thesis project. By focusing on one facet of the complex problem, the intricate 
biology of the malaria parasite, this doctoral dissertation attempts to provide insight into the 
role that drug resistance plays in the treatment of Plasmodium falciparum malaria. Though 
the goal of this work was never to answer the overarching question explicitly, it continues to 









Chapter 1: Introduction 
 
1.1 Malaria: history, epidemiology, and biology 
  
Malaria is a parasitic infectious disease that has plagued humans, amongst other species, for 
millennia. Despite this long history and global efforts to eradicate the disease, 435,000  
thousand people died of complications caused by malaria in 2017 and an estimated 3.2 billion 
people—roughly half of the people on earth—are at risk of infection (World Health 
Organization, 2018). Though these statistics might suggest otherwise, malaria is a treatable 
disease that can be cured. However, one of the greatest obstacles to malaria elimination is the 
ability of the malaria parasite, Plasmodium, to develop drug resistance and evade death by 
antimalarial chemotherapy (Menard and Dondorp, 2017). This thesis aims to provide insight 
into the biological mechanisms of drug resistance in the malaria parasite. With a focus on 
malaria in Southeast Asia, this work combines clinical and functional genetic studies to 
elucidate molecular modes of resistance to the widely-used antimalarial drug, piperaquine. 
 
1.1.1 History of malaria 
Malaria is caused by a unicellular protozoan parasite of the genus, Plasmodium. The parasite 
is from a larger group of eukaryotic organisms in the phylum, Apicomplexa. Plasmodium are 
some of the most promiscuous parasites on our planet, with over a hundred Plasmodium 
species known to infect a diverse array of mammals, reptiles, and birds (Levine, 1988, 
Schlagenhauf, 2004). The malaria species that infect humans today are believed to have 
originated as zoonotic diseases that were transmitted from non-human primates to humans in 
Africa and spread with human migrations throughout the world (Carter and Mendis, 2002, 
Bruce-Chwatt, 1965). Today, more species of malaria infect primates than any other 
mammalian orders (Cox, 2010, Garnham, 1996). Six of those Plasmodium species infect 
humans: P. falciparum, P. vivax, P. ovale (recent work has distinguished two distinct species 
of P. ovale that infect humans (Sutherland et al., 2010)), P. malariae, and P. knowlesi. 
Though exact dates of transmission to humans is unknown, evidence of malaria-like 
symptoms have been present in human civilizations for centuries (Carter and Mendis, 2002) 
and more recently, detection of Plasmodium antigens in remains from antiquity have 








Early descriptions of malaria can be found in writings and artifacts from civilizations in 
Mesopotamia, India, China, Egypt, Greece, and Rome (Bruce-Chwatt, 1988). Over 2,000 
years ago in India, the Atharvaveda scripts described the periodic fevers of what was very 
likely malaria and bestowed upon it the title “king of diseases” (Kaur and Singh, 2017). The 
oldest book of medicine from China, the Nei Ching or “Canon of Medicine”, describes both 
the fevers and enlarged spleens of what was likely malaria-infected individuals. In 400 BC, 
Hippocrates was one of the first to write, in detail, about the paroxysmal fevers of malaria 
and associated malaria with the air—as were most ailments attributed at that time. Diseases 
that were then invisible to the naked eye were believed to be caused by “miasma,” a 
poisonous vapor in the air, often believed to emanate from swamps and decaying matter. 
Hippocrates associated certain environments and seasons with fevers that he described as 
“tertian” (P. falciparum/P. vivax/P. ovale, for which fevers recur every third day), “quartan” 
(P. malariae, fevers return every fourth day), or “intermittent.” He also recorded the strong 
association of splenomegaly with the disease (Bruce-Chwatt, 1988). This almost ethereal 
association of malaria with the air infiltrated civilizations for centuries, much like an actual 
noxious substance would, earning the disease its name, “mal’aria” or “bad air” amongst the 
citizens of Rome in the 1600s (Hempelmann and Krafts, 2013). Though incorrectly 
attributing malaria to vapors from foul-smelling swamp waters, they astutely connected the 
importance of stagnant water and time of year to the disease (Cunha and Cunha, 2008).  
 
It was not until centuries later during the Golden Age of Microbiology in the 1800s, that the 
capabilities for identifying the causal agent of malaria emerged (Maloy and Schaechter, 
2006). The long-searched for culprit of the disease was discovered in 1880 by French army 
doctor, Charles Louis Alphonse Laveran while stationed in Algeria, during the Franco-
Prussian War (Bruce-Chwatt, 1981). In a fresh blood sample from an afflicted soldier, 
Laveran identified live Plasmodium parasites on a microscope slide by noticing moving 
filaments and pigment-containing cells. Laveran named the organism, Oscillaria malariae 
(Bruce-Chwatt, 1981). In 1885, two Italian scientists, Ettore Marchiafava and Angelo Celli, 
created a new genus for the malaria parasite called, Plasmodium (McFadden, 2012, 
Marchiafava, 1885). The nomenclature change was based on Marchiafava and Celli’s 
observations that the parasites, when inside of erythrocytes, or red blood cells (RBCs), had 
multiple-nuclei and an ameboid-like shape that resembled a slime-mold of the same name, 
plasmodium (McFadden, 2012, Marchiafava, 1885). During this same time period, a cohort 







that the Plasmodium genus was made of distinct species that caused different forms of 
malaria (Cox, 2010). 
 
Despite these insights into the biology of Plasmodium, it took over a decade from when the 
parasite was first discovered to determine how it was transmitted from person-to-person. In 
the early 1890s, Patrick Manson hypothesized that malaria was transmitted by mosquitoes 
(Manson, 1894). This theory was later confirmed in 1897 by Sir Ronald Ross (Cox, 2010, 
Manson, 1898). Under the mentorship of Manson, Ross had observed pigmented bodies 
(what we now know as oocysts) in the midgut of an Anopheles mosquito that had bitten a 
malaria-infected patient (Ross, 1897). It should be noted that at the same time, Grassi and 
colleagues had also documented the Plasmodium life cycle in the mosquito and demonstrated 
that the Anopheles mosquito was the only vector for the parasite (Cox, 2010). 
 
1.1.2 Malaria today: global burden and epidemiology 
When Laveran, Ross, and the other influential researchers mentioned above made their 
discoveries in the late 19th century, malaria existed on every continent except Antarctica 
(Figure 1.1). As can be seen on the map in Figure 1.1, malaria extended through both 
temperate and tropical regions, spreading as far north as Russia. Interventions by mankind 
from 1900-2002 substantially reduced the number of countries at risk of malaria from around 
140 to 88, shrinking the land distribution of Plasmodium endemicity by half (Hay et al., 
2004, Murray et al., 2012).  
 
This reduction was made possible through national and global efforts in malaria endemic 
regions. Such strategies combined multidisciplinary approaches to reduce the malaria burden 
including, antimalarial drugs, insecticides, insecticide-treated bed nets, malaria surveillance 
tools, improved sanitation, and many other measures. This work has been achieved and 
sustained in the 21st century by many organizations and programs, including the Centers for 
Disease Control and Prevention (CDC) in the United States, the World Health Organization 
(WHO), the United Nations (UN), and the Bill & Melinda Gates Foundation, to name a few 
(World Health Organization, 2018). In spite of these efforts, the risk of malaria infection 
remains in approximately 100 countries and territories. 
 
According to the most recent Malaria Report from the World Health Organization, malaria 
occurs in 87 countries with the majority of cases caused by P. falciparum and P. vivax 







falciparum and P. vivax have widespread global distributions with distinct regions of 
prevalence, with P. falciparum predominating in Sub-Saharan Africa and Southeast Asia 
(SEA), while P. vivax is most prominent in South America, SEA, and the Western Pacific. P. 
falciparum is the most dangerous malaria species and causes the highest rates of morbidity 
and mortality due to its ability to progress to severe malaria. P. vivax is sometimes referred to 
as “benign” malaria because it is often asymptomatic and progression to severe malaria is 
less common (Carter and Mendis, 2002, Price et al., 2007). However, benign is misleading 
because P. vivax also contributes to morbidity and mortality, though to a lesser extent than P. 
falciparum (Price et al., 2007). Furthermore, P. vivax and P. ovale have dormant liver stages 
that can relapse in infected individuals months or even years after initial infection. The less 
prevalent P. malariae and P. ovale have been identified in all malaria endemic regions, but 
their incidence rates are lower than P. falciparum and P. vivax, although studies suggest that 
it is likely these species are underreported due to missed detection, misdiagnosis, or co-
infection with P. falciparum or P. vivax (Mueller et al., 2007, Doctor et al., 2016). P. 
knowlesi, a zoonotic parasite in macaque monkeys that also infects humans, has a less clearly 
delineated geographical distribution, but has been demonstrated in patients throughout SEA, 
with incidence rates recently reported on the rise in Malaysia (Barber et al., 2017, Cooper et 
al., 2019). Similar to P. malariae and P. vivax, it is hypothesized that P. knowlesi infections 
are underreported due to misdiagnosis as one of the other species (Shearer et al., 2016). It 
should also be acknowledged that P. knowlesi infections are currently being reported in 
countries that are making strides in eliminating the human malarias, so further studies are 
warranted and its prevalence should not be overlooked (Shearer et al., 2016). 
 
From an epidemiological perspective, there were 219 million malaria cases in 2017 and 
435,000 deaths (World Health Organization, 2018). The largest proportion of infections 
(92%) and deaths (93%) were in Sub-Saharan Africa. P. falciparum represented 99.7% of 
cases in Africa and 62.8% of malaria cases in SEA (World Health Organization, 2018). P. 
vivax was responsible for the majority of malaria infections outside of Africa, contributing to 
74.1% of cases in the Americas and 37.2% of cases in SEA (World Health Organization, 
2018). All individuals in malaria endemic regions are at risk of infection, but the severity and 
likelihood of illness is greatly increased for children under the age of five, pregnant women, 
and immunocompromised individuals. Children accounted for over half of the malaria deaths 
(61%) in 2017 (World Health Organization, 2018). These statistics show that this disease 









Figure 1. 1. The global distribution of malaria in the 20th century. The maps show the risk of 
malaria from P. falciparum, P. vivax, P. malariae, and P. ovale from circa 1900 to 2002, as estimated 
by Hay et al. (Hay et al., 2004). The figure has been reprinted from Hay et al. (2004) with permission 




Figure 1. 2. The global incidence of P. falciparum and P. vivax malaria in 2017. A.) Incidence of 
P. falciparum malaria in all age groups in 2017. B.) Incidence of P. vivax malaria in all age groups in 
2017. The maps are reprinted from The Malaria Atlas Project (2019) and are available in the public 
domain under the Creative Commons Attribution 3.0 Unported License. 
 
Malaria disproportionately affects populations living in extreme poverty. The disease is both 
a cause of and result of poverty, and the cycle continues to repeat itself (Teklehaimanot and 







widest poverty gaps—Nigeria, the Democratic Republic of the Congo, Mozambique, India, 
and Uganda—comprised almost half of the total number of malaria cases globally (World 
Health Organization, 2018). This inextricable link between malaria and poverty has long 
been acknowledged (Teklehaimanot and Mejia, 2008, Feachem et al., 2019), but the steps for 
unravelling the two requires multidisciplinary approaches that remain complex. Economic, 
social, and political factors, amongst many other dynamics combined with ecological 
conditions in tropical regions, favors the continued transmission of malaria. Though progress 
has been made through the aid of the aforementioned programs (CDC, WHO, UN, Gates 
Foundation) the current World Malaria Report shows that no significant progress in reducing 
the malaria burden was made within the last three years from 2015-2017 (World Health 
Organization, 2018).  
 
In spite of these issues, all hope for malaria elimination (reduction of the disease to zero new 
incidences in a distinct region) and eradication (permanent removal of disease pathogen) 
should not be quelled. There has been a considerable reduction of the malaria burden since 
2010 and although overall global statistics from 2015-2017 have stalled, country specific 
advancements are numerable. Sri Lanka eradicated malaria in 2016. In 2017, Rwanda 
reported 430,000 less malaria cases than in 2016 and India had a 24% decrease in malaria 
infections. Furthermore, 46 countries had less than 10,000 cases of malaria in 2017 (World 
Health Organization, 2018).  Continued reduction of the malaria burden and eventual 
eradication is possible in this century. Experts believe eradication could be possible by 2050 
and have put forth the slogan, “malaria eradication within a generation” (Feachem et al., 
2019).  
 
In addition to the social, economic, and political factors that must be addressed, continued 
scientific advancements are imperative for the goals of eradication to be realized. Although 
malaria remains a curable disease, drug resistance and the potential for it to develop threatens 
the efficacy of the limited number of antimalarial drugs currently available. As endemic 
countries strive to reduce the burden caused by malaria, it is necessary to understand the 
mechanisms of drug resistance, which is the focus of this dissertation. Drug resistance has 
been reported in both P. falciparum and P. vivax malaria (Bloland, 2001, Cui et al., 2015, 
Blasco et al., 2017, Price et al., 2009, Dayananda et al., 2018). Due to the global burden of P. 
falciparum malaria and its resistance to currently available drugs in SEA, P. falciparum 
malaria is the focus of this dissertation. Investigation of the mechanisms of drug resistance in 







mechanisms through which resistance can develop. For these studies to be possible, it is 
necessary to understand both the life cycle and pathogenesis of P. falciparum. 
 
1.1.3 P. falciparum life cycle 
The life cycle of P. falciparum consists of three phases (Figure 1.3): a sexual stage in the 
mosquito vector (sporogonic cycle), an asexual stage in the liver of the human host (exo-
erythrocytic cycle), and an asexual stage in the blood of the human host (intraerythrocytic 
cycle) (Cowman et al., 2016, Miller et al., 2013). The parasite is an obligate intracellular 
pathogen in liver hepatocytes and erythrocytes, which facilitates the parasite’s ability to 
avoid detection by the host’s immune system.  
 
The life cycle begins when a P. falciparum-infected female Anopheles spp. mosquito takes a 
bloodmeal from a human host. Male mosquitoes do not bite, so are thus not able to spread 
malaria. When the female mosquito bites an individual, the contents of the mosquito’s saliva, 
including anticoagulants and P. falciparum sporozoites, are injected into the human host’s 
blood. The sporozoites enter the bloodstream and migrate to the liver (30-60 minutes) where 
they invade hepatocytes and take ~6 days to mature into schizonts that contain ~40,000 
merozoites per hepatocyte (Miller et al., 2013, Phillips et al., 2017). This stage is clinically 
silent and the infected individual does not present with any symptoms. During P. vivax and 
P. ovale infections, it is during this exo-erythrocytic stage that some sporozoites differentiate 
to hypnozoites which can remain dormant in the liver for weeks to years before maturing to 








Figure 1. 3. The life cycle of P. falciparum. The life cycle begins when an infected female 
Anopheles mosquito bites a human host and sporozoites are inoculated into the host and migrate to the 
liver (liver/exo-erythrocytic stage) where they invade hepatocytes and form liver schizonts. When the 
liver schizonts rupture, they release merozoites that invade erythrocytes to start the asexual blood 
(intraerythrocytic) stage. When merozoites egress from the ruptured schizonts, they can reinvade 
erythrocytes to propagate the asexual cycle, or differentiate to sexual stage gametocytes. As 
gametocytes mature, they differentiate into male and female gametocytes that are taken up by a 
mosquito during a blood meal. Once inside the mosquito midgut (sporogonic/mosquito stage), the 
male and female gametes fuse to form a zygote that becomes an ookinete and then develops into an 
oocyst. When the matured oocyst ruptures, it releases sporozoites that migrate to the mosquito 
salivary glands to be transferred to a human host when the mosquito takes its next blood meal to 
repeat the cycle. The figure is reprinted from Maier et al. (2019) (Maier et al., 2019) with permission 
from Elsevier. 
 
The intraerythrocytic stage commences when an infected hepatocyte bursts and releases the 
hepatic merozoites into the bloodstream where they invade erythrocytes. Merozoite invasion 
into the erythrocyte takes about 1-2 minutes (Weiss et al., 2015). The intraerythrocytic cycle 
is when clinical symptoms present and is marked by three distinct forms of parasite growth: 
ring, trophozoite, and schizont (Figures 1.3-1.4) (Bannister and Mitchell, 2003, Bannister et 
al., 2000). Upon invading the host erythrocyte, the parasite enters the ring stage and begins to 
grow within the host cell over the course of 24 hours. The stage name is based on how the 
early ring stage parasite looks on a Giemsa-stained blood smear, with the nucleus off to one 
side and the disc-like cytoplasm adjacent (Figure 1.4). During the ring stage, the parasite 
begins to digest the host cell hemoglobin to obtain nutrients in the form of amino acids. 







2003, Bannister et al., 2000, Cowman et al., 2016) and provides an osmotic balance within 
the erythrocyte (Lew et al., 2003). Following the ring stage the parasite enters the stage of 
highest metabolic activity, trophozoite (~24-36 hours), and continues to feed off of the host 
cell hemoglobin. As trophozoites mature and enter the schizont stage (~36-48 hours), they 
undergo asexual replication to yield ~16-32 daughter merozoites. When the schizont has fully 
matured after ~48 hours, the merozoites egress, or rupture, from the host erythrocyte (Figure 
1.4). This process destroys the erythrocyte as the merozoites are released into the 
bloodstream where they can invade a new erythrocyte to continue the intraerythrocytic cycle 
(Cowman and Crabb, 2006, Cowman et al., 2016). This intraerythrocytic asexual cycle will 
continue until it is cleared by the host’s immune system or an antimalarial drug, or until it 




Figure 1. 4. The asexual and sexual intraerythrocytic life cycles of P. falciparum. A.) The 48-hour 
life cycle of P. falciparum asexual parasites as observed in Giemsa-stained blood smears. B.) A 
schematic of the sexual stages of P. falciparum gametocytes, including progression from sexual stage 
gametocytes in the human host to the mosquito vector. The image in part B was modified from 
Delves et al. (Delves et al., 2016) and reprinted with permission from Springer Nature Publishing. 
 
During the asexual intraerythrocytic stages, a portion of merozoites will commit to the sexual 
stage by undergoing a process called gametocytogenesis (Baker, 2010, Ngotho et al., 2019). 
The time at which this developmental conversion occurs is the topic of much debate and 
remains to be fully elucidated, but studies have shown it is regulated by the transcription 
factor, AP2-G (Kafsack et al., 2014, Sinha et al., 2014). It was previously shown that 







cycle as committed parasites before reinvading as gametocytes in the next cycle (Baker, 
2010). Recent studies have shown in addition to this pathway, parasites can undergo a 
developmental switch within the same asexual life cycle that increased AP2-G expression 
occurs (Bancells et al., 2019). Once committed to sexual development, gametocytogenesis 
consists of five stages (I-V), with the earliest stage (stage I) morphologically 
indistinguishable from asexual parasites (Figure 1.4) (Ngotho et al., 2019). Gametocytes 
require ~12 days to develop and the mature stages are identifiable by their “falciform” shape, 
from which falciparum earned its name (Figure 1.4). During development, the gametocytes 
are sequestered in the bone marrow to escape splenic clearance (Joice et al., 2014). In the 
final maturation stages, the gametocytes differentiate into haploid male (microgamete) or 
female (macrogamete) forms, which can remain in circulation for several days (Smalley and 
Sinden, 1977). The male and female gametocytes are the infective forms that are taken up by 
the mosquito during a blood meal (Ngotho et al., 2019). Once inside the mosquito midgut, 
the male gametocyte undergoes a process called exflagellation (induction) by which it 
becomes motile and fuses with the female macrogametocyte to form a diploid zygote 
(Phillips et al., 2017). In ~24 hours the zygote becomes an ookinete which enters the 
mosquito midgut epithelium and develops into an oocyst. When the oocyst is fully matured 
(after ~2 weeks), it releases thousands of haploid, motile sporozoites that travel to the 
mosquito’s salivary glands where they can be transferred by mosquito bite to the next host to 
restart the cycle (Figure 1.3) (Barillas-Mury and Kumar, 2005). Given that the Anopheles 
adult lifespan is 2-3 weeks in nature, this development cycle enables just enough time for the 
P. falciparum life cycle to be propagated (Clements, 1992, Centers for Disease Control, 
2018). 
 
The intraerythrocytic stage of P. falciparum malaria is the focus of this study. As will be 
discussed in later sections of this introduction, asexual P. falciparum isolates can be 
cultivated and maintained in vitro using human erythrocytes (Trager and Jensen, 1976). This 
enables the parasite to be studied using molecular biology techniques and tools. 
 
1.1.4 Pathogenesis of P. falciparum malaria: asymptomatic, uncomplicated, severe 
disease 
A malaria infection can be categorized as asymptomatic, uncomplicated, or severe. As 
described by the name, asymptomatic infections do not present with symptoms, due to the 
host’s immunity or other factors. However the infection can still be spread to mosquitoes 







malaria is characterized by the classic malaria symptoms (described in the next section), but 
with no signs of severe disease. All species of Plasmodium can cause asymptomatic 
infections and uncomplicated malaria (Phillips et al., 2017). Severe malaria includes the 
symptoms of uncomplicated malaria in addition to multi-organ complications (Wassmer and 
Grau, 2017). Severe malaria is predominantly caused by P. falciparum but P. vivax and P. 
knowlesi can also cause severe disease (Phillips et al., 2017). 
 
1.1.4.1 Uncomplicated P. falciparum malaria 
The severity of Plasmodium spp. infection varies greatly depending on the species and a 
multitude of host factors, including inherited factors of resistance (such as sickle hemoglobin 
trait), age, prior exposure, and immunity levels (Bruce-Chwatt, 1985). In general, 
uncomplicated malaria is infamously recognized for its classic symptoms: acute fevers, 
sweats, headache, myalgia, fatigue, nausea, and vomiting. The symptoms are notorious for 
their paroxysmal, or sudden, onset. 
 
The classic fevers observed in malaria infections correspond to the intraerythrocytic life 
cycle of the Plasmodium species. There are no clinical symptoms associated with the 
exoerythrocytic stage (liver stage), the sexual stage (gametocytogenesis), or when 
sporozoites are injected into the host bloodstream, aside from mild inflammation at the 
mosquito bite site (Bruce-Chwatt, 1985). In P. falciparum, P. vivax, and P. ovale infections, 
the intraerythrocytic life cycle is ~48 hours, which corresponds to fevers every third day 
(tertian). P. malaria has a 72 hour lifecycle with fevers every fourth day (quartan) and P. 
knowlesi has a 24 hour life cycle with fevers spiking daily (quotidian) (Bruce-Chwatt, 1985). 
The febrile episodes are the body’s response to the rupture of infected erythrocytes. Although 
the P. falciparum life cycle is ~48 hours, the fevers are often irregular and do not adhere to 
the periodicity observed with respect to infection by the other Plasmodium species (Bartoloni 
and Zammarchi, 2012). All symptoms are also non-specific and could be caused by a 
plethora of other infectious diseases present in malaria endemic regions (for example, 
dengue, chikungunya, bacterial septicaemia and typhoid). The physical findings are also 
nonspecific and can include splenomegaly, hepatomegaly, jaundice, and abdominal pain. 
Therefore, malaria should be diagnosed by a laboratory test, particularly microscopy 
(Mathison and Pritt, 2017). 
 
The gold standard for malaria diagnosis is to create a blood film, or smear, to directly 







entail spreading a drop of malaria infected blood on a glass microscopy slide. The slides are 
then fixed in methanol and stained with a Giemsa solution. A component of Giemsa binds to 
the phosphate groups of DNA while other components in the Giemsa solution stain the 
nucleus and cytoplasm differently so they can be visualized by light microscopy. Since 
erythrocytes do not contain DNA, the only positively stained cells on a patient blood smear 
are white blood cells and malaria-infected erythrocytes. The microscopy examination can be 
performed immediately upon request and by any trained microscopist. As part of malaria 
control and elimination efforts, many countries have standardized training and protocols for 
performing microscopy-based malaria diagnoses. Figure 1.5 shows an example of a 
handbook for performing diagnostic malaria microscopy in Cambodia, for which the 
guidelines have been translated from English to Khmer, the official language.  
 
Rapid diagnostic tests (RDTs) are another way to detect malaria infections quickly. These 
tests detect malaria-specific antigens in minutes, such as histidine-rich protein 2 (HRP2) 
(Wellems and Howard, 1986, Wellems and Howard, 1995), by using a drop of patient blood 
(Rock et al., 1987, Beadle et al., 1994, Shiff et al., 1993). Because RDTs can have false 
negatives, they should always be combined with microscopy. Additionally, multiple studies 
within the last three years have noted P. falciparum infections with deleted HRP2/3 genes 
(Mathison and Pritt, 2017, World Health Organization, 2018, World Health Organization, 
2017a), necessitating the need for microscopy to be jointly performed alongside RDTs and 
also demonstrating a need for new diagnostic tests to be developed. 
 
There is also the possibility that malaria infections are undetectable by microscopy, as often 
seen with asymptomatic malaria infections. Many studies have developed various PCR, 
quantitative (qPCR), and droplet digital PCR (ddPCR) methods to detect lower limits of 
parasitemia (Tham et al., 1999, Lee et al., 2002, Koepfli et al., 2016). However, these 
methods do not offer the rapid results that RDTs and microscopy can provide and they also 
require more advanced laboratory equipment and materials that may not be available in the 
field. Advancements in diagnostic tests would greatly aid malaria elimination efforts and it 
will be interesting to see how the field changes in the next decade as countries push for 










Figure 1. 5. Microscopy-based malaria diagnosis is the gold standard in all malaria endemic 
countries. This is a microscopy book that is used to train microscopists in Pursat Province, 
Cambodia. The P. falciparum isolates used in this dissertation were obtained from field sites in 
Cambodia and the photograph was taken during a field site visit to Pursat Province. 
 
1.1.4.2 Severe P. falciparum malaria 
P. falciparum is responsible for most cases of severe malaria, which often results in death. 
Young children are the population most impacted by severe disease but adults can progress to 
severe malaria as well. The pathophysiology of severe malaria is complex and not fully 
understood, but in general it is characterized by three coinciding conditions: severe anemia, 
metabolic acidosis, and cerebral malaria (Miller et al., 2013). Within the last two decades, 
research has also demonstrated that severe malaria results in multi-organ damage not limited 
to the brain and includes other organs such as the kidneys and pulmonary system (Miller et 
al., 2002, Wassmer and Grau, 2017, Wassmer et al., 2015).  
 
One of the major causes of P. falciparum pathogenesis in severe malaria is its ability to cause 
infected erythrocytes to adhere to the endothelial lining of blood vessels, including those in 
the brain which results in cerebral malaria (Wassmer and Grau, 2017, Wassmer et al., 2015). 
This sequestration of infected erythrocytes drastically affects blood perfusion throughout the 
body. The effects of this cause different clinical presentation in children and adults, with 
complications in children predominantly resulting in cerebral malaria, seizures, 
hypoglycemia, and severe anemia. In adults, there is often kidney failure, jaundice, and 
pulmonary edema (Wassmer et al., 2015). Metabolic acidosis is a key symptom in both 







intraerythrocytic stages of the parasite and death often occurs within 48 hours after 
presentation of the disease (White, 2004). This means the parasites present at the onset of 
severe malaria symptoms will ultimately contribute to death, so preventing their maturation 
and reinvasion is vital.  
 
In the context of severe malaria, it is important that the drugs are stage-specific to prevent the 
ring stages from progressing and the parasitemia from increasing. In the context of 
uncomplicated malaria, it is important to lower parasitemia as fast as possible, and prevent 
the likelihood that the disease will become severe (White, 2004). The way this is achieved is 
chemotherapy.  
 
1.2 Antimalarial chemotherapy 
The current frontline treatments for uncomplicated P. falciparum malaria worldwide are 
artemisinin combination therapies (ACTs) (World Health Organization, 2018, World Health 
Organization, 2015). ACTs combine a potent short-acting artemisinin derivative with a long-
acting partner drug with a different mechanism of action. Severe malaria is treated with 
intramuscular (IM) or intravenous (IV) artesunate, an artemisinin derivative, for at least 24 
hours followed by standard course of an ACT (World Health Organization, 2018).  
 
P. falciparum has demonstrated resistance to nearly every antimalarial drug it has come in 
contact with and presently, decreased susceptibility of the parasite to both artemisinin and 
several commonly used partner drugs has been reported in multiple countries in SEA 
(Amaratunga et al., 2016, Dondorp et al., 2009, Denis et al., 2006, van der Pluijm et al., 
2019, Blasco et al., 2017). This is of great concern as there are a limited number of drugs 
available to treat uncomplicated and severe malaria. In order to put antimalarial drug 
resistance into perspective, it is first necessary to delve into the history of antimalarial drug 
therapies.  
 
1.2.1. Brief history of widely used antimalarial drugs: from monotherapies to 
combination therapies 
1.2.1.1 Quinine 
Extracted from the bitter bark of a cinchona tree, quinine was the first treatment discovered 
for malaria in the 1600s (Figure 1.6) (Tse et al., 2019, Butler et al., 2010, Arrow, 2004). The 







chemists, Joseph Pelletier and Jean Biename Caventou in 1820 and the structure of this 
compound from nature has inspired many synthetic treatments for malaria (Arrow, 2004).  
 
Early anecdotal observations of quinine resistance were recorded in 1884 and 1910 (Talisuna 
et al., 2004). In the 1960s, quinine resistance was reported in human volunteers in SEA and 
Brazil, and later associated with treatment failures in SEA in the 1980s-90s (Peters, 1970, 
Peters, 1987, Pukrittayakamee et al., 1994). More recently, treatment failures were observed 
in Uganda when comparing quinine to the ACT, artemether-lumefantrine (Achan et al., 
2009). In spite of intermittent periods of resistance, quinine is still an effective treatment for 
malaria in many regions and can still be used as a “drug of last resort” to treat severe malaria 
when an artemisinin derivative is unavailable (Achan et al., 2011, Schlitzer, 2007, Bloland, 
2001). One reason for the continued efficacy of quinine is likely due to decreased use of the 
drug as newer drugs with higher therapeutic efficacy and less toxicities have become 
available (Achan et al., 2011). Quinine has severe side effects, both at standard therapeutic 
levels and when overdosed, which include tinnitus, blurred vision, confusion, vertigo, skin 
rashes, cardiotoxicity, nausea, and many additional symptoms referred to broadly as 
cinchonism (Achan et al., 2011). The mechanism of quinine action remains to be fully 
elucidated, but it is postulated to exert its antiplasmodial effects by accumulating in the 
parasite’s digestive vacuole and interfering in heme detoxification (Figure 1.7) (Blasco et al., 
2017, Greenwood et al., 2008).  
 
Quinine remained the only available drug to treat malaria until the 20th century (Talisuna et 
al., 2004, Tse et al., 2019). This changed after the First World War when Germany made a 
push to develop synthetic antimalarial drugs after suffering huge losses to malaria during the 
war because of their inability to access quinine (Butler et al., 2010). The process to find 
quinine analogues that would be toxic to the malaria parasite began years before the war with 
the dye, methylene blue. Based on the compound’s similarity to quinine and it’s toxic effects 
on malaria parasites, it was used as a structural basis for synthesizing quinine-like 
compounds. (Presently, methylene blue is back in the spotlight and being considered in 
various combinations for malaria treatment (Tse et al., 2019). Shortly after the war in the 
early 1930s, mepacrine (also called quinacrine) and plasmochin (also called pamaquine) were 
the first synthetic antimalarial compounds synthesized as quinine analogues (Schlitzer, 
2007). Plasmochin was not widely used due to toxicities, but mepacrine was used during the 
Second World War as an antimalarial prophylactic (Tse et al., 2019). Mepacrine also has 







2019). Both plasmochin and mepacrine are no longer used for malaria prophylaxis or 
treatment, however the aminoquinoline-based structures of both plasmochin and mepacrine 
led to two of the most commonly used antimalarial drugs: primaquine and chloroquine. 
Modifications of the plasmochin structure led to primaquine, and mepacrine helped to inspire 
the discovery of chloroquine (Schlitzer, 2007).  
 
Chloroquine (originally called resochin) was synthesized in 1934 by the group of German 
chemists employed to synthesize a new quinine-like compound (Figure 1.6), but it was 
believed to be too toxic. Sontochin (3-methylchloroquine) followed after chloroquine and it 
was believed to have fewer side effects, so it was given to German troops during the Second 
World War. During the war, the Allies acquired sontochin and when Americans tried to 
increase the drug’s efficacy, they synthesized what they thought was a new drug, 
chloroquine. However, upon comparing resochin and chloroquine, they realized they were 
the same drug (Arrow, 2004). Similar to quinine’s proposed mechanism of action, 
chloroquine inhibits heme detoxification (Wellems and Plowe, 2001). Chloroquine has also 
been shown to accumulate in the parasite digestive vacuole (Figure 1.7) (Ridley, 1998, 
Sullivan et al., 1996). 
 
1.2.1.2 Chloroquine 
The deployment of chloroquine for the treatment of malaria had an enormous impact on the 
eradication of malaria in many countries in the first half of the 20th century. Chloroquine’s 
potential was fully realized in the 1950s-1960s during WHO’s Global Malaria Eradication 
Program (GMEP) (Wellems and Plowe, 2001, Croft, 1999). The GMEP (1955-1969) was 
immensely successful in eliminating malaria in multiple countries by combining the 
affordable chloroquine with the deployment of the insecticide, 
dichlorodiphenyltrichloroethane (DDT), and malaria case surveillance. The program 
eliminated malaria in North America, Europe, the Caribbean, parts of Asia, and Central 
America (Croft, 1999). However, many African countries were not included in the GMEP 
(the program did not involve these countries due to logistical/“technical” challenges) and 
thus no successes were observed in Africa (World Health Organization, 2001, Alonso et al., 
2011). The GMEP ended in 1969 due to the emergence of both chloroquine resistance and 
insecticide resistance combined with the lack of organization for the necessary infrastructure 
and surveillance measures within individual countries—demonstrating that a single approach 








Chloroquine resistance emerged from four independent locations (Wellems and Plowe, 2001, 
Talisuna et al., 2004). The first was in SEA on the Thai-Cambodian border in 1957 
(Harinasuta et al., 1965). Around the same time period, another foci was reported in South 
America in Colombia and Venezuela (Payne, 1987). The last two emergences were in Papua 
New Guinea (1970s) and in Africa beginning in Kenya and Tanzania in 1978 (Peters, 1987, 
Talisuna et al., 2004). From these locations, chloroquine-resistant P. falciparum spread 
throughout endemic areas. 
 
1.2.1.3 Antifolates: sulfadoxine/pyrimethamine (SP), proguanil 
A combination of antifolate drugs were also used to treat malaria in response to the reduced 
efficacy of chloroquine. These drugs function by blocking steps in the folate synthesis 
pathway in bacteria, protozoa, and fungi. The pyrimidine analogue, proguanil (synthesized in 
1945), was a product of the push to generate new drugs after the Second World War (Tse et 
al., 2019, Arrow, 2004). In the 1950s-1960s, pyrimethamine and sulfadoxine were also 
developed. When the drugs were introduced as monotherapies, it was quickly realized that 
they could not be used alone. Sulfadoxine and pyrimethamine (SP) were then combined to 
reduce the likelihood of drug resistance, but resistance continued to develop rapidly. In 1967, 
SP was introduced in Thailand and resistance was documented in the same year (Wernsdorfer 
and Payne, 1991). Today, SP is not used to treat malaria unless it is combined with an 
artemisinin derivative, most commonly with artesunate. SP is also used successfully as 
intermittent preventive treatment in pregnancy (IPTp) (World Health Organization, 2018, 
World Health Organization, 2015). IPTp is a public health measure designed to prevent 
malaria in pregnant women by administering antimalarial drugs during their pregnancy. It is 
recommended by WHO that pregnant women in moderate to high transmission areas in 
Africa receive IPTp at the beginning of their second trimester until the end of their 
pregnancy. 
 
With widespread chloroquine resistance and the unreliable efficacy of SP, the pressure to 
find new antimalarial drugs was greatly increased (again at a time of war) during the Vietnam 
War, when all sides were subjected to the malaria scourge. During this time period, the US 
Army Medical Research and Development Command, the Walter Reed Army Institute of 
Research (WRAIR), and WHO sought to discover new drugs as well as promote research 
into parasitology and malariology, for which efforts had died down after the GMEP (Alonso 
et al., 2011). Concurrently, the Chinese government, which was supporting the North 







pharmacologists, doctors, and other biomedical experts to discover new antimalarial drugs 
(Butler et al., 2010). It was through this project that the next drug to revolutionize the malaria 
field was discovered: artemisinin (Tu, 2011). 
 
1.2.1.4 Artemisinin 
Artemisinin was discovered by Tu Youyou in 1972 as part of the efforts of Project 523. Tu 
extracted the compound from the Artemisia annua plant, commonly referred to as sweet 
wormwood or qinghao in Chinese (Tu, 2011). The plant had been used by Chinese herbalists 
for thousands of years as a treatment for a variety of maladies and around 300 AD, Ge Hong 
published the use of qinghao for fevers in the book, A Handbook of Prescriptions for 
Emergencies (Tu, 2011). Similar to quinine, another natural compound that had been known 
for its antipyretic properties, artemisinin was re-“discovered” and chemically isolated for the 
treatment of malaria. In contrast to quinine, artemisinins have few side effects and are well 
tolerated (White, 2008). Artemisinins are the fastest-acting, most potent malarial drugs 
available. The compounds are active against all erythrocytic asexual stages of parasite 
development and have also been shown to kill sexual stage gametocytes (Skinner et al., 1996, 
Adjalley et al., 2011), but they have no effect on liver stages (Meister et al., 2011). The 
mechanism of action of artemisinin is the topic of continued debate and remains a complex, 
to-be-continued story (Meshnick, 2002, Cui and Su, 2009). Artemisinins are prodrugs and 
one theory is when artemisinin is activated (some theories believe it is activated by heme in 
the erythrocyte (Figure 1.7) (Wang et al., 2015, Meshnick, 2002), it generates toxic free 
radicals or reactive oxygen species (ROS) that cause damage to any nearby cellular targets 
(Tilley et al., 2016, Blasco et al., 2017). Additional studies have also suggested that activated 
artemisinins have many targets they can bind resulting of alkylation of both lipids and 
proteins (Wang et al., 2015). Thus, artemisinin likely has many ways through which it exerts 
its antiparasitic effects. 
 
Early clinical trials by Tu and colleagues in the 1970s showed that artemisinin was very 
effective at clearing parasites, however some recrudescences were observed (Cui and Su, 
2009). Recrudescence means that the malaria infection has persisted at an undetectable level 
and when it reoccurs at a detectable level, it is termed a recrudescent infection. In spite of the 
recrudescences, the potency of artemisinin prompted the development of several artemisinin 
derivatives that are still recommended for malaria treatment today: dihydroartemisinin 
(which is the active metabolite of artemisinin), artemether, and artesunate (World Health 







The short half-lives of artemisinin derivatives (~1 hour) are believed to be one of the main 
reasons why recrudescences are observed (Cui and Su, 2009). Because the Chinese scientists 
were aware of the pitfalls of artemisinin monotherapy early on, they performed multiple 
efficacy studies to optimize treatment regimens. In comparing 3-, 5-, and 7-day artemisinin 
monotherapy efficacy studies, Li et al. (Li et al., 1984) found that a 7-day course of 
artemisinin was most effective with only 5% treatment failures (Cui and Su, 2009, Li et al., 
1984). Acknowledging that administering artemisinin monotherapy over the course of one 
week was neither feasible for patient compliance nor cost-efficient, Li and colleagues also 
tested artemisinin combination therapies (Li et al., 1984). Li et al. found the combination 
therapy artesunate-piperaquine to be most successful and after further optimization, 
artesunate was replaced with dihydroartemisinin and the two drugs, dihydroartemisinin-
piperaquine, were co-formulated and first produced in Vietnam as CV8 in 1997 (Cui and Su, 
2009). After slight changes of the drug dosages based on WHO recommendations, the 
combination therapy was marketed as Artekin® (Cui and Su, 2009). These early findings in 
the 1980s/90s set the stage for the current antimalarial regimens and combination therapies 
used today. 
 
1.2.2.1 Combination therapies in malaria: ACTs 
Combination therapies are common treatment regimens for many diseases, including 
tuberculosis, HIV, cancer, and autoimmune diseases (Ascierto and Marincola, 2011). The 
justification for combination therapies is that by using two or more drugs with different 
mechanisms of action, resistance is less likely to develop. Another potential advantage of a 
combination therapy is that the course of the disease is likely to be lessened in duration 
and/or severity as a result of more rapidly killing/inhibiting the causal agent. One of the 
classic examples of a disease in which multidrug therapies are standard course is 
tuberculosis. As early as the 1940s/50s, multiple drugs were used (and needed) to effectively 
cure patients infected with Mycobacterium tuberculosis, the causal agent of tuberculosis 
(Kerantzas and Jacobs, 2017).  
 
If combination therapies were common in tuberculosis, why did it take decades after the 
emergence of chloroquine resistance for the malaria field to use combination therapies for the 
treatment of malaria? Perhaps it was the lack of available antimalarial drugs or the toxicities 
(quinine) that some drugs cause when used alone. Or, maybe it was the concern that using 
multiple drugs might cause the development of resistance to all currently available drugs? As 







resistance to all four drugs, termed excessively drug-resistant tuberculosis (XDR-TB) has 
emerged and become a significant global health concern (Johnston et al., 2009). 
Alternatively, perhaps the cost of multidrug therapies was the prohibitive barrier. Although 
SP, described above, was a combination of two drugs, it was not considered a combination 
therapy in the true sense of the regimen, for SP combined drugs with similar mechanisms of 
action. Of note, several studies also combined mefloquine with SP in the 1980s when SP was 
largely failing (Khim et al., 2005). However, the first regulated and recommended 
combination therapies for the treatment of malaria were ACTs. 
 
In 2001, WHO recommended ACTs as the first-line treatment for uncomplicated P. 
falciparum malaria (World Health Organization, 2001). Currently, there are five ACTs 
recommended by WHO: artemether + lumefantrine; artesunate + mefloquine; artesunate + 
amodiaquine; dihydroartemisinin + piperaquine; and artesunate + 
sulfadoxine/pyrimethamine. A sixth ACT, artesunate + pyronaridine, has received positive 
reviews (Pryce and Hine, 2019) and is under consideration for being recommended by WHO 
(World Health Organization, 2018). 
 
The rationale behind ACTs is that the potent artemisinin compound is responsible for 
clearing most parasites in the first several days of treatment while the partner drug, which has 
a different mechanism of action and a longer half-life, clears any remaining parasites. All 
ACTs are administered over a 3-day treatment course. This is designed to promote treatment 
efficacy and patient compliance as well as reduce the risk of resistance (World Health 
Organization, 2018, World Health Organization, 2015, World Health Organization, 2001). 
As mentioned above, the mode of action of artemisinin is still unknown but it has been 
suggested that the parasite rapidly kills parasites by actively damaging nearby proteins and 
other targets within the parasite (Wang et al., 2015). Similar to artemisinin, the exact 
mechanism of the partner drugs is unknown, but all are posited to target hemoglobin 
degradation or the detoxification of heme in the parasite digestive vacuole (Greenwood et al., 
2008, Blasco et al., 2017) (Figure 1.7). This is not entirely surprising based on the chemical 
structures of the drugs. Piperaquine (PPQ) and amodiaquine (AQ) are 4-aminoquinilones, 
like chloroquine. Lumefantrine (LUM) and mefloquine (MQ) are aryl amino alcohols, like 
quinine (Figure 1.6). With the 3-day treatment course, any parasites that survive treatment 
and reinvade after 48 hours would still be exposed to a maximal dose of artemisinin on day 3 
as well as to the partner drugs. After the artemisinin derivative has been rapidly cleared from 







parasites over the next couple of days to weeks depending on the drug. The half-lives of the 
recommended partner drugs range from ~4 days to over 20 days. Mefloquine and piperaquine 
have the longest half-lives around ~21-28 days (Tarning et al., 2008), the half-life of 
amodiaquine is ~7 days (Stepniewska et al., 2009), lumefantrine is ~5 days, and sulfadoxine 
and pyrimethamine half-lives are ~4 to ~8 days, respectively. 
 
 
Figure 1. 6. Structural similarities of antimalarial drugs.  
 
1.2.2.2 ACTs: dihydroartemisinin-piperaquine  
The combination therapy that is the focus of this study is dihydroartemisinin-piperaquine 
(DHA-PPQ). As mentioned above, DHA-PPQ was first co-formulated by Li et al. in the late 
1980s/90s (Cui and Su, 2009), however piperaquine was first synthesized in the 1960s (Davis 
et al., 2005). Piperaquine is a bisquinoline drug that was synthesized independently in China 
at the Shanghai Research Institute of Pharmaceutical Industry and in France at Rhone-
Poulenc. Structurally, it resembles two linked chloroquine molecules (Figure 1.6). In China, 
it was used as frontline antimalarial monotherapy and as prophylaxis starting in 1978. 
However, by the 1980s piperaquine-resistant parasites emerged, so the monotherapy was 
discontinued (Davis et al., 2005). It was not until the studies by Li et al. with CV8 that 












Figure 1. 7. Antimalarial drugs depicted with their proposed mechanism of action in the 
erythrocytic (asexual) blood stage of P. falciparum. The process of hemoglobin degradation is 
depicted in the parasite digestive vacuole (light blue) and common antimalarial drugs (green) are 
depicted near their proposed site of action. Of note, chloroquine (CQ) and piperaquine (PPQ) are 
shown interfering with heme detoxification. PfCRT (yellow) is shown on the digestive vacuole 
membrane with a mutation (red circle) that enables the efflux of CQ. PfMDR1 (yellow) is also shown 
on the digestive vacuole membrane (with increased copies) transporting mefloquine (MFQ) into the 
vacuole. Artemisinin (ART) is depicted in its proposed mode of action that causes oxidative stress 
and alkylation of proteins and lipids. This figure was reprinted from Blasco et al. (Blasco et al., 2017) 
with permission from Springer Nature Publishing.  
 
Since their implementation, ACTs have been responsible for the immense decline of P. 
falciparum malaria mortality and transmission worldwide (World Health Organization, 2018, 
World Health Organization, 2015). However, over the last decade, both artemisinin 
resistance and resistance to two commonly used partner drugs, mefloquine and piperaquine, 
has been reported in SEA (Blasco et al., 2017, van der Pluijm et al., 2019, Wongsrichanalai 
and Meshnick, 2008). Western Cambodia and the region along the Thai-Cambodian border 
are the sites where ACT treatment failures were first reported (Noedl et al., 2008). SEA has 
long been regarded one of the prominent foci of drug-resistant malaria. As detailed above, 
resistance to many of the former frontline therapies (quinine, chloroquine, SP) emerged and 
spread throughout SEA, with all three treatment failures materializing first on the Thai-
Cambodian border. Unlike the development of chloroquine resistance, which emerged in 







failures are contained in SEA, at least for the time being. These failures severely threaten the 
disease’s ability to be qualified as “treatable,” for few other drugs are available as viable 
options. In order to understand the current setting of ACT resistance in SEA, it is necessary 
to understand the history of drug resistance in Cambodia and the genetic landscape through 
which parasites have developed resistance.  
 
1.3 Drug-resistance in P. falciparum 
1.3.1 ACT failures: emergence of artemisinin and partner drug resistance in 
Cambodia 
In 2001, Cambodia was one of the first countries to implement ACTs with the inclusion of 
artesunate-mefloquine (AS-MQ) in their nationwide treatment guidelines (Figure 1.8) 
(World Health Organization, 2001). Less than four years after AS-MQ implementation, 
therapeutic efficacy studies reported >10% failure rates from 2001-2004 (Denis et al., 2006, 
Wongsrichanalai and Meshnick, 2008). Mefloquine was used as a monotherapy in Cambodia 
in the early 1990s (Figure 1.8) and was stopped due to resistance in the early 2000s, shortly 
before AS-MQ was introduced (Wongsrichanalai and Meshnick, 2008, Lim et al., 2009). It is 
therefore not entirely surprising that the combination treatment eventually failed. This caused 
a shift from AS-MQ to DHA-PPQ therapy in 2008 and DHA-PPQ was implemented 
nationwide in 2010 (Figure 1.8). By 2013, DHA-PPQ showed significant failure rates, 
specifically in Western Cambodia where rates were nearly 50% (Amaratunga et al., 2016, 
Leang et al., 2015, Saunders et al., 2014, Spring et al., 2015). This prompted an efficacy 
study by Amaratunga et al. in 2014-2015 to determine if AS-MQ could be reintroduced in 
Cambodia (Amaratunga et al., 2019). This study showed that AS-MQ was highly effective 
with recrudescence reported in only 1 patient out of 296 (Amaratunga et al., 2019). The 
continued reports of DHA-PPQ failures (van der Pluijm et al., 2019) and the demonstration 
that parasites returned to AS-MQ susceptibility prompted the reintroduction of AS-MQ and 
the use of triple-ACTs (TACTs) in Cambodia from 2015 to the present day (World Health 
Organization, 2017b). The triple therapy includes DHA-PPQ + mefloquine and has been 








Figure 1. 8. Timeline of antimalarial drug use for the treatment of P. falciparum malaria in 
Cambodia. The period of time each drug has been used is indicated in color on the timeline. ACTs 
(red arrow) were introduced in 2001 in Cambodia. The approximate time widespread resistance 
developed (chloroquine and SP) or >10% treatment failures were first reported (AS-MQ (Denis et al., 
2006) and DHA-PPQ (Amaratunga et al., 2016, Leang et al., 2013)) is indicated by the black arrows. 
Currently both triple ACTs (TACT) consisting of DHA-PPQ + MQ and AS-MQ are being used to 
treat uncomplicated P. falciparum malaria. A map of Cambodia is shown above the timeline and the 
shaded regions indicate three provinces where drug efficacy studies have been performed: from West 
to East, Pursat, Preah Vihear, and Ratanakiri. This dissertation has used parasite isolates from these 
three provinces and full details for the clinical sites will be discussed in Chapter 2 (General 
methodology). 
 
In order to understand how piperaquine resistance emerged and continues to spread in SEA, 
it is necessary to identify and characterize genetic changes in parasite populations that 
promote increased survival to piperaquine. 
 
1.3.2 Assessing drug-resistance in P. falciparum 
Antimalarial drug resistance is defined as the ability of parasites to survive and/or multiply in 
the clinical setting despite treatment with the appropriate medication and dose. This 
definition necessarily includes that the parasite must have been exposed to the drug for the 
duration of time needed for the drug to exert its full antimalarial properties, ensuring drug 
compliance and proper absorption (taken with a fatty meal, etc.). This verifies that resistance 
is due to parasite adaptations and not due to the inability of the drug to “gain access to the 
parasite” (Bloland, 2001, Bruce-Chwatt, 1986). In such in vivo drug efficacy studies, true 
resistance is confirmed only after both remaining parasitemia and adequate serum drug 








Apart from the clinical setting, general ways to study and measure drug resistance include: 
surrogate in vitro assays, animal models, and detection of molecular markers (for example, 
by PCR assays or genomic studies) (Bloland, 2001). Surrogate in vitro assays test the effect 
of compounds on the parasites outside of the human host in cell culture, usually by a measure 
of survival. In Plasmodium, this is most easily performed with P. falciparum and P. knowlesi, 
since they have been adapted to grow in cell culture (Trager and Jensen, 1976, Moon et al., 
2013). In vitro tests enable direct parasite biology to be assessed in response to specific drugs 
in a controlled environment outside of a host, however some notable disadvantages are also 
inherent because they are outside of the host. For example, if a prodrug needs to be cleaved 
within the host to its active metabolite (such as proguanil), it cannot be tested unless the 
compound is available and stable in its active form (as is the case with DHA). There is also 
no way to test the effects that host immunity may have on infection in in vitro settings. 
Nevertheless, in vitro work has provided much insight into the complex biology of the 
malaria parasite. Animal models (such as mice or non-human primates) can support both 
parasite biology studies and transmission studies under in vivo conditions. Lastly, molecular 
genomics studies encompass many techniques and approaches to enable molecular markers 
of resistance to be identified. In turn, they provide fundamental insight for highlighting the 
genetic candidates and pathways that in vitro studies can investigate. Candidate molecular 
markers can consist of any genetic variation including, single nucleotide polymorphisms 
(SNPs), copy number variations, insertions or deletions in the genome, and other such 
variations that are associated with the resistant-phenotype. It is then up to functional studies 
to verify if these markers are causal determinants of resistance. 
 
1.3.3 The genetic basis of resistance  
Drug resistance is the result of spontaneous and rare genetic mutations that alter genes 
directly or change the expression of genes (White, 2004).  Sometimes a single genetic event 
is enough to produce a resistant phenotype, other times multiple genes may be involved. 
Furthermore, the resistance may be associated with the genetic background (epistasis) 
(White, 2004). P. falciparum has an approximate spontaneous mutation rate of 1.0–9.7 × 10−9 
mutations per base pair per generation in asexual culture (Bopp et al., 2013). Considering an 
average malaria infection can present with around ~1012 parasites in the blood stream (which 
is about 2% parasitemia in the bloodstream), it is likely that random mutations will occur 
during several asexual life cycles (Cowell and Winzeler, 2019, White, 2004). These mutation 
rates are in the absence of selective drug pressure and are thought to be independent of the 







both a survival and fitness advantage would be favored. ACT partner drugs with long half-
lives, such as mefloquine and piperaquine offer a favorable selective environment because 
they remain in the bloodstream at suboptimal levels for weeks post initial infection.  
 
There are many ways that parasites can develop resistance to antimalarial drugs. In general, 
two of the main mechanisms through which resistance is achieved are by: decreased 
availability of a drug at its target site (frequently due to mutations in transporter genes) 
and/or modification of the drug target (Paloque et al., 2016). 
 
1.3.4 The parasite digestive vacuole and antimalarial drugs 
Many antimalarial compounds, specifically ACT partner drugs, are believed to exert their 
effects in the parasite digestive vacuole by disrupting a crucial pathway: hemoglobin 
degradation (Figure 1.7). The digestive vacuole, located inside the parasite’s cytosol and 
sometimes referred to as the food vacuole, is a membrane-bound organelle with an acidic pH. 
The digestive vacuole is the site of hemoglobin degradation (Wunderlich et al., 2012), during 
which 60-80% of the host cell hemoglobin is digested (Wunderlich et al., 2012). The parasite 
uses the degraded amino acids as a source of nutrients, since they have limited capabilities 
for de novo amino acid synthesis and exogenous uptake of amino acids (Goldberg et al., 
1990).  
 
Hemoglobin is the major protein in all erythrocytes that is responsible for carrying 
oxygenated blood throughout the body. Hemoglobin consists of four globin chains each 
containing a heme group, which consists of an iron ion in a heterocyclic ring surrounded by 
pyrrole molecules, called a porphyrin. In adults, hemoglobin A (HbA) is the most common 
form of hemoglobin and consists of two alpha globin chains and two beta globin chains. In 
SEA, hemoglobin E (HbE) is a very common variant and consists of two alpha globin chains 
and two mutant beta globin chains (Munkongdee et al., 2016). In Africa, hemoglobin S 
(HbS) consists of two alpha globin chains and two beta globin chains with a different 
mutation that results in sickle cell anemia. Individuals who are heterozygous for the sickle 
cell trait have protection from malaria infection (Weatherall and Clegg, 2001). In contrast, 
some studies have shown that HbE does not provide protective advantage against infection 
with P. falciparum malaria in studies in Thailand (Lithanatudom et al., 2016, Carter and 
Mendis, 2002) and in Cambodia (personal communication with Dr. Chanaki Amaratunga) 
where parasites may invade and develop normally in HbE erythrocytes. It is worth 







for P. falciparum to invade HbE erythrocytes in vitro (Chotivanich et al., 2002). The authors 
suggest that although HbE does not prevent infection, it could prevent high parasitemias, 
however further in vivo and in vitro studies are necessary to further validate these findings. 
 
When the parasite breaks down hemoglobin, heme is released as a toxic byproduct. To 
prevent oxidative damage from the reactive iron-heme groups, enzymes in the digestive 
vacuole convert (detoxify) the reactive heme to inert hemozoin crystals (Wunderlich et al., 
2012). The hemozoin is what accounts for the characteristic brown pigment in malaria 
parasites that can be seen in the digestive vacuole when viewed by light microscopy. (This is 
the same pigment that Laveran and Ross distinguished when identifying Plasmodium in the 
blood and mosquitoes, respectively.) There are many different enzyme families that facilitate 
hemoglobin degradation and heme detoxification. Four plasmepsin enzymes (plasmepsins 1-
4) are aspartic proteases that localize to the digestive vacuole and digest hemoglobin. 
Plasmepsins 1 and 2 initiate hemoglobin digestion and plasmepsins 3 and 4 aid in 
degradation after initial cleavage (Banerjee et al., 2002, Goldberg et al., 1991, Francis et al., 
1997). Falcilysins and falcipains, cysteine proteases and metalloproteases, respectively, 
function downstream of the plasmepsins to further degrade hemoglobin (Subramanian et al., 
2009, Eggleson et al., 1999). Another enzyme, heme detoxification protein (HDP) helps to 
generate inert hemozoin crystals from heme (Jani et al., 2008, Nakatani et al., 2014). Studies 
have also suggested a role for a glutathione-dependent process of heme degradation 
(Ginsburg et al., 1998). These are just a few examples of the various proteins and often 
overlapping processes that take place to achieve hemoglobin metabolism in the digestive 
vacuole. Such overlapping and redundant functions of many hemoglobin-degrading proteins 
may explain why many genes encoding these enzymes can be knocked out (Moura et al., 
2009, Omara-Opyene et al., 2004, Bonilla et al., 2007) without compromising parasite 
viability. 
 
Multiple transporters and ion pumps are also located on the membrane of the digestive 
vacuole. Two transporters that function in drug resistance are the chloroquine resistance 
transporter, PfCRT and the multidrug resistance protein 1 (PfMDR1). PfCRT has been 
shown to efflux substrates from the digestive vacuole into the parasite cytosol, while 
PfMDR1 has been shown to import substrates from the cytosol into the digestive vacuole 









In order to understand the mechanisms of drug resistance and prevent the emergence and 
spread of resistance, it is important to discover the genetic determinants of resistance and 
their corresponding markers. 
 
1.4 Genetic background and mechanisms of resistance in SEA  
1.4.1 Chloroquine 
Chloroquine is a weak base and its mode of action is believed to be through its localization to 
the parasite’s acidic digestive vacuole, where it disrupts heme detoxification (Wellems and 
Plowe, 2001). When chloroquine is inside the acidic vacuole, it becomes protonated and 
builds up inside the organelle (Homewood et al., 1972, Yayon et al., 1984). Once inside the 
digestive vacuole, it disrupts heme detoxification and results in parasite death due to the 
build-up of its own toxic byproduct (Figure 1.7) (Wellems and Plowe, 2001).  
 
The mechanism of chloroquine resistance is through the parasite’s ability to prevent the 
accumulation of chloroquine in the digestive vacuole. This is accomplished via the 
transporter, PfCRT (Wellems et al., 1991). PfCRT is a highly polymorphic protein with 10 
transmembrane domains consisting of 424 amino acids located on chromosome 7 
(PF3D7_0709000). Mutations in the pfcrt gene, specifically K76T, were found to play a role 
in chloroquine resistance in vitro and were also associated with clinical resistance in field 
studies across endemic regions (Fidock et al., 2000, Carlton et al., 2001, Bray et al., 2005, 
Picot et al., 2009). The switch from the positively charged lysine residue to the uncharged 
threonine residue enables protonated-chloroquine to be effluxed from the digestive vacuole 
(Lehane and Kirk, 2008, Martin and Kirk, 2004, Martin et al., 2009). The PfCRT K76T 
mutation is found in almost all chloroquine-resistant isolates, regardless of geographic 
location. 
 
Mutations in the multidrug transporter, PfMDR1, have also been associated with decreased 
susceptibility to chloroquine. PfMDR1 is a transporter in the ATP-binding cassette (ABC) 
transporter family consisting of 1419 amino acids on chromosome 5 (PF3D7_0523000) 
encoding a predicted 12 transmembrane domain protein. The homologous protein in 
mammalian cells is often referred to as P-glycoprotein (P-gp). Several studies have found an 
N86Y mutation in pfmdr1 that, when jointly present with PfCRT mutations, decreases 
parasite susceptibility to chloroquine (Foote et al., 1990, Babiker et al., 2001, Sa et al., 2009). 
Molecular studies have found that editing the pfmdr1 N86Y mutation into chloroquine-







However, additional work has shown that the N86Y mutation alone is not enough to confer 
chloroquine resistance (Djimde et al., 2001, Valderramos and Fidock, 2006) and further work 
is needed to assess the role of the pfmdr1-N86Y mutation in modulating chloroquine 
resistance in the field.  
 
Recent studies have found that the PfCRT K76T mutation has reverted to a majority of 
wildtype after removal of chloroquine pressure in some countries in Africa (Mohammed et 
al., 2013, Mwanza et al., 2016) and China (Wang et al., 2005). However, the mutation 
remains at some level nearly everywhere (SEA, South America, and Africa). Residual 
persistence at low levels could be due to the continued use of chloroquine for symptomatic 
relief or for the treatment of presumed P. vivax. An alternative reason could be that the 
mutation is fixed in a population, because the sensitive parasites without the mutation did not 
survive (Cowell and Winzeler, 2019). Notably, studies by Pelleau et al. in French Guiana 
have found that in spite of the fixed PfCRT K76T allele, parasites are again chloroquine 
susceptible and they have identified a PfCRT C350R mutation that associates with the 
chloroquine-sensitive phenotype (Pelleau et al., 2015). This study also found that the PfCRT 
C350R mutation decreased parasite susceptibility to piperaquine in vitro. They hypothesized 
that this mutation could be due to increased pressure from piperaquine, as DHA-PPQ is 
available in the region (Pelleau et al., 2015). 
 
In the context of chloroquine-resistance, mutations in PfCRT and PfMDR1 have both served 
as molecular markers of potential resistance, with PfCRT having the causal role in resistance. 
It was on this genetic background that mefloquine was introduced as a monotherapy and later 
as a partner of ACTs in Cambodia. 
 
1.4.2 Mefloquine: monotherapy and ACT 
Mefloquine is an aryl amino alcohol that was synthesized as a derivative of quinine at the 
Walter Reed Army Institute of Research (WRAIR) shortly after the Vietnam War during the 
push to discover new antimalarials in the 1960s-1970s (Arrow, 2004). Five years after its 
introduction in SEA, mefloquine resistance was reported in Thailand in the early 1980s 
(Nosten et al., 1991, Boudreau et al., 1982).  
 
Resistance to mefloquine has been shown to be the result of a pfmdr1 copy number variation 
(Figure 1.7). Rather than a point mutation as observed in chloroquine resistance, mefloquine 







1988a, Cowman et al., 1994, Reed et al., 2000, Lim et al., 2009, Price et al., 2004). 
Furthermore, increasing the number of pfmdr1copies, increases the level of resistance in vitro 
(Sidhu et al., 2006). The pfmdr1 amplification may also result in cross-resistance to the 
partner drug, lumefantrine, which is another aryl amino alcohol. Some studies have found an 
association of artemether-lumefantrine treatment failures and increased pfmdr1 copy numbers 
(Price et al., 2006). However, increased pfmdr1 copy numbers are infrequent in African 
countries, where artemether-lumefantrine is often used (Cheeseman et al., 2016). 
 
As widespread AS-MQ treatment failures occurred throughout SEA and countries were 
switching to DHA-PPQ, the list of molecular markers of drug resistance continued to grow. 
In addition to monitoring PfCRT mutations, studies began tracking PfMDR1 mutations and 
copy numbers. 
 
1.4.3 DHA-PPQ: piperaquine resistance in concert with decreased artemisinin 
susceptibility 
In 2008, decreased susceptibility of parasites to artemisinin in vivo was reported in Western 
Cambodia (Dondorp et al., 2009, Noedl et al., 2008). Over the next couple of years, 
decreased artemisinin susceptibility was documented at other sites in Cambodia, Thailand, 
Vietnam, Myanmar, Laos, and China (Fairhurst and Dondorp, 2016). 
 
As briefly mentioned in the previous sections of this introduction, both the mechanism of 
action of artemisinin and the mechanism of artemisinin resistance have sparked continued 
debate and the discussion is ongoing. Multiple genome-wide association studies (GWAS) 
have been conducted to uncover molecular markers that associate with decreased artemisinin 
susceptibility in vivo and in vitro (Cheeseman et al., 2012, Takala-Harrison et al., 2013). 
Work by Ariey et al. identified mutations in the propeller domain of a kelch protein (K13) 
that associated with artemisinin resistance in vivo and in vitro (Ariey et al., 2014). The 
Tracking Resistance to Artemisinin Collaboration (TRAC) study further validated these 
studies in a multi-country collaboration that confirmed the association of several K13 
mutations and decreased artemisinin susceptibility in vivo (Ashley et al., 2014). Genome 
editing studies also found an association between the K13 mutations and artemisinin 
resistance in vitro, as measured by a “ring-stage assay” that involves a short pulse of DHA on 
early ring stage parasites (Ghorbal et al., 2014, Straimer et al., 2015, Witkowski et al., 2013). 
Previous studies identified five K13 mutations that associated with the artemisinin-resistant 







al., 2015) and a more recent study by the Worldwide Antimalarial Research Network 
(WWARN) identified 20 K13 mutations (WWARN, 2019).  
 
The K13 protein (PF3D7_1343700) is postulated to serve a role in the parasite’s response to 
oxidative stress through multiple protein-protein interactions (Ariey and Menard, 2019). The 
P. falciparum K13 protein is homologous to the human KLHL12 and KLHL2 proteins and 
Keap1, which function in ubiquitin-based degradation of proteins and oxidative stress 
responses, respectively (Dhanoa et al., 2013, Itoh et al., 1999). Recent findings have also 
raised the intriguing postulation that P. falciparum gametocytogenesis may be improved by 
certain K13 mutations, and thus promote transmission to mosquitoes as a parasite survival 
mechanism (Ashley et al., 2014, Lozano et al., 2018). 
 
It should be emphasized there are multiple studies that have observed artemisinin-resistant 
phenotypes in the absence of K13 mutations, suggesting additional molecular determinants of 
resistance exist, and thus further work is necessary to determine if and how these may impact 
artemisinin resistance (Demas et al., 2018, Sa et al., 2018, Sutherland, 2017, Su et al., 2019). 
 
1.4.4 Piperaquine resistance 
Less than four years after the reports of decreased artemisinin susceptibility, DHA-PPQ 
treatment failures were reported in Western Cambodia (Spring et al., 2015, Amaratunga et 
al., 2016). Most recently, clinical studies have demonstrated very high treatment failures with 
an average of 50% treatment failures in parts of Cambodia, Vietnam, and Thailand (van der 
Pluijm et al., 2019).  
 
Multiple GWAS studies were performed to identify potential molecular markers of 
piperaquine resistance. A GWAS of 297 Cambodian isolates revealed single-nucleotide 
polymorphisms (SNPs) on chromosome 13 in genes that encode a putative exonuclease (exo-
E415G) (PF3D7_1362500) and a putative mitochondrial carrier protein (mcp-N252D) 
(PF3D7_1368700) that associate with reduced PPQ susceptibility in vitro and DHA-PPQ 
failures in patients (Amato et al., 2017). Additionally, a copy number variation (CNV) in the 
plasmepsin 2 (PM2) and plasmepsin 3 (PM3) genes on chromosome 14 associated with 
reduced susceptibility to piperaquine (Witkowski et al., 2017). Specifically, increased copies 
of PM2-3 are associated with increased parasite survival under piperaquine pressure. Little is 
known about the putative exonuclease protein and mitochondrial carrier proteins on 







and PM3 in hemoglobin degradation in the parasite’s digestive vacuole (Banerjee et al., 
2002).  
 
More recent studies have also demonstrated a role for mutations in the familiar transporter, 
PfCRT. Drug pressure experiments conducted over eight years ago identified a PfCRT-
C101F mutation and a deamplification of pfmdr1 in parasites that had been pressured with 
piperaquine in vitro. Genome editing of the C101F mutation in parasites decreased parasite 
susceptibility to piperaquine, but increased sensitivity to chloroquine (Dhingra et al., 2017). 
Another recent study identified three mutations in culture-adapted isolates from Cambodia 
that exhibited ex vivo piperaquine resistance: PfCRT H97Y; PfCRT M343L; and PfCRT 
G353V (Duru et al., 2015). Genome editing of these three mutations and an additional 
mutation observed in patient isolates, PfCRT F145I, was found to confer piperaquine 
resistance in vitro (Ross et al., 2018a). Additional GWAS studies have continued to find 
these mutations associated with piperaquine failures in patients and have also reported two 
new mutations associated with PPQ-resistance, PfCRT T93S and PfCRT I218F (Hamilton et 
al., 2019). These piperaquine resistance-associated mutations are all on the PfCRT K76T 
genetic background and the parasites still demonstrated reduced chloroquine susceptibility in 
ex vivo and in vitro survival assays (Amaratunga et al., 2016). 
 
The piperaquine-resistant parasites isolated from Cambodia have single copies of pfmdr1, 
indicating that the parasite population reverted back to a single copy of pfmdr1 after the 
removal of mefloquine pressure from the region. One hypothesis is that piperaquine gains 
access to the digestive vacuole through PfMDR1 (Witkowski et al., 2017), so reducing 
pfmdr1 expression could reduce the amount of piperaquine in the digestive vacuole. It is also 
possible that the pfmdr1 copy number expansion results in a fitness cost, so in the absence of 
mefloquine pressure, there is no need (and is metabolically disadvantageous) for the parasites 
to maintain it. 
 
It is hypothesized that increased tolerance to artemisinin facilitated the emergence of 
piperaquine-resistant parasites. This is further supported by the genetic background of the 
parasites, as the majority piperaquine-resistant parasites have K13-C580Y mutations 
(Amaratunga et al., 2016, van der Pluijm et al., 2019). Out of 2465 parasite genomes, 82% of 
parasites that highly associated with the piperaquine-resistant phenotype were K13-C580Y, 








Several studies have hypothesized that piperaquine (like chloroquine and the other ACT 
partner drugs) interferes with heme detoxification and/or hemoglobin degradation. This is 
supported by transmission electron microscopy (TEM) studies by Sachanonta et al. that show 
distended digestive vacuoles with undigested hemoglobin and fewer hemozoin crystals than 
the untreated control after treatment with piperaquine (Figure 1.9) (Sachanonta et al., 2011). 
It is possible that increased PM2-3 copy numbers could enable the parasite to circumvent any 
inhibition caused by the drug. In a similar fashion to the mechanism of chloroquine 





Figure 1. 9. Transmission electron microscopy of P. falciparum infected erythrocytes. A.) Low-
power TEM of the control sample (no drug) in the trophozoite stage B.) Low-power TEM of treated 
sample after 4-hour exposure to piperaquine in the trophozoite stage. The asterisks (*) indicate 
undigested hemoglobin in the distended digestive vacuole. Abbreviations indicate: nuclease (N), food 
vacuole (FV), and hemozoin crystal (H). The images in this figure were modified and reproduced 






















1.5 Specific aims 
The purpose of my thesis work has been to elucidate the molecular mechanisms of 
piperaquine resistance. This dissertation has utilized molecular genomics, in vitro gene 
editing, and drug-pressure experiments to provide new insight into piperaquine resistance in 
P. falciparum. 
 
In the first research chapter (Chapter 3), I sought to design a high-throughput assay that could 
be utilized for analyzing copy number amplifications of the hemoglobin degrading proteases, 
plasmepsin 2 and plasmepsin 3, using low quantities of genomic DNA. I developed methods 
to detect and monitor plasmepsin 2-3 copy numbers using both traditional PCR and qPCR 
methods. I then examined the role of the PM2-3 amplification in piperaquine resistance by 
generating and transfecting a plasmid for overexpressing the PM2-3 enzymes.   
 
In the second research chapter (Chapter 4), I aimed to assess the effects of the putative 
exonuclease (PF3D7_1362500) and mitochondrial carrier protein (PF3D7_1368700) SNPs 
(exo-E415G and mcp-N252D) on susceptibility to piperaquine and other commonly used 
antimalarial drugs. I used CRISPR-Cas9 genome editing to introduce the wildtype and 
mutant SNPs into the lab strain Dd2 and evaluate the phenotypes of piperaquine response in 
these transformants. 
 
In the final research chapter (Chapter 5), I aimed to select for a piperaquine-resistant 
phenotype in vitro using a potential hypermutator P. falciparum parasite line. After 
generating piperaquine-resistant parasites, I used whole genome sequencing to compare 
genetic differences between the parental parasites and the piperaquine-pressured parasites. 
Through this analysis, I identify gene candidates that may play a role in the piperaquine-















Chapter 2:  General Methodology 
 
2.1 Cultivation of Plasmodium falciparum  
Parasites were cultivated in vitro following the methods developed by Trager and Jensen with 
minor modifications (Trager and Jensen, 1976). All cell culture work was conducted in a 
sterile biological safety cabinet and the mandatory safety precautions of each institution were 
followed (United States, Biosafety Level-2/BSL-2; United Kingdom, Containment Level-
3/CL3). 
 
2.1.1 In vitro culture maintenance 
Asexual stages of P. falciparum isolates adapted for cell culture were grown in complete 
media (CM) consisting of Roswell Park Memorial Institute medium (RPMI)-1640 (Thermo 
Fisher Scientific) supplemented with 0.5-1% Albumax II (a serum substitute), GlutaMAX 
(Gibco, L-glutamine substitute), HEPES (20 mM, pH 7.0), 2.0 g/L sodium bicarbonate, and 
gentamicin (25 µg/ml) with 2-3% O+ human erythrocytes, more commonly referred to as red 
blood cells (RBCs). All parasite lines used in this study were adapted for continuous culture 
in Albumax II, a human serum substitute, but when specified, field isolates were also 
supplemented with 1.25-5% pooled human AB serum (Innovative Research). Unless noted 
otherwise, parasites were maintained in routine continuous culture at 0.5-2% parasitemia in 
CM at 2-3% hematocrit and stored at 37°C in non-vented tissue culture flasks (Corning) after 
addition of mixed gas containing 1% O2, 3% CO2, and 96% N2.  
 
2.1.2 Determination of parasite culture hematocrit and parasitemia  
Hematocrit is defined as the proportion (% volume) of red blood cells per volume of blood or 
culture. For the purposes of this thesis and as widely standardized for in vitro cultivation of 
P. falciparum (Trager and Jensen, 1976), hematocrits ranged from 1-5% depending on the 
parasite line and experimental procedure. P. falciparum can invade and grow in all human 
blood types, but O+ RBCs were used preferentially due to their compatibility with any serum 
type (Jensen, 1988, Schuster, 2002). Leukocyte-depleted RBCs were obtained from healthy 
O+ donors weekly (Interstate Blood Bank, USA or National Health Service (NHS), UK) and 
added fresh to cultures at least once per week. Before use in cultures, the blood was aliquoted 
and washed twice with incomplete media (ICM) (RPMI-1640, with no additional 
supplements) by centrifugation at 3000 RPM for 10 minutes, without brake to ensure 







of ICM was aspirated and CM was added to dilute the packed cells to 50% hematocrit. 
Aliquots were stored at 4°C and used to maintain cultures for up to two weeks. When 
specified, 10% citrate-phosphate-dextrose-adenine (CPDA), an anticoagulant/whole blood 
preservative was added to the 50% hematocrit aliquot to prolong RBC integrity in long-term 
culture experiments (see sections 2.3-2.4).  
 
Parasitemia denotes the quantification of parasites in the blood. Parasites can be measured in 
the blood using light microscopy or flow cytometry. The methods used for this study were 
based on the degree of quantitative accuracy required. Flow cytometry was utilized when 
more accurate parasite counts were necessary or to detect very low parasitemias (see section 
2.7 on flow cytometry). Light microscopy was preferred for day-to-day culturing and 
accurate staging of the 48-hour P. falciparum life cycle. 
 
To view and quantify P. falciparum parasitemia in cell cultures, medium was aspirated from 
the culture and ~1.5-2 µl of the pRBCs were spread on a glass microscope slide to create a 
thin film or “smear” of blood. Thin smears of every culture were made at least once weekly 
to quantify the percent parasitemia. The blood smears were fixed in 100% methanol, stained 
with 10% Giemsa (Sigma-Aldrich) for 10 minutes, then viewed with the 100X objective 
under oil immersion. Components in the Giemsa staining solution attach to DNA, making the 
stain particularly useful for detecting malaria parasites in cell culture, since their RBC hosts 
are devoid of a nucleus. Thus, any Giemsa stained cells on the blood smear can be viewed 
and counted as a parasite. (Note this restricted to in vitro parasite cultures or other samples 
depleted of leukocytes; in patient blood, leukocytes and any circulating reticulocytes 
(younger RBCs) contain DNA and would stain positive as well.) Parasitemia was calculated 
by dividing the number of parasite-infected red blood cells (iRBCs) by the total number of 
RBCs (iRBCs) + uninfected RBCs) times one hundred (iRBCs/total RBCs*100= % 
parasitemia). For each smear, at least 500 cells were counted to obtain the % parasitemia. 
 
Parasitemias of continuous cultures ranged between 0.5-5%, depending on the parasite line 
and experiment. For specific experimental protocols, parasitemias were grown above 5%, but 
culture medium was changed at least once daily to avoid nutrient depletion and stress. High 
parasitemias and other environmental conditions of in vitro cultures have been shown to 
stress asexual stage parasites and promote the irreversible conversion of asexual stages to 
gametocytes, the non-replicating, sexual stage of parasites (Carter and Miller, 1979). 







the more frequent medium changes and blood replenishment occurred to prevent increased 
gametocyte production. 
 
2.1.3 Thawing and cryopreservation of parasites 
To minimize effects from long-term in vitro cultivation, parasites were grown in culture for 
up to 2-3 months then discarded after a fresh aliquot of the isolate was thawed. Parasite lines 
adapted for continuous culture were cryopreserved as described below and stored in a -80°C 
freezer or in liquid nitrogen. Frozen cryovials were thawed for 2-3 minutes in a 37°C 
incubator. All thawing solutions were warmed to 37°C before use. After thawing, the volume 
of the isolate was measured and transferred to a 50 mL centrifuge tube. Slowly, 0.1x the 
volume of 12% NaCl was added dropwise to the culture with gentle, intermittent 
shaking/swirling between drops. The tube was left standing at room temperature for 5 
minutes. Next, 10x the volume of 1.6% NaCl was added to the isolate dropwise, while 
shaking/swirling. The mixture was left at room temperature undisturbed for an additional 5 
minutes. Then the tube was centrifuged at 1500 RPM, room temperature for 5 minutes. The 
supernatant was aspirated and 10x the volume of 0.9% NaCl/0.2% dextrose was added 
dropwise to the pellet while slowly swirling the tube. The culture was centrifuged as before 
at 1500 RPM for 5 minutes. After aspirating the remaining thawing solution, the pellet was 
resuspended in pre-warmed CM and transferred to a culture flask and fresh RBCs were 
added, depending on the volume of thawed blood, for a final hematocrit of 1-3%. 
 
Cryopreservation of the parasites was performed as soon as the cultures contained at least 1-
2% of ring-stage parasites. Such ring-stage parasitemia is necessary because the method for 
freezing-down the cultures only preserves ring-stages. The culture was centrifuged at 2500 
RPM for 5 minutes. The medium was aspirated and the volume of the packed culture was 
estimated and 1.66x the pellet volume of pre-warmed Glycerolyte 57 (Fenwal) solution was 
added to the pellet dropwise, with gentle shaking. The solution was transferred to a labelled 
cryovial (up to 1 mL per vial) and stored in a -80°C freezer or liquid nitrogen. 
 
2.1.4 Synchronization of parasites: sorbitol and Percoll gradients 
In P. falciparum-infected patients, the populations of parasite stages may be asynchronous or 
synchronous (Hawking et al., 1968, Hawking, 1970, Garcia et al., 2001). Ring stages 
predominate in circulation because mature trophozoite and schizont stages are sequester in 







better than mature stages during cryopreservation, so that freshly established cultures tend to 
be synchronous, but these will become asynchronous after several life cycles (Trager and 
Jensen, 1976, Haynes et al., 1976). For many experimental procedures, stage-specificity is 
crucial, so two main methods of synchronization were employed by this study: sorbitol lysis 
and Percoll gradient separation. 
 
2.1.5 Sorbitol synchronization 
Sorbitol synchronization was used to obtain ring-stage populations of parasites (Lambros and 
Vanderberg, 1979). A stock solution of 5% D-sorbitol was prepared in deionized water and 
filtered (0.2 µm).  Cultures containing mostly rings (less than 10-12 hours post-invasion) 
were centrifuged at 2500 RPM for 5 minutes, medium aspirated and the volume of the 
pellets/pRBCs was measured. The pellets were resuspended in10x the pellet volume of pre-
warmed 5% sorbitol, vigorously mixed and left at 37°C for 10-15 minutes. After incubation, 
the tubes were centrifuged at 2500 RPM for 5 minutes and resuspended in 10x volume of 
ICM. Cells were again centrifuged at 2500 RPM for 5 minutes, media was aspirated and cells 
were resuspended in CM to maintain the culture volume at 2-3% hematocrit. 
 
2.1.6 Percoll gradients for parasite synchronization 
Percoll gradients were used to separate late-stage parasites from early stages (Kramer et al., 
1982, Stanley et al., 1982). Percoll enrichment was performed using either a 35%/65% 
gradient when at the National Institutes of Health (USA) or using a 63% single gradient when 
at the Wellcome Sanger Institute (UK). Variations in the protocols at each institute were 
based only on the availability of resources at each location and no differences were observed 
in experimental results from either Percoll procedure. 
 
For the 35%/65% gradient procedure (Miao and Cui, 2011), a 90% stock of Percoll (GE 
Lifesciences) was made by diluting 9 volumes of Percoll in 1 volume of 10X PBS. The 90% 
Percoll stock was kept at 4°C for up to 1 month before making a fresh stock. On the day of 
synchronization, a solution of 7.5 U/mL heparin (Sigma) in ICM, referred to as heparinized 
RPMI, was prepared and warmed at 37°C. Aliquots of 35% and 65% Percoll were made by 
diluting the pre-warmed 90% Percoll stock with heparinized RPMI. Cultures to be 
synchronized were centrifuged at 2500 RPM for 5 minutes and resuspended in heparinized 
RPMI and left standing at 37°C for 15 minutes. While parasites were incubating, Percoll 







then layering 35% Percoll on top, being careful not to create any bubbles or disturb the 
separation between the two solutions. The culture was then added on top of the 35% layer 
and a distinct separation between the culture and the Percoll layers was observed. The 
gradients were layered in 3’s with 3 mL of 65% Percoll, followed by 3 mL of 35% Percoll, 
and 3 mL of culture consisting of ~300 µL packed RBCs. After adding all three layers the 
tubes were centrifuged for 15 minutes at 1000g with no brake. After centrifugation the top 
layer containing debris was discarded (see Figure 2.1), the next layer containing the 
enriched, mature parasitized RBCs was saved and added to a tube containing 10 mL of pre-
warmed ICM. The bottom pellet containing early stages and uRBCs was washed in 10 mL of 
ICM or discarded as necessary for the particular experiment. The tubes were centrifuged at 
1000g for 5 minutes then resuspended in the desired volume of CM and/or RBCs. 
 
The 63% Percoll procedure was performed by diluting Percoll to 63% with ICM and 10X 
PBS. This protocol does not use heparin. The culture was centrifuged at 800g for 5 minutes 
while 5-6 mL of pre-warmed 63% Percoll was added to 15 mL tubes. After centrifugation, 
the pellet (at least 1-1.5 mL of pRBCs) was resuspended in 5 mL of CM and layered on top 
of the 63% Percoll. The gradient was centrifuged at 1200g for 12 minutes, 0 break. After 
centrifugation, the layers were treated the same as for the aforementioned 35%/65% gradient, 
with the top debris layer aspirated and discarded, the middle late-stage layer saved and 
bottom pellet saved, if desired. The separated stages were washed in 10 mL of prewarmed 
CM by centrifugation at 800g for 5 minutes and resuspended in the volume of CM and RBCs 










Figure 2. 1. Schematic of Percoll gradients. A.) Schematic of a 35%/65% Percoll gradient. The 
topmost cell suspension layer is aspirated, the distinct band in the middle between the 35% and 65% 
layers are enriched late-stage parasites, which can be seen in the Giemsa smear. The bottom pellet 
contains uninfected RBCs (uRBCs) and early-stage parasites. B.) Schematic of a 63% Percoll 
gradient. 
 
2.2 Parasite lines 
2.2.1 Cambodian field isolates 
The patient isolates used for this study were obtained from cohort studies performed from 
September 2012 through December 2013 in three Cambodian provinces (ClinicalTrials.gov 
number, NCT01736319) (Amaratunga et al., 2016). All samples were collected from patients 
aged 2-65 years with acute, uncomplicated P. falciparum malaria. The isolates were adapted 
to in vitro parasite culture (Amaratunga et al., 2016) using previously published methods 
(Trager and Jensen, 1976, Haynes et al., 1976) and cultivated with the same culture 
conditions used for established parasite lab lines (see Section 2.1). The field isolates used 
during the course of this thesis research are summarized in Table 1.   
 
The isolates referred to as piperaquine-resistant (PPQ-R) in this study are from the Western 
Cambodian province of Pursat or the Northwestern province of Preah Vihear. Isolates 
referred to as piperaquine-sensitive (PPQ-S) are from the Eastern province of Ratanakiri or 
Preah Vihear (Figure 2.2). Since PPQ-S parasites may recrudesce for various reasons and not 
all PPQ-R infections will recrudesce in immune patients, final categorization of lines as PPQ-
R or PPQ-S was established by parasite susceptibility to piperaquine as determined in ex 
vivo, in vitro, and piperaquine survival assays (PSAs) (Duru et al., 2015, Amaratunga et al., 







genotyping msp1, msp2, and glurp, the genetic markers used to distinguish recurrent 
infections from new infections (Snounou and Beck, 1998). Using both genotypic and 
phenotypic data, we were then further able to distinguish both the PPQ-R and PPQ-S 
populations of parasites (Table 2.1). The parasites referred to as PPQ-R have non-
synonymous single nucleotide polymorphisms (SNPs) in the genes encoding the following 
proteins: K13 C580Y, MCP-N252D, exo-E415G, and several contain mutations in PfCRT 
including H97Y, M343L, and A366T. They also have two or more copies of plasmepsin 2 
and plasmepsin 3 and one copy of pfmdr1 (Table 2.1). In contrast the PPQ-S group of 
parasites are wildtype for: K13 C580, MCP-N252, exo-E415, and they have a single copy of 
plasmepsin 2 and plasmepsin 3; similarly, they have one copy of pfmdr1 (Table 2.1) but 
none of the PfCRT mutations noted in the PPQ-R parasites (Amaratunga et al., 2016). Details 
of these lines were published after whole genome sequencing in Amato et al. 2017 (Amato et 
al., 2017).  
 
The Cambodian field isolate, PH-0212-C, was also used in this study and detailed in Table 
2.1. It was obtained from Pursat, Cambodia in 2010 (Amaratunga et al., 2012) 
ClinicalTrials.gov, number NCT00341003) and has an intermediate resistance to PPQ and 
some of the mutations present in the isolates from 2012-2013 (Table 2.1). 
 











Figure 2. 2. Map of Cambodia highlighting the three provinces where samples were collected 
during clinical trials. From West to East, Pursat (red) is identified as “KH1” in the NIH sample 
identification code, Preah Vihear (blue) is “KH2,” and Ratanakiri (green) is “KH3.” 
 
2.2.2 Long-term laboratory-adapted parasite lines  
The laboratory strains (lab strains) used in this study are differentiated from the 
contemporary Cambodian isolates in that the lab lines are widely used parasite lines that have 
been maintained in vitro for many years. The lab strains, 3D7 and Dd2, were used for the 
purposes of this research and are included in Table 2.1.  
 
The 3D7 parasite is a clone of NF54, which originated from a patient living near the Schiphol 
Airport, Amsterdam in the Netherlands, who had never been abroad (Ponnudurai et al., 1981, 
Walliker et al., 1987). The exact origin of the NF54 isolate is still unknown, but genetic 
studies suggest that it is from Africa (Preston et al., 2014, Su, 2014). 
 
The Dd2 parasite is a Southeast Asian line derived as a clone from the W2-MEF line (a 
mefloquine pressured clone of W2) (Oduola et al., 1988a) which was obtained from an 













2.3 Transfection of P. falciparum field isolates and laboratory lines 
 
2.3.1 Transfection of P. falciparum using DNA-loaded red blood cells 
Transfections of pre-loaded RBCs were performed using previously published methods (Wu 
et al., 1995, Deitsch et al., 2001) and based on the findings that P. falciparum takes up pre-
loaded DNA from within its host RBC. Approximately 350 µL of 50% uninfected RBCs 
(uRBCs) or 175 µL of packed RBCs were aliquoted for each transfection and spun down in 
15 mL centrifuge tubes for 5 minutes at 2500 RPM and washed twice with 5 mL of cytomix. 
During the washing steps, late-stage parasites (schizonts) to be transfected were enriched 
from cultures by Percoll gradient (Section 2.1.4) then gassed and incubated at 37°C. After 
the final wash of uRBCs, all cytomix was aspirated from the pellet and 50-100 µg of plasmid 
DNA in cytomix was added to each pellet for a final volume of 400 µL per tube. The 
contents of each 15 mL tube were transferred to 0.2 cm cuvettes and electroporated using a 
Bio-Rad GenePulser Xcell (Bio-Rad) set for 0.310 kV, 975 µFD, infinity resistance. Time 
constants were monitored with the desired range between 10-14 ms. Only 1-2 cuvettes were 
electroporated at a time and immediately following the pulse, contents were transferred to 15 
mL culture tubes with 10 mL of CM and were incubated in the cell culture hood or at 37°C 
for 15-30 minutes. After recovering, the tubes of electroporated RBCs were centrifuged at 
2500 RPM for 5 minutes and supernatant was aspirated. RBC lysis is expected in the 
supernatant, so it appears redder in color than normal. The cells were washed with ICM and 
then resuspended in ~5 mL CM. The Percoll enriched parasites (~30-50 µL pellet) were 
resuspended in CM for a final concentration of ~10 µL pRBCs/mL and 1 mL was added to 
each transfection for a final 2-3% hematocrit culture. Cultures were gassed and incubated at 
37°C. The next day (day 1 post-transfection), all transfections were smeared to ensure 
parasitemia was not too high (>4-5%) or too low (unobservable or <0.5%). If the parasitemia 
was too high, the cultures were cut and if parasitemia was too low, the cultures were watched 
closely or discarded. On day 1 or day 2 post-transfection, parasites were selected with drug-
supplemented CM, containing either 1-10 nM WR99210 (Jacobus Pharmaceuticals) or 2 
µg/mL blasticidin (BSD) (Thermo-Fisher Scientific) depending on the plasmid used and 
parasite transfected. The drug concentrations used for selection were based on the IC50 values 
for the particular drug for each distinct parasite line. Optimally, parasites were selected with 








Transfections were smeared daily until they were observed to die off due to drug pressure 
(about 4-6 days post-transfection, depending on the drug). After that point, transfections were 
smeared only 1-2 times per week until around Day 18. If field isolates were not up by days 
50-60, they were discarded. 
 
Due to the challenges associated with the transfection of field isolates, variations of this 
general transfection protocol were performed to enhance transfection efficiency and are 
detailed within each data chapter when relevant.  
 
2.3.2 Transfection of ring stage P. falciparum 
Transfection of ring stage parasites was performed similar to DNA-loaded RBCs (section 
2.3.1). In ring stage transfections, ring stage parasites (iRBCs) are directly electroporated. 
This procedure was predominantly performed using lab lines (Dd2), rather than field isolates, 
because this method causes direct stress to the parasites upon electroporation and lab lines 
are well-adapted to culture conditions and procedures. 
 
Ring-stage parasites were collected at 5-6% ring-stage parasitemia, with earlier rings 
preferred. For every transfection, 3-5 mL of a culture at 2-3% hematocrit and 5-6% ring-
stage parasitemia was centrifuged at 2500 RPM for 5 minutes and resuspended and washed 
in 5 mL cytomix. After the wash, 50-100 µg of plasmid DNA was added to each 15 mL tube 
in a total volume of 400 µL of cytomix and transferred to a 0.2 cm cuvette and electroporated 
under the same conditions described above (section 2.3.1). Immediately following 
electroporation, transfections were transferred to 15 mL tubes containing 10 mL of 
prewarmed CM then left in the 37°C incubator to recover for 1 hour. After recovery, 
transfections were centrifuged and washed in ICM at 2000 RPM for 5 minutes. Cultures were 
resuspended in medium for a final 2-3% hematocrit, gassed, and incubated overnight. As 
detailed above (2.3.1), cultures were smeared the following day and cut if parasitemias were 
too high. Drug was added on Day 1 post-transfection, using 1-5 nM WR99210 (Jacobus 
Pharmaceuticals) or 2 µg/mL blasticidin (BSD) (Thermo-Fisher Scientific) depending on the 
plasmid and parasite transfected. 
 
Ring-stage transfections were supplemented with fresh blood containing 10% citrate-
phosphate-dextrose-adenine (CPDA), an anticoagulant/whole blood preservative used to 
prolong RBC integrity since lab lines could take approximately 15-25 days to come up. If 







2.4 Parasite cloning by limiting dilution 
To obtain isogenic parasite lines after positive transfections were confirmed, the bulk cultures 
were cloned by limiting dilution to obtain individual parasites (Rosario, 1981). Samples were 
plated in 96-well plates at 0.6 parasites per well and 1% hematocrit. For all cloning 
procedures, the cloning plates were set up in freshly washed blood prepared with 10% 
CPDA. Field isolates were plated at 0.8-1.2 parasites/well at 1% hematocrit in conditioned 
medium due to their slower growth rate. Conditioned medium was prepared by filtering spent 
medium from the specific isolate and diluting 1:2 or 1:4 with fresh CM. Conditioned medium 
was stored at 4°C for up to 3 days then discarded. Weekly, 0.5% fresh RBCs and CM or 
conditioned CM were added to each plate. Around days 17-18, plates were screened for 
parasite growth using a 1X SYBR Green I solution in lysis buffer. This technique takes 
advantage of the properties of SYBR to fluoresce upon intercalating between DNA bases. 
Since only parasitized RBCs contain DNA, only wells that contain living parasites will 
produce a measurable level of fluorescence when exposed to SYBR Green I.  Aliquots from 
the cloning plates (~20 µl) were resuspended thoroughly in the lysis buffer solution 
(consisting of 10 mM Tris-HCl, 5 mM EDTA, 0.1% w/v saponin, and 1% v/v Triton X-100) 
and 1X SYBR Green I (Invitrogen, 10,000x stock) and incubated in the dark at 37°C for 20 
minutes then read on a microplate reader (FLUOstar Omega) using a 485/535 nm excitation 
and emission filter. Positive wells with values higher than the background wells containing 
CM and RBCs-only were screened by smear. If parasites were observed, the clones were 
expanded and saved for genomic DNA (gDNA) extraction, cryopreservation, and continuous 
cultures were maintained for functional assays. 
 
2.5 Saponin lysis and genomic DNA extraction from cultivated parasites 
Parasites were collected for genomic DNA using a saponin solution to selectively 
permeabilize infected RBC membranes to remove host cell hemoglobin content.  When 
cultures reached at least 2% parasitemia of late stages (trophozoites and schizonts) at 2-3% 
hematocrit in 10 mL-12 mL volume, cultures were spun down at 2500 RPM for 5 minutes 
and resuspended in 0.15% saponin (Sigma-Aldrich) in 1X phosphate buffered saline solution 
(PBS). Saponin solutions were made fresh on the day of the experiment from 1% or 10% 
stocks stored at 4°C for several months. Tubes were left to rest for 3-5 minutes at room 
temperature then were centrifuged at 4000 RPM, washed at least twice with 1X PBS, until 
the sample turned from red to a brownish/black color and the pellets were stored at -20°C or 







extract genomic DNA from thawed saponin pellets. DNA was eluted using the kit buffer 
(buffer AE) or water, depending on the experimental procedure. 
 
2.6 In vitro parasite survival assays 
 
2.6.1 Antimalarial drug preparation 
Antimalarial drugs were obtained from the Worldwide Antimalarial Resistance Network 
(WWARN) and Sigma. Stocks were prepared according to solubility as follows: piperaquine 
in 0.5% lactic acid in water; dihydroartemisinin (DHA) and lumefantrine (LUM) in dimethyl 
sulfoxide (DMSO); and chloroquine (CQ) and mefloquine (MQ) in water.  
 
2.6.2 Drug sensitivity assays 
The in vitro susceptibility of parasites to several commonly used antimalarial drugs was 
assessed using standard 72-hour dose-response SYBR Green I fluorescence-based assays 
(Bacon et al., 2007, Smilkstein et al., 2004). Drug stocks were prepared in CM at 2x the 
desired concentration and 1:2 serial dilutions were made by adding 50 µl per well in 
duplicate in a 96-well plate (Figure 2.3). The second to last wells in column 11 served as a 
no drug control (CM only) to measure maximum parasite growth and the last wells in column 
12 contained RBCs only (1.5% hematocrit) to measure background fluorescence of the RBCs 
(Figure 2.3). Synchronous ring-stage parasites (0-10 hours) were added (50 µl per well at 3% 
hematocrit) to obtain a 1% parasitemia and 1.5% hematocrit in a final volume of 100 µl per 
well. The concentrations for each drug were: PPQ and MQ: 400 nM; CQ: 10 µM; DHA: 100-
400 nM; and LUM: 100 nM. The drug assay plates were incubated in a chamber with mixed 
gas at 37°C  for 72 hours. After the incubation period, parasites were lysed using a SYBR 
Green I solution. A 2x SYBR-lysis buffer solution was prepared by adding 2x SYBR (added 
fresh from a 10,000x stock) to a 2x solution of lysis buffer (20 mM Tris, pH 7.5, 5 mM 
EDTA, 0.016% w/v saponin, 0.08% v/v Triton X-100). After 72 hours, an equal volume of 
the SYBR-lysis buffer solution (100 µL) was added directly to the volume in the drug assay 
plates and mixed thoroughly. Plates were incubated in the dark at 37°C for 20 minutes then 
measured on a microplate reader (FLUOstar Omega) using a 485/535 nm excitation and 
emission filter. For all experiments in this study, the half maximal inhibitory concentration 
(IC50) was taken as the drug concentration at which the SYBR green fluorescence was 50% 
of the value measured in the no drug (control) wells. Parasite survival (% growth) was 
determined by comparing fluorescence of the parasites exposed to drug (exposed) to 







by subtracting the background fluorescence of RBCs-only. GraphPad Prism 8 Version 8.0.2 
was used to generate dose-response curves using a non-linear regression model for 
log(inhibitor) vs. normalized response(variable slope) to calculate IC50 values with standard 
deviation (SD). All assays were performed in duplicate in three independent experiments. 
Statistical comparisons between parasite lines were performed using Mann-Whitney U tests. 
 
 
Figure 2. 3. Schematic for IC50 drug assay 96-well plate layout. Maximum drug concentration is 
plated in column 12 (2x the desired concentration) and serial 1:2 dilutions are plated in the following 
wells up to column 10. Column 11 (orange) contains no drug (parasites only) and column 12 contains 
RBCs only. Rows A and B (grey) contain CM or PBS only to account for any edge effects due to 
evaporation. Up to three drugs can be assayed on one plate. 
 
2.6.3 Piperaquine survival assays (PSAs) 
Piperaquine survival assays (PSAs) were performed following the procedure detailed by 
Duru et al. 2015 (Duru et al., 2015). Parasite lines were tightly synchronized 1-2 weeks prior 
to the assay by 5% sorbitol lysis and when parasitemia reached 3-5%, a Percoll gradient was 
performed on ~45 hour schizonts (segmented schizonts) and allowed to invade fresh RBCs 
for up to 3 hours. After incubation, the parasites were immediately sorbitoled and adjusted to 
0.8–1.5% parasitemia with a 2% hematocrit. The cultures were then plated in a 48-well plate 
(in triplicate) and exposed to 200 nM piperaquine (from the Worldwide Antimalarial 
Resistance Network (WWARN) or Sigma) or the control vehicle (0.5% lactic acid in water) 







1% O2, 3% CO2, and 96% N2 at 37°C. After 48 hours, cultures were washed once with ICM 
(10 mL) resuspended in complete medium and placed in a new well and cultured for an 
additional 24 hrs (Figure 2.4). After 72 hours, smears of all samples were prepared and flow 
cytometry was performed to measure viability. The proportion of viable parasites in exposed 
and non-exposed cultures was evaluated by counting 250,000 events per sample. Based on 
the accuracy of flow cytometry for measuring parasitemia (Amaratunga et al., 2014), the 
flow cytometry data was taken to represent viable parasites per well rather than counting 
10,000 RBCs per treatment (Duru et al., 2015). However, the slides for microscopy were still 
counted after performing flow cytometry (at least 1000 cells per slide) to ensure the values 
obtained via flow cytometry were similar to the number of viable cells viewed and counted 
by microscopy. The parasite growth rate was defined as the non-exposed (NE) parasitemia at 
72 hours/initial parasitemia (INI) at time zero (growth rate= NE/INI).  The percent survival 
was defined as the number of viable parasites in PPQ-exposed (PPQ)/# of viable parasites in 
non-exposed (NE) x 100 (% survival=PPQ/NE*100). The % survival data was graphed and 
analysed using GraphPad Prism Version 8.0.2.  Statistical comparisons between parasite lines 
were performed using Mann-Whitney U tests. 
 
 
Figure 2. 4. PSA 48-well plate setup. Each treatment condition non-exposed (NE) and treated (PPQ) 
is performed in triplicate. After 48 hour incubation with PPQ, the drug is washed off and the cultures 
are plated in a new well in the 48-well plates. 
 
 
2.7 Quantification of viable parasites using flow cytometry 
Flow cytometry was utilized to measure parasitemia following the methods described by 
Amaratunga et al. (Amaratunga et al., 2014). This procedure utilizes two fluorescent dyes: 







Fisher Scientific), which stains mitochondria and is a marker for actively metabolizing (live) 
cells.  
 
For quantification of viable parasites in PSAs, 100 µL of culture from each treatment 
condition was collected in a 96-well plate and washed twice with 1X PBS. For measuring the 
parasitemia of other cell cultures, at least 20 µL of packed iRBCs were collected. Two 
controls were included for each flow cytometry assay: a stained-RBC only sample (2% 
hematocrit) and an unstained-RBC only sample to control for background fluorescence. After 
aspirating the final wash for all samples, the cells (except for the unstained-RBC only 
control) were resuspended in 100 µL of a SYBR Green I (0.4x)/MitoTracker Deep Red (0.6 
µM) solution and incubated for 20 minutes at 37°C in the dark. After incubation, the cells 
were washed twice in 1X PBS and resuspended in 200 µL of 1X PBS. A 1:10 dilution of the 
stained samples was made in a final volume of 200 µL PBS and read on a flow cytometer 
(BD Accuri, NIH and CytoFLEX and Beckman Coulter CytoFLEX, Sanger).  
 
The excitation and emission spectra for SYBR Green I is 497/520 nm and MitoTracker Deep 
red is 644/665 nm enabling the fluorescent dyes to be measured using the FITC (FL1) and 
APC (FL4) filters, respectively. A range of 200,000-250,000 events were recorded for each 
sample and subsequent data was analyzed and gated using FlowJo (Version 10.5.3). 
 
Samples that stained positive with both SYBR and MitoTracker were recorded as live cells. 
Samples that stained with only SYBR green were counted as dead and only the percentage 
from the SYBR + MitoTracker gate was used to calculate the parasitemia for each culture 
(Figure 2.5). Samples were gated using the side scatter (SSC) vs. forward scatter (FSC) view 
(Figure 2.5A) of all events to obtain a population of “non-debris” by removing all debris 
outside of the gate (Figure 2.5B). Using the non-debris population, a single cell (singlet) 
population was obtained by gating the population in the forward scatter-area (FSC-A) by 
forward scatter-height (FSC-H) view (Figure 2.5C). Parasitemias were then quantified by 
gating the quadrants in FL1 (FITC/SYBR) vs. FL4 (APC/MitoTracker) (Figure 2.5 D-E). 
Quadrant 1 (Q1, upper left) shows cells that are SYBR positive only and counted as dead 
since SYBR fluorescence only indicates the presence of DNA. Quadrant 2 (Q2, upper right) 
shows SYBR + MitoTracker positive cells, which is taken to be the parasitemia or percentage 









Figure 2. 5. Flow cytometry quantification of parasitemia using SYBR Green I and 
MitoTracker Deep Red. A.) Side-scatter (SSC) and forward scatter (FSC) view of all 250,000 
events. B.) The population of cells was gated to remove debris. C.) The non-debris population was 
further gated to obtain single cells only (singlets). D.) Example of a non-exposed (NE) sample from a 
PSA. The parasitemia is represented in the top right corner of quadrant 2 (Q2). Q2 contains cells that 
stained positively for SYBR and MitoTracker. E.) Example of a PPQ-treated sample from a PSA with 
a PPQ-sensitive isolate. The population in Q1 (upper left) represents SYBR-positive parasites and the 
population in Q2 shows few live cells, as expected in a PPQ-sensitive isolate. The flow cytometry 
data was analyzed using FlowJo (Version 10.5.3). 
 
2.8 Molecular cloning techniques 
2.8.1 Transformation of competent bacteria cells  
Bacterial transformations were carried out using competent E. coli cells (XL10-Gold 
Ultracompetent cells, Agilent Technologies or 10-beta Electrocompetent E. coli, NEB). 
Plasmid DNA (~1-50 ng of DNA in 2-10 µL) was added directly to competent cells on ice 
and incubated for 30 minutes. After incubation, the transformations were heat-shocked at 
42°C for 30 seconds, placed back on ice for 2 minutes then recovered in 1 mL of SOC broth 
for 1-2 hours at 37°C. The transformations were plated on LB agar plates containing 100 
µg/mL ampicillin (LB + ampicillin plates) and incubated at 37°C overnight. The following 
day, colonies were inoculated in LB broth supplemented with 100 µg/mL ampicillin and 
incubated overnight, at 37°C, shaking (~180 RPM). Cultures were harvested the next day at 








2.8.2 Plasmid preparation: mini, midi, and maxi preparations 
Plasmids for all experiments were prepared using mini, midi, or maxi preparation (prep) kits 
(Qiagen, NIH; Macherey-Nagel, Sanger). For molecular cloning work, less plasmid DNA 
was needed, so mini preps were performed and DNA was eluted using water or the elution 
buffer supplied with the kit. For transfections, large amounts of plasmid DNA were required 
and were obtained via maxi preps. Plasmid DNA for use in transfections was resuspended in 
cytomix. Glycerol stocks of bacterial cultures were made by combining a 1:1 mixture of 
glycerol and the bacteria culture in a cryovial. Stocks were stored at -80°C. 
 
2.8.3 Polymerase chain reaction (PCR) protocols  
PCR reactions were performed using SapphireAmp Fast PCR Master Mix (Takara Bio Inc) 
or CloneAmp HiFi PCR Premix (Takara Bio Inc) and reaction conditions were set based on 
the manufacturer’s recommendations. Each reaction contained 10 µM of the forward and 
reverse primers, 2x SapphireAmp Fast PCR Master Mix or CloneAmp HiFi PCR, the DNA 
template (1-2 µl for approximately ~20 ng DNA), and up to 10 or 20 µL of water. For the 
Sapphire mix, the thermocycler (GeneAmp 9700 PCR machine, Thermo Fisher) conditions 
were as follows: 92°C for 2 minutes, followed by 30 cycles of 92°C for 30 seconds, 55-59°C 
for 30 seconds (temperature was dependent on primers), 66°C for 1.5 minutes, followed by a 
1 minute extension at 66°C. For CloneAmp: denaturation at 98°C for 2 minutes, followed by 
30-35 cycles of 98°C for 10 seconds; 55°C for 30 seconds, and elongation at 68°C for one 
minute.  
 
2.8.4 DNA sequencing 
PCR products were purified using a PCR purification kit (Qiagen or Macherey-Nagel) and 
sent for sequencing by Genewiz (USA) when at the NIH or to Eurofins (Europe) when at the 
















Chapter 3: Detection, surveillance, and evaluation of molecular 
markers of piperaquine resistance: plasmepsin 2-3 copy number 
assays and functional studies 
 
3.1 Declaration of work 
 
The following chapter includes excerpts of data from a manuscript in which I am co-first 
author submitted for pre-print publication on bioRxiv on 4th July 2019 (Jacob et al., 2019). 
This chapter also contains copy number data that was performed for a manuscript in 
preparation in which I am a contributing author (Amaratunga et al., 2019). The content 
included in this chapter is my own work and does not include work done in collaboration 
with others unless directly stated. 
 
3.1.1 Significance and purpose of study 
 
Antimalarial drug resistance is an unrelenting obstacle to malaria control programs. As 
countries push toward malaria elimination, drug resistance and the potential for resistance to 
develop pose constant threats to treatment efforts which rely solely on chemotherapy. In 
Southeast Asia (SEA), parasites have developed some degree of resistance to nearly every 
malaria drug currently available, with the most recent emergence to artemisinin combination 
therapies (ACTs) (World Health Organization, 2018). ACTs are the recommended front-line 
treatments for Plasmodium falciparum malaria worldwide (World Health Organization, 
2018) and decreased susceptibility of parasites to both artemisinin and one of the widely used 
partner drugs, piperaquine (PPQ), have been reported in multiple locations throughout SEA 
(Duru et al., 2015, Leang et al., 2015, Spring et al., 2015, Saunders et al., 2014, Amaratunga 
et al., 2016, Chaorattanakawee et al., 2015, Imwong et al., 2017). It is therefore necessary to 
have reliable methods for detecting and evaluating resistant phenotypes. The purpose of this 
study was to combine clinical data from Cambodia with genomic studies to develop assays 
for detecting one of the molecular markers of piperaquine (PPQ) resistance, a copy number 
variation (CNV) in the plasmepsin 2 and plasmepsin 3 (PM2-PM3) genes. In addition to 
assay development, this study designed and performed in vitro functional studies to examine 









3.1.2 Introduction  
 
In 2008, dihydroartemisinin-piperaquine (DHA-PPQ) was deployed as frontline treatment for 
uncomplicated P. falciparum malaria in Cambodia and implemented nationwide in 2010 
(Amaratunga et al., 2016). Since that time, drug efficacy studies have monitored for 
treatment failures, which are defined as greater than 10% recrudescence (persistence of the 
infection). As soon as 2010 in Western Cambodia, approximately 25% and 11% failure rates 
to DHA-PPQ treatment were observed in Pailin and Pursat provinces, respectively (Leang et 
al., 2013). By 2013—less than 3 years after nationwide drug implementation—widespread 
failure rates were observed throughout Cambodia, reaching as high as 50% (Duru et al., 
2015, Leang et al., 2015, Spring et al., 2015, Saunders et al., 2014, Amaratunga et al., 2016, 
Chaorattanakawee et al., 2015). Genomic studies (Amato et al., 2017, Witkowski et al., 2017) 
on parasite samples collected from patients in three Cambodian provinces from 2012-2013 
(Amaratunga et al., 2016) found several regions of the parasite genome that associated with 
treatment failures in patients and reduced PPQ susceptibility in vitro. Specifically, genome-
wide association studies (GWAS) revealed copy number variations (CNVs) in the plasmepsin 
2 (PM2) and plasmepsin 3 (PM3) genes on chromosome 14 as well as nonsynonymous 
single-nucleotide polymorphisms (SNPs) on chromosome 13 in genes encoding a putative 
exonuclease, PF3D7_1362500 (exo-E415G), and a putative mitochondrial carrier protein, 
PF3D7_1368700  (mcp-N252D) (Amato et al., 2017, Witkowski et al., 2017). Further work 
also reported mutations in the chloroquine resistance transporter gene (pfcrt) that confer 
varying levels of resistance to PPQ in both field isolates and the lab-adapted strain, Dd2 
(Ross et al., 2018a, Agrawal et al., 2017, Duru et al., 2015). These molecular markers are on 
a mutant kelch13 (K13) propeller domain background, the genetic marker for artemisinin 
resistance, so it is hypothesized that the rapid decline of piperaquine efficacy was due to 
widespread artemisinin resistance in Western Cambodia, which put increased pressure on the 
partner drug, allowing parasites to quickly develop resistance to piperaquine.  
 
Copy number variations or polymorphisms describe an amplification (increase) or decrease 
in the number or copies of a gene in the genome. CNVs are common in many eukaryotes, 
including humans, mice, and malaria parasites and are often associated with drug resistant 
phenotypes (Freeman et al., 2006, Anderson et al., 2009). In P. falciparum, the significant 
role CNVs could play in drug resistance was seen in the multidrug resistant-1 gene (pfmdr1) 
(Anderson et al., 2009). An increase in the copy number of the pfmdr1 gene was found to 







1993, Price et al., 2004). Mefloquine was used in Cambodia from 2001 as the ACT, 
artesunate-mefloquine (AS-MQ) until 2008, when the partner drug failed with widespread 
amplification of pfmdr1. Since the introduction of DHA-PPQ in 2008, the pfmdr1 
amplification has declined with parasite populations predominantly reverting back to single 
copies of pfmdr1 and increased copies of PM2-3 (Amaratunga et al., 2016, Amato et al., 
2017, Witkowski et al., 2017).  
 
The PM2-3 CNV observed in Cambodian parasite isolates exposed to DHA-PPQ treatment 
consists of an amplification of both the PM2 and PM3 genes. Whole genome sequencing 
(WGS) data shows that the breakpoint of parasites with at least two copies of PM2-3 lies in 
the ends of the plasmepsin 1 and plasmepsin 3 genes, creating a duplication of the full 
plasmepsin 2 gene and a chimeric plasmepsin 3 in which the  3’ end of PM3 is replaced with 
the 3’ end of plasmepsin 1 (depicted in Figure 3.5) (Amato et al., 2017).  Plasmepsins 1-4 
(PM1-PM4) are enzymes located in the digestive vacuole of the parasite that function as 
proteases during the intraerythrocytic stages of the parasite lifecycle by degrading 
hemoglobin (Banerjee et al., 2002). Hemoglobin degradation also generates heme, which is a 
toxic by-product that causes oxidative stress to the parasite, so it is converted to inert 
hemozoin crystals (Wunderlich et al., 2012). Though the mechanism of piperaquine action is 
unknown, one hypothesis is that it interferes with the hemoglobin degradation pathway, 
similar to chloroquine, and prevents hemoglobin degradation or heme detoxification. Thus a 
potential role for the PM2-3 gene amplification could be to overcome any inhibitory effects 
that piperaquine may have on the process. It should also be noted that the plasmepsins are 
redundant enzymes, and additional proteases such as falcilysins and falcipains also facilitate 
hemoglobin degradation (Liu et al., 2006), so it is possible that piperaquine is affecting 
earlier stages of the degradation pathway in which the plasmepsins are involved. However, 
these are speculations that have yet to be tested in molecular studies. 
 
The emergence of DHA-PPQ resistance greatly threatens the efficacy of the remaining ACTs 
worldwide. With the availability of molecular markers of piperaquine resistance, it is 
imperative to have robust assays that can be used to monitor the presence and frequency of 
these markers in contemporary parasite isolates across endemic regions. Functional studies 
are also necessary for providing insight into the biological mechanisms of resistance. This 
study has developed quantitative PCR (qPCR) assays to measure the copy number of PM2 
and PM3 using genomic DNA. I have also developed a PCR-based breakpoint assay to detect 







number assays are sensitive, reliable, and cost-efficient methods for detecting the breakpoint 
quickly. In addition to assays for monitoring the PM2-3 CNV, I performed functional studies 




Examine the role of the amplification of hemoglobin degrading proteases, PM2 and PM3 
(PM2-PM3), in piperaquine resistance 
(1) Development of qPCR and breakpoint PCR-based assays to detect PM2-3 resistance-
associated copy number variation 
a. Breakpoint PCR validation and comparison with SYBR-based qPCR assay 
using samples from DHA-PPQ study (Amaratunga et al., 2016)  
b. Analysis of PM2-3 copy numbers in samples from AS-MQ study 
(Amaratunga et al., 2019)  
(2)  Study the functional role of the PM2-3 amplification by genetic modulation of PM2-
3 copy numbers in vitro 
a. Overexpression of PM2 and both PM2-3 in a piperaquine-sensitive 
Cambodian field isolate with a single copy of the PM2-3 genes 
 
3.2 Materials and methods 
 
3.2.1 Parasite samples 
 
Field isolates used in breakpoint PCR and qPCR assays were obtained from clinical trials 
conducted in 3 sites (Ch. 2, Figure 2.2) in Cambodia: Pursat, Preah Vihear, and Ratanakiri 
between 2012-2015 (clinicaltrials.gov ID: NCT01736319) (Amaratunga et al., 2016). In the 
clinical trial from 2012-2013, patients presenting with uncomplicated P. falciparum malaria 
were treated with DHA-PPQ at all sites (Amaratunga et al., 2016). In the clinical trial from 
2014-2015, patients were treated with artesunate-mefloquine (AS-MQ) at all sites 
(Amaratunga et al., 2019). Genomic DNA (gDNA) was obtained from 200 µL of whole-
blood taken at the time of diagnosis. Control samples used for validation and assay 
optimization were obtained from gDNA extracted from the lab strains, 3D7 and Dd2, and 
from field isolates (Ch. 2, Table 2.1)  growing in continuous culture for which WGS data 










Figure 3. 1. Whole genome sequencing data displaying average coverage on chromosome 14 for 
isolate 163-KH1-004 (PH1345_C) as viewed using the LookSeq browser. (Manske and 
Kwiatkowski, 2009). The dashed line represents the average coverage and the blue represents the 
number of reads at the approximate positions on chromosome 14: 283100-300550, encompassing the 
genes of plasmepsins 1, 2, and 3, PF3D7_1407900-PF3D7_1408100. All field isolates used for copy 
number controls were validated for increased PM2-3 copy number using the LookSeq browser. 
 
3.2.2 Plasmepsin 2-3 duplication breakpoint PCR assay  
 
Whole genome sequencing data from piperaquine-resistant P. falciparum isolates obtained 
from clinical trials in Cambodia were used to identify the breakpoint of the PM2-3 
amplification. PCR primers were manually designed to amplify the region surrounding the 
breakpoint (Amaratunga et al., 2016, Amato et al., 2017, Witkowski et al., 2017). Primers AF 
(forward 5’-CCACGATTTATATTGGCAAGTTGATTTAG -3’) and AR (reverse 5’-
CATTTCTACTAAAATAGCTTTAGCATCATTCACG-3’) amplify a 623 base pair (bp) 
product surrounding the breakpoint located at the 3’ end of plasmepsin 1 (PM1). Primers BF 
(forward - 5’-CGTAGAATCTGCAAGTGT TTTCAAAG-3’) and BR (reverse 5’- 
AATGTTATAAATGCAATATAATCAAACGACATCAC-3’) amplify a 484 bp product 
surrounding the breakpoint located at the 3’ end of PM3. BF + AR amplify the junction 
between the breakpoint and produce a 497 bp product in isolates with PM2-3 amplifications. 
These primers face opposite directions in samples without duplications and are not expected 
to amplify a product in single copy isolates. Both control (AF + AR; BF+ BR) and 
duplication (BF + AR) primer sets were used with all samples and single copy isolates were 
only noted if the control primer sets amplified a product and duplication PCR was negative. 
Two or more copies were annotated as >1 copy of PM2-3 only if both the control and 
duplication primer sets produced a product. PCR reactions contained 10 µl SapphireAmp 
Fast PCR Master Mix (Takara Bio Inc), 0.3 µl of each primer (Integrated DNA 
Technologies), 1 µl of genomic DNA up to 20 µl final volume with water. PCR conditions 
were: 92°C for 2 minutes, followed by 30 cycles of 92°C for 30 seconds, 59°C for 30 








3.2.3 SYBR green validation of plasmepsin 2-3 copy number using quantitative PCR 
 
PCR primers for estimating PM2 copy number amplification were designed manually inside 
the PM2 gene (forward - 5’-CTTATACTGCTTCAACATTTGATGGTATCCTTGG-3’; 
reverse - 5’-GGTTAAGAATCCTGTATGTTTATCATGTACAGGTAAG-3’). Previously 
described primers for P. falciparum lactate dehydrogenase (ldh) (Lim et al., 2013), were used 
as the control for a single copy gene (forward - 5’-AGGACAATATGGACACTCCGAT-3’; 
reverse - 5’-TTTCAGCTATGGCTTCATCAAA-3’). Similar to the assays performed by 
Jacob et al. (Jacob et al., 2019), assays for amplifying PM2 and PM3 individually were 
compared to determine if each gene could be used as a marker of duplication and no major 
differences were observed (data not shown). PM2 primers only were used for higher 
throughput in SYBR green assays, since each gene, PM2 and ldh must be analyzed in 
separate reactions. Real-time PCR reactions were carried out in 20 µl volumes in a 96-well 
plate (Bio-Rad) containing 10 µl SensiFAST SYBR No-ROX mix (2x) (Bioline Inc.), 300 
nM of each primer, and 2 µl genomic DNA. Reactions were performed using a CFX Connect 
Real-Time PCR Detection System (Bio-Rad) using the following conditions: 5 minutes at 
95°C, followed by 40 cycles of 10 seconds at 95°C, 20 seconds at 58°C, and 20 seconds at 
60°C. Relative copy number was calculated on the basis of the 2-ΔΔCt method for relative 
quantification. ΔΔCt was calculated as (Ctldh –Ctpfplasmepsin2) - (Ctldh cal -Ctpfplasmepsin2 cal), where 
cal is the calibration control of genomic 3D7 DNA with one copy of both ldh and PM2. DNA 
from an isolate with two copies of PM2-3 (PH1387-C) (Amaratunga et al., 2016) was used as 
an internal plate control. All samples were analyzed in triplicate and each plate was 
replicated in triplicate. A relative copy number of 1.5 or greater was recorded as 2 copies. 
 
3.2.4 Overexpression of PM2 and PM3 
For overexpression of both the PM2 and PM3 genes, I used the pDC2-cam-mrfp-2A-gfp-bsd-
attP plasmid (Straimer et al., 2012). This plasmid was selected to enable stoichiometric 
amounts of both PM2 and PM3 to be expressed by utilizing the same promoter and a 2A-
“skip” peptide to separate the two genes. Gibson assembly for all plasmids was performed 
using the HiFi DNA Assembly reagent and accompanying protocol from New England 








3.2.4.1 Gibson assembly of a PM2-only overexpression plasmid: pDC2-cam-PM2-2A-
gfp-bsd-attP 
Before assembling a PM2 and PM3 overexpression plasmid, a single PM2-only expression 
plasmid was made by inserting the PM2 gene into the pDC2-cam-mrfp-2A-gfp-bsd-attP 
plasmid. The mrfp segment was excised from the pDC2-cam-mrfp-2A-gfp-bsd-attP plasmid 
using the enzymes, AvrII and BglII (NEB) (Figure 3.2A). The PM2 gene was PCR-
amplified from genomic 3D7 DNA using the primers, PM2_OE_F and PM2_OE_R (Table 
3.1), which included overlap (lowercase letters) with the plasmid for Gibson assembly. No 
stop codon was included after the PM2 gene to ensure translation would carry on through the 
2A-skip peptide to the 2A-gfp segments (Figure 3.2A). 
 
The reverse primer (PM2_OE_R) used to amplify the PM2 gene contains a BglII-2A overlap 
region (Figure 3.2A) by including the BglII restriction site (AGATCT), but uses the “T” 
from the end of PM2 and this T is highlighted in red in primer, PM2_OE_R (Table 3.1). 
Because of this, the plasmid generated by Gibson assembly was missing this nucleotide (read 
as an “A” in the forward sequence) (Figure 3.2B). This does not affect PM2 expression, but 
changes the reading frame downstream of PM2, so gfp is not translated. The shift in the 
reading frame causes the nearest stop codon to be located in the 2A-skip peptide and no 
longer at the end of gfp, as originally designed. Since the reading frame was shifted after the 
full length PM2 gene, this study was able to use this plasmid to examine the role of PM2-
only gene overexpression (since it would be translated) but needed to use a different 









Figure 3. 2. Plasmid design and assembly for overexpression of plasmepsin 2 (PM2). A.) The 
pDC2-cam-mrfp-2A-gfp-bsd-attP plasmid was digested with AvrII and BglII to obtain the plasmid 
backbone and the PM2 gene (light blue) was inserted via Gibson assembly. B.) Sequence 
chromatograms of pDC2-cam-PM2-2A-gfp colonies (colonies 1 and 2) aligned with the reference 
sequence of the inserted PM2 through the 2A peptide sequence. A red box highlights the region 
missing the “A” nucleotide (indicated with a red arrow) in the forward sequence. This missing 
nucleotide does not affect PM2 expression, but shifts the reading frame downstream of PM2 so that 
the nearest stop codon is located in the 2A-skip peptide and gfp is not translated. 
 
3.2.4.2 Gibson assembly of the PM2-2A-PM3 overexpression plasmid 
Briefly, the mrfp-2A-gfp segment was excised from the pDC2-cam-mrfp-2A-gfp-bsd-attP 
plasmid using the enzymes, AvrII and XhoI (NEB) (Figure 3.3A). The PM2 gene was PCR-
amplified from the PM2-2A-gfp plasmid made by this study and described above (3.2.4.1, 
Figure 3.2) using the primers, p1632 (forward - 5’-
ACCTAATAGAAATATATCACCTAGG – 3’) and p1633 (forward - 5’- 
GCCAGATCTTAAATTCTTTTTAGCAAGAGC – 3’) (Table 3.1). The reverse primer, 
p1633 includes the “T” (highlighted in red) that was not included in the previous plasmid to 
correct the shift in the reading frame (Table 3.1). A 2A-PM3 fragment was synthesized (Life 
Technologies) including regions for overlap with the pDC2 plasmid backbone and the PM2 







(100 ng) were assembled using a ratio of 2:1 = insert:vector and incubated at 50°C for 20 
minutes. A no insert control with digested plasmid only was tested using an equivalent 
amount of plasmid and no insert. After assembly, 5 µl of the reactions were transformed into 
competent E. coli (Ch. 2, Section 2.8.1) and LB + ampicillin plates were screened for 
colonies the next day. 
 
Correct insertion of PM2 and PM3 into the pDC2 plasmid was confirmed by sequencing 
(Figure 3.3C-D), using the primers:  p364 (5’- GGGCCCGCATGCTTAGCTAATTCG - 3’) 
and p648 (5’- GATTCTTCTTGAGACAAAGGC - 3’), which produce a 649 bp product. 
Following sequence confirmation, the plasmid was midi-prepped (Ch.2, Section 2.8.2) and 
parasites were transfected (Ch.2, Section 2.3.2). 
 
Table 3. 1 Primers for the development of PM2-PM3 overexpression plasmids 
 
The “T” highlighted in red in p1633 is the nucleotide that was not included in the PM2-only plasmid 










Primer name Primer (5' - 3') sequence Description
PM2_OE_F
acctaatagaaatatatcacctaggATGGATATTACAGTAA
GAGAACATG PM2 forward primer with Gibson overlap
PM2_OE_R
ctctgccctctccgccgccagatcTAAATTCTTTTTAGCA
AGAGCAATAC PM2 reverse primer with Gibson overlap
p1632 ACCTAATAGAAATATATCACCTAGG
PM2-2A forward primer, binds CAM 
promoter upstream of PM2 insertion site 
in the pDC2-cam-PM2-2A-GFP-bsd-attP 
plasmid
p1633 GCCAGATCTTAAATTCTTTTTAGCAAGAGC
PM2-2A reverse primer, binds 2A region 











Figure 3. 3. Plasmid design and assembly for overexpression of PM2 and PM3. A.) The pDC2-
cam-mrfp-2A-gfp-bsd-attP plasmid was digested with AvrII and XhoI to obtain the plasmid 
backbone. The fragments for Gibson assembly: PM2 (1384 bp), 2A-PM3 (1487 bp), and digested 
plasmid (6380 bp) with an excised mrfp-2A-gfp fragment (1482 bp) were run on a 1% agarose gel to 
confirm sizes. B.) The pDC2-cam-PM2-2A-PM3-bsd-attP plasmid after Gibson assembly. C.) 
Sequence of PM2-2A-PM3 colony 1 aligned with the reference sequence of the inserted PM2 through 
the 2A peptide to PM3. Black boxes indicate regions of overlap with the sequence alignment and 
plasmid map. D.) Sequence chromatogram of PM2-2A-PM3 colony 1 aligned with the reference 
sequence through the end of the inserted PM3 gene. Black boxes indicate regions of overlap with the 
reference sequence alignment and plasmid map. The top sequence above the reference is the 
consensus sequence for all reads. 
 
3.2.4.3 Determination of drug selection concentration by IC50 assays 
 
Successful transfection of the episomal plasmid was verified by drug selection with 
blasticidin (BSD). To determine the concentration of BSD to use on the transfected field 
isolate, 163-KH3-005 (005), (a “PPQ-sensitive” parasite, Ch. 2, Table 2.1) an IC50 assay was 







which is the same concentration used for lab strains, could be used for the 005 isolate. The 
transfected parasites were kept under constant drug selection in order to maintain the 




Figure 3. 4. Dose-response curve for field isolate 163-KH3-005 after 72-hour exposure to 
blasticidin (BSD). The curve represents 4 technical replicates with an IC50 value of 0.697 Error bars 
represent SD. 
 
3.2.4.4 Use of flow cytometry to screen for pDC2-cam-mrfp-2A-gfp-bsd-attP plasmid in 
transfected parasites 
 
The transfected 005 and Dd2 parasites were screened for the presence of GFP using flow 
cytometry as described in Chapter 2 (Ch. 2, section 2.7). Approximately 50 µl of a 3% 
hematocrit culture transfected with the pDC2-cam-mrfp-2A-gfp-bsd-attP plasmid was added 
to 200 µl of PBS and washed twice, then resuspended in 200 µl of PBS and 10 µl of this 
dilution was added to a further 200 µl of PBS. No stain was added to any of the samples. A 
non-transfected 005 parent line was analyzed as a control along with the transfected 005 and 
Dd2 lines. Each sample was read on a CytoFLEX (Beckman Coulter) flow cytometer using 



















3.3.1 PM2-3 breakpoint assay validation 
 
In order to develop a method for detecting the PM2-3 copy number variations, I designed 
PCR primers that amplify the breakpoint of the PM2-3 amplification observed in Cambodian 
isolates (Figure 3.5A). The breakpoint assay identifies copy number amplification in isolates 
that contain 2 or more copies of PM2 and PM3 (Figure 3.5B). As expected, no PCR products 
were observed in samples with a single copy of PM2-3 (Figure 3.5B). Control primers 
confirmed that the regions surrounding the PM2-3 amplification were present in all isolates 
(Figure 3.5C) and verified that absence of amplification using the duplication primer sets 
was not due to lack of DNA or low quality DNA. 
 
Further verification of the breakpoint assay was performed via sequence analysis of the BF + 
AR PCR product. Sequence data revealed the same breakpoint location as observed by WGS 
(Figure 3.5D). All Cambodian samples that were positive for PM2-3 amplifications as 
detected by the breakpoint assay (>1 copy) were in 100% concordance with qPCR and WGS 
data that called 2 or more copies of PM2. Sequencing chromatogram review of PCRs 
representing 2 and 3 copy samples showed that the breakpoints for representative 2 and 3 
copy samples were identical. These sequencing results combined with the identical PCR sizes 
























Figure 3. 5. Schematic of plasmepsin 2-3 gene duplication. A.) Gene model depicting the PM2-3 
breakpoint (dashed blue lines) observed in Cambodian isolates. Primer positions are labeled in the 
single copy (top) and multi-copy (bottom) isolates. B.) Amplification primer set BF + AR amplifies a 
product in an isolate with two copies (PH1387-C) and three copies (PH1265-C) of PM2-3. No 
product is observed for the single copy (PH1310-C) isolate or in the DNA-negative control (-). C.) 
Control primers amplify a product in the single copy (PH1310-C) and multi-copy isolates (PH1387-
C; PH1265-C). No product is observed in the DNA-negative control (-). D.) Sequence chromatograms 
of the breakpoint PCR product of primer set BF + AR using 3 copy isolate, PH1265-C. The primers 
sequence through the breakpoint between the 3’ end of PM3 and the 3’ end of PM1. The sequence of 
isolate, PH1265-C is represented in color with the chromatograms. The reference sequences for PM3 
and PM1 are shown in black and indicated with the black arrow. Viewed from the top, the PM3 
sequence stops (red arrows) and aligns with the PM1 sequence due to the formation of the chimeric 
PM3-PM1 gene. The sequence proceeds through the breakpoint (red arrows) to align with the 














3.3.2 PM2-3 breakpoint assay utility in comparison with SYBR green assay 
 
To test the utility of using the breakpoint assay for rapid surveillance of large sample sizes 
for which WGS data is not yet completed or available, I performed breakpoint PCR on 99 
samples from patients treated with DHA-PPQ in Cambodia from 2012-2013 (Amaratunga et 
al., 2016). I found that 90% of samples from Pursat had increased copies of PM2-3, 22% of 
samples from Preah Vihear had increased copies, and 3.2% of samples from Ratanakiri had 
increased PM2-3 copies (Figure 3.6A).  
 
The qPCR-based assay results for the same 99 samples from patients treated with DHA-PPQ 
showed approximately 90% of samples from Pursat had increased PM2-3 copy numbers, 
while 16% of samples from Preah Vihear had increased copies and Ratanakiri samples were 
all single copy PM2-3 by the qPCR method (Figure 3.6B).  
 
I compared the results of the breakpoint assay with the qPCR SYBR green assay and found 
that 93/99 samples tested with the breakpoint PCR assay matched qPCR data for the same 
samples, a 94% concordance. The six non-concordant samples were determined to be >1 
copy by breakpoint PCR (Figure 3.6A), but qPCR read them as single copy isolates (Figure 
3.6B). This included 1 sample from Ratanakiri, 2 samples from Preah Vihear, and 3 samples 
from Pursat that had >1 copy by breakpoint PCR but single copy by qPCR (Figure 3.6). The 
six non-concordant samples were repeated, always producing the same results. These results 
could suggest that the breakpoint PCR assay is more sensitive than the qPCR assay for 
detecting the breakpoint in samples that are polyclonal. Minor clones containing the 
duplication in field isolates would not be detected in the qPCR assay, however, they would 
be detected by the breakpoint assay. One limitation of the breakpoint assay is that there is no 
high-throughput way to determine if these samples are false positives. The best way to check 
would be to examine WGS data for each sample, however these samples were selected for 
breakpoint PCR because WGS data for the samples either failed or was not chosen for WGS 
analysis due to insufficient or low-quality DNA. Another way to assess if the six non-
concordant breakpoint PCR samples were false positives would be to sequence the PCR 
product and see if the PM3-PM1 chimeric sequence is present, which would provide 










Figure 3. 6. Comparison of the breakpoint PCR and qPCR assays for measuring PM2-3 copy 
numbers. A.) Proportion of samples with 1 copy or >1 copy of PM2-3 as determined by breakpoint 
PCR. B.) Proportion of samples with 1, 2, or 3 copies of PM2 as determined by qPCR analysis. For 
both breakpoint PCR (A) and qPCR (B) assays a total of 99 isolates were analyzed from 3 Cambodian 
provinces during 2012-2013 after treatment with DHA-PPQ. 
 
3.3.3 Analysis of PM2-3 copy number in isolates from patients treated with 
artesunate-mefloquine 
The breakpoint PCR assay was utilized to detect the PM2-3 breakpoint in samples from a 
clinical trial conducted in 3 provinces in Cambodia from 2014-2015 to test the efficacy of 
artesunate-mefloquine (AS-MQ) (clinicaltrials.gov ID: NCT01736319) (Amaratunga et al., 
2019). The prevalence of PM2-3 amplifications in 295 total patient isolates from Pursat, 
Preah Vihear, and Ratanakiri were 96%, 93%, and 24%, respectively (Figure 3.7). As seen in 
Figures 3.6-3.7, the proportion of multi-copy parasites is continuing to increase in the 3 











Figure 3. 7. Proportion of samples with >1 copy or 1 copy of PM2-3 as determined by 
breakpoint PCR analysis in 3 Cambodian provinces from 2014-2015. A total of 295 patient 
isolates from 3 Cambodian provinces were analyzed after treatment with AS-MQ. 
 
3.3.4 Overexpression of PM2 and PM3 in Cambodian isolates 
It was hypothesized that the increased PM2-3 copy numbers are not only associated with 
piperaquine resistance, but could also serve a causal role in the resistant phenotype. To test 
this hypothesis directly, this study used transgenic approaches to generate isogenic parasite 
lines that overexpressed PM2 and PM3 in stoichiometric amounts. The best way to do this 
was to link expression of both genes to a single promoter, with the genes separated by a 2A 
viral skip peptide. The peptide results in translation that continues to the downstream gene 
with a break in the peptide bond, and has been used when 1:1 stoichiometric expression of 
two genes is desired, such as for immunoglobulin heavy and light chains or T-cell receptors 
(Szymczak et al., 2004). The plasmid used by this study was codon-optimized for P. 
falciparum and used successfully by Straimer et al. for dual protein expression of RFP and 
GFP (Straimer et al., 2012). 
 
3.3.4.1 Overexpression of PM2 in Cambodian field isolate, 163-KH3-005 
This study first assessed if overexpression of PM2-only had any effect on susceptibility to 
piperaquine. I transfected the PM2 overexpression plasmid into a PPQ-sensitive isolate from 
Cambodia, 005, and found little to no differences in parasite susceptibility to piperaquine in 










Figure 3. 8. Transgenic piperaquine-sensitive parasites (005) carrying the PM2 overexpression 
plasmid showed no shift in PPQ IC50 values. A.) Dose-response curves for three 005-transfectants 
with the PM2 overexpression plasmid (T1, T2, T3) compared to the parental line (005). Error bars 
represent SD (n=2). B.) Significance was determined using Mann-Whitney U tests comparing the 




3.3.4.2 Confirmation of the pDC2-cam-PM2-2A-PM3 plasmid and pDC2-cam-mrfp-2A-
gfp-bsd-attP plasmid in transfected parasites by flow cytometry and PCR 
To fully recapitulate the PM2-3 CNV observed in clinical isolates, I next aimed to 
overexpress both PM2 and PM3 in the 005 field isolate and Dd2. 
 
Field isolate, 005 and lab strain, Dd2 were transfected with the PM2-2A-PM3 overexpression 
plasmid and the pDC2-cam-mrfp-2A-gfp-bsd-attP plasmid as a transfection control.  
 
As soon as there was a detectable parasitemia (around days 14-15 post-transfection for both 
lines), the 005 isolate and Dd2 transfectants with the control pDC2-cam-mrfp-2A-gfp-bsd-
attP plasmid were screened for the presence of GFP and RFP by flow cytometry (Figure 
3.9). Fluorescence was detected in the Dd2 transfected parasite, as demonstrated by the 
presence of a population of cells positive in the FITC (GFP) and PE (RFP) channels (Figure 
3.9, right panel). However, no fluorescence in the FITC or PE channels was observed for the 
005 transfected parasite (Figure 3.9, middle panel), which showed a similar profile to the 
non-transfected 005 parent line (Figure 3.9, left panel). The experiment was repeated twice 









Figure 3. 9. Flow cytometry assessment of transgenic parasites. Flow cytometry assessment of 
GFP transgene expression (FITC channel) and RFP transgene expression (PE channel) in transfected 
parasite lines 005 and Dd2, compared with a non-transfected control line (left panel). 
 
Although the pDC2-cam-mrfp-2A-gfp-bsd-attP plasmid was transfected as a control to 
monitor transfection success by measuring GFP/RFP fluorescence, it could have no 
relationship to whether or not the PM2-2A-PM3 plasmid was successfully transfected. 
Therefore, to determine if the 005 and Dd2 parasite lines were successfully transfected with 
the both the PM2-2A-PM3 plasmid and pDC2-cam-mrfp-2A-gfp-bsd-attP, the transfections 
were screened using plasmid-specific primers (Figure 3.10). As seen in Figure 3.10, both 
plasmids are present in the 005 and Dd2 transfected lines. Due to time constraints the PPQ 
response of the PM2-3 transgenic lines was not yet tested (as well as RNA and protein 




Figure 3. 10. PCR confirmation of the PM2-2A-PM3 plasmid in transfected 005 and Dd2 
parasites. PCR confirmation that the pDC2-cam plasmid backbone was present in transfections. Lane 
L is the 1 kb ladder (Bioline); lanes 1-2 and 5-7 are field isolate 005 transfected with the pDC2-cam-
PM2-2A-PM3 plasmid and lanes 3-4 are field isolate 005 transfected with the control pDC2-cam-
mrfp-2A-gfp-bsd-attP plasmid. Lane 8 is Dd2 transfected with the control pDC2-cam-mrfp-2A-gfp-
bsd-attP plasmid and lanes 9-10 are Dd2 transfected pDC2-cam-PM2-2A-PM3 plasmid. Lanes 11 and 









3.4 Discussion and future work 
The novel breakpoint and qPCR assays developed by this study are sensitive, reliable, and 
cost-efficient methods for detecting the PM2-3 gene amplifications. They can be used in 
place of WGS or in areas where sequencing is not feasible, as they require considerably less 
time and facilities, allowing for copy number analysis within the same day of sample 
collection. Both assays can be performed with very little genomic DNA (2-5 ng of gDNA) 
which is useful in many endemic regions where only filter paper blood spots are available. 
The qPCR and breakpoint assays are also high-throughput, with the possibility of using 96-
well plate analysis, making them ideal for surveillance throughout malaria endemic regions. 
 
The qPCR-based PM2-3 CNV assay measures discrete number of copies, which is especially 
useful in determining if the number of PM2-PM3 copies is increasing in parasite populations 
throughout countries where DHA-PPQ was previously used or is still currently in use. One 
disadvantage of the qPCR method is the arbitrary relative assignment of 1 vs. 2 copies. For 
the purposes of this study, a value of “2 copies” was set as a relative copy number of 1.5 or 
greater. This leaves the potential that a sample read as 1.44 copies in the qPCR assay, for 
example, would be counted as single copy, when it actually had two copies of PM2-3. The 
same could be said for a 1.5 relative copy number actually being a single copy parasite, 
rather than multicopy. In spite of the inherent potential errors with relative copy number, 
because qPCR methods do not rely on the primer location in reference to an estimated 
breakpoint, they can be used broadly. 
 
The breakpoint PCR assay (Figure 3.4) also effectively determines increased PM2-3 copy 
number in field isolates and can be used in areas where qPCR is infeasible. Since the assay 
detects the presence of the breakpoint, it does not have the same problems as WGS and qPCR 
with calling average or relative copy numbers and is positive only if the breakpoint is 
present. The sensitivity of this assay also enables the detection of minor clones, which proves 
advantageous, given the potential for polyclonal infections. The basic laboratory equipment 
needed for breakpoint-PCR makes it possible for analysis to be conducted at field sites, rather 
than shipping the samples to another laboratory within the country or outside of the country 
to wait for results. However, a notable disadvantage of this method is that the breakpoint 
assay was designed with primers specific to the PM2-3 breakpoint observed in Cambodian 
field isolates (Amato et al., 2017).  The PCR primers used to detect the Cambodian 
breakpoint observed to date may not amplify a product in samples that contain different 







copy number variations in the same gene can arise independently on different genetic 
backgrounds and result in distinct molecular breakpoints of amplification. Though this study 
has observed over 300 samples from Cambodia with the same breakpoint (Figures 3.6-3.7), 
Witkowski et al. (Witkowski et al., 2017) have reported different breakpoints in Cambodian 
isolates. Therefore, both breakpoint and qPCR assays should be performed for the most 
accurate results, when possible. 
 
This thesis (Figures 3.6-3.7) and other studies (Amato et al., 2017, Jacob et al., 2019, 
Witkowski et al., 2017) have shown that parasites with the PM2-3 copy number expansion 
are increasing in prevalence in Cambodia. The breakpoint and qPCR assays have shown that 
the proportion of parasites with more than one copy of PM2-3 has increased in the 3 
Cambodian provinces where samples were collected from 2012 to 2015 (Figures 3.6-3.7). 
These parasite samples have been obtained from clinical studies carried out by Amaratunga 
et al. in 2012-2013 (Amaratunga et al., 2016) and 2014-2015 (Amaratunga et al., 2019). 
From these clinical trials, we know that the patients in all 3 provinces (Pursat, Preah Vihear, 
and Ratanakiri, Ch. 2 Figure 2.2) were treated with the same drug regimens, specifically 
DHA-PPQ in the 2012-2013 trial followed by AS-MQ in the 2014-2015 trial. As discussed in 
Chapter 2 (Section 2.2.1), field isolates from these three Cambodian provinces from 2012-
2013 varied in their susceptibility to PPQ, with parasites from Ratanakiri (Eastern 
Cambodia), being largely susceptible to PPQ and also containing single copies of PM2-3. It 
will be important to determine if the parasites with increased PM2-3 copy numbers from 
Ratanakiri in 2014-2015 (Figure 3.7) remain susceptible to PPQ, since the parasite samples 
from this study were successfully treated with AS-MQ, but not exposed to DHA-PPQ. The 
2014-2015 parasite samples were the most recent samples this thesis had access to, but recent 
studies by van der Pluijm et al. reported that PM2-3 amplifications were present in 72% of 
samples from Ratanakiri collected from 2015-2018 (van der Pluijm et al., 2019). Continued 
and future work is thus needed to monitor if and how the PM2-3 copy number expansion 
changes in this region. In areas where WGS is not possible, the breakpoint and qPCR 
methods designed by this study can provide efficient, cost-effective methods for real-time 
analysis of PM2-3 copy numbers. 
 
In addition to assays for monitoring the PM2-3 CNV, I developed methods to test for the 
effects of increased copies of PM2-3 on piperaquine response. To mimic the CNV observed 
in field isolates encompassing both PM2 and PM3, I generated both a PM2-only 







amounts of both genes using the 2A skip peptide (Figure 3.3). Initial comparisons of PM2-
only overexpression in PPQ-sensitive isolate, 005, showed no significant difference in 
parasite survival to piperaquine (Figure 3.7). This could indicate that both genes, PM2 and 
PM3, are needed to obtain a resistant phenotype. To test this hypothesis, I transfected the 
same PPQ sensitive isolate, 005, and the Dd2 lab strain with the PM2-2A-PM3 vector. 
Confirmation of the presence of the plasmid in the PPQ-sensitive field isolate 005 and Dd2 
lab strain was demonstrated via PCR (Figure 3.10). I also transfected the unmodified pDC2-
cam-mrfp-2A-gfp-bsd-attP plasmid as a transfection control (Figure 3.10). Curiously, the 
study was only able to detect GFP and RFP fluorescence in the Dd2 transfectants (Figure 
3.9) and not the 005 isolate, although both the Dd2 and 005 transfectants were PCR-positive 
for the plasmids and maintained on the appropriate BSD selection pressure to maintain the 
episomal plasmid (Figure 3.10). Since the pDC2-cam-mrfp-2A-gfp-bsd-attP plasmid was 
used as a transfection control to determine if the parasites could be successfully transfected, 
the lack of GFP and RFP fluorescence in the 005 transfectants will not be pursued further, 
since the PCR results and the growth of the parasites on BSD pressure show that both 
plasmids (mrfp-2A-gfp and PM2-2A-PM3) are present in the transfected parasites. However, 
plasmid-rescue of the episomal plasmid from the 005 parasites, and sequencing of the mrfp-
2A-gfp cassette would be the first step in determining why expression of the reporter genes is 
not observed. 
 
Future work will now prioritize further characterization of the PM2-3 transfected lines. 
Before performing further parasite survival assays to assess the impact of PM2-3 
overexpression on PPQ sensitivity, it is necessary to examine both PM2-3 RNA and protein 
levels to determine if the overexpression plasmids have resulted in increased RNA and 
protein in the transfected parasites compared to the non-transfected parent lines. Samples 
have been saved for qPCR analysis to compare PM2-3 transcript expression levels and 
preliminary Western blots to compare protein expression in the parental non-transfected and 
transfected lines have been performed but must be optimized.  
 
Recent functional studies have provided insight into the role of the PM2-3 amplification in 
response to antimalarial drug pressure. Loesbanluechai et al. 2019 (Loesbanluechai et al., 
2019) demonstrated that overexpression of either PM2 or PM3 individually in the 3D7 
parasite background had no effect on parasite susceptibility to piperaquine, artemisinin, and 
chloroquine. Consistent with this result, I did not observe any survival difference in response 







(Figure 3.7). Interestingly, Bopp et al. 2018 found that increased PM2-3 copy numbers in 
PPQ-resistant field isolates enhanced survival to PPQ (Bopp et al., 2018). It should be noted 
that the isolates with increased PM2-3 copy numbers and survival under PPQ pressure in the 
study by Bopp et al. were kelch13 C580Y or Y493H mutants, and were not generated by 
transgenic methods but were naturally multicopy for PM2-3 (Bopp et al., 2018). Additional 
studies on PM2 and PM3 knockouts in 3D7 parasites showed decreased survival to PPQ, 
though the differences in PPQ IC50 survival assays appeared minor (Mukherjee et al., 2018). 
It is therefore possible that the PM2-3 amplification needs to be present in the same genetic 
background of artemisinin resistance (K13 mutant or other potential genetic variants). 
Furthermore, it may be necessary for the PM2-3 amplification to be in the presence of other 
molecular markers of PPQ resistance for the effects of the amplification to manifest. In 
subsequent chapters, I will explore other potential markers of piperaquine resistance, 
including SNPs in the putative exonuclease protein, PF3D7_1362500 (exo-E415G), putative 
mitochondrial carrier protein, PF3D7_1368700 (MCP-N252D), and PfCRT. It is also 
necessary to further examine the role of knocking out or knocking down PM2 and PM3, thus 
future functional work is critical. 
 
I have made over four separate attempts (in duplicate) to transfect the PM2-2A-PM3 plasmid 
into multiple field isolates with K13 C580Y mutations, one of the molecular markers of 
artemisinin resistance. Additional attempts were made with the generous help of my lab 
colleague, Dr. Sophie Adjalley. All attempts to date have been unsuccessful. Studies have 
shown that laboratory strains such as Dd2 and 3D7 are genetically different from more 
recently adapted field isolates (Mackinnon et al., 2009), which could contribute to difficulties 
experienced in field isolate transfections. Due to the lack of additional field isolates 
transfected with the PM2-2A-PM3 plasmid, my studies in field isolates with various genetic 
backgrounds (K13, exo-E415G, MCP-N252D, PfCRT) are ongoing. Transfection protocols 
have been optimized using different machines (Bio-Rad electroporator and Amaxa 
electroporator) and conditions (pre-loading RBCs versus direct transfection of ring-stage 
parasites and use of conditioned media) but these changes have yet to result in transfected 
field isolates. Transfections of schizonts rather than loaded RBCs or ring-stage parasites has 
also been widely used for transfections of P. knowlesi (Moon et al., 2013) and could be 
attempted with the field isolates used in this study. Additional transfection attempts with field 
isolates could also vary the concentrations of BSD used for plasmid selection (increasing the 







progress has been made in transfecting the 005 isolate with the dual PM2-2A-PM3 
overexpression plasmids and future work on RNA and protein expression is forthcoming.  
 
As antimalarial drug resistance continues to thwart treatment efforts, it is imperative to have 
assays and functional studies to assess molecular markers of drug resistance. This thesis has 
developed two novel assays that can be used to monitor for the PM2-3 molecular marker of 
piperaquine resistance. In a proof of concept of assay reliability and ease of use, I spent one 
month in Cambodia (April 2017) teaching our NIH-based team in Phnom Penh how to 
perform the assays, where the procedures were quickly introduced without any technical 
issues. In addition to the copy number assays, I have also developed a PM2-3 overexpression 
plasmid that can be used to assess the effects of stoichiometric overexpression of both PM2 
and PM3. Though future work is necessary, the tools developed by this study have formed a 
































Chapter 4: Examination of the role of single nucleotide 
polymorphisms in an exonuclease protein and mitochondrial 
carrier protein in piperaquine resistance 
 
4.1 Declaration of work 
The following chapter includes data obtained from plasmids designed by Dr. Marcus Lee and 
edited parasite lines obtained from Dr. Manuela Carrasquilla. Dr. Lee provided all plasmids 
used for CRISPR-Cas9 editing in this study. Dr. Carrasquilla generated Dd2-edited parasite 
lines that contained the wildtype and mutant exonuclease SNPs. Both Drs. Lee and 
Carrasquilla are cited accordingly in the relevant sections of this chapter for their generous 
contributions to this work.  
 
4.1.1 Significance and purpose of study 
Advances in genetic studies and technologies have greatly enhanced our current 
understanding of malaria parasites. Whole genome sequencing (WGS) technologies allow for 
real-time monitoring and detection of genetic changes in parasite populations throughout 
widespread endemic areas. These technologies enable us to track genetic changes as they 
occur and provide useful information for both control efforts and the potential elimination of 
the disease (Ariey et al., 2014, Miotto et al., 2015, Manske et al., 2012, Wootton et al., 2002, 
Dondorp et al., 2009). With the use of genome wide association studies (GWAS), we can 
identify potential molecular markers of drug resistance by comparing single nucleotide 
polymorphisms (SNPs), copy number variations, insertion and deletion polymorphisms 
(indels), and other genetic changes in parasite populations. However, the identified molecular 
markers of resistance may have no phenotypic relevance or causal relationship to the 
resistance observed. Alternatively, the molecular marker could have a more indirect impact 
on resistance, for example to compensate for the fitness cost of another mutation. In order to 
understand how drug resistance develops, and definitively test whether a marker is necessary 
and sufficient to confer resistance, it is necessary to perform functional studies. We can 
harness the clues GWAS provides and use them as a roadmap for assessing the mechanisms 
of resistance of various antimalarial drugs. The purpose of this study was to use CRISPR-
Cas9 gene editing to investigate the role of two nonsynonymous SNPs associated with 
piperaquine resistance: a putative exonuclease protein SNP, PF3D7_1362500 (exo-E415G 







SNP) (Amato et al., 2017). This study fills a knowledge gap in the lack of functional data for 
molecular markers of piperaquine resistance by examining phenotypic and functional 
relevance of the genotypes observed. 
 
4.1.2 Introduction  
The ability of the P. falciparum parasite to adapt to the selective pressure of antimalarial 
drugs is a major impediment to treatment regimens. The use of specific antimalarial drugs in 
distinct geographic regions can also have an immense effect on the evolution of parasite 
populations in different areas. It is therefore necessary to have a means to detect and track 
these genetic changes as they occur. Whole genome sequencing (WGS) of P. falciparum was 
first published in 2002 (Gardner et al., 2002, Hall et al., 2002) and such technologies have 
revolutionized malaria control and treatment programs by enabling widespread surveillance 
of malaria parasite populations throughout the globe. When combined with clinical studies 
and in vitro drug susceptibility profiles, genome wide association studies (GWAS) enable 
identification and genetic tracking of molecular markers of resistance (Ariey et al., 2014, 
Miotto et al., 2015, Manske et al., 2012, Wootton et al., 2002, Dondorp et al., 2009, Amato et 
al., 2017, Witkowski et al., 2017, Imwong et al., 2017). This information can provide clues 
for uncovering mechanisms of resistance, though molecular markers may eventually be 
found to play little to no causal role in the drug-resistant phenotype. As artemisinin and 
partner drug resistance continue to spread throughout Southeast Asia (SEA), it is crucial to 
elucidate and understand mechanisms of antimalarial drug resistance in order to aptly inform 
current and future malaria treatment strategies. 
 
As detailed in Chapter 1, artemisinin combination therapies (ACTs) are the first line 
treatment for P. falciparum malaria and function by combining a potent short-acting 
artemisinin derivative with a long-acting partner drug with a different mechanism of action 
(World Health Organization, 2018). Over the last decade, dihydroartemisinin-piperaquine 
(DHA-PPQ) has been the ACT commonly used in many countries in SEA, including 
Cambodia, Thailand, Myanmar, and Vietnam, among others (World Health Organization, 
2015). However, both artemisinin and piperaquine resistance have been reported at multiple 
sites in Cambodia and neighboring countries (Cui et al., 2015), with the most recent reports 
from 2015-2018 documenting an even further decline of DHA-PPQ efficacy, with efficacy 
rates of 12%, 38%, and 47% in Northeastern Thailand, Western Cambodia, and Southwestern 








In order to monitor and investigate the causes of DHA-PPQ resistance, multiple studies have 
reported independent molecular markers of resistance for both artemisinin and piperaquine 
resistance. Several mutations in the kelch 13 (K13) gene have been accepted as markers of 
artemisinin resistance (Ariey et al., 2014, Miotto et al., 2013) and multiple studies (outside 
the scope of this doctoral thesis) have focused on determining the mechanism of artemisinin 
resistance (Meshnick et al., 1991, Tilley et al., 2016, Bridgford et al., 2018, del Pilar Crespo 
et al., 2008, Klonis et al., 2013, Heller and Roepe, 2019, Mok et al., 2015, Mok et al., 2011, 
Rocamora et al., 2018, Sa et al., 2018, Straimer et al., 2015), which is a complex and 
unfinished story. Molecular markers of piperaquine resistance were first reported in 2017 
(Amato et al., 2017, Witkowski et al., 2017) and have emerged on a K13 mutant background 
(Imwong et al., 2017, Amato et al., 2018). As discussed in Chapter 3, amplification of the 
plasmepsin 2 and plasmepsin 3 (PM2-3) genes on chromosome 14 associates with DHA-PPQ 
failures in patients (Witkowski et al., 2017, Amato et al., 2017) and the amplification is 
currently used as a reliable marker of piperaquine resistance (Chapter 3) (Jacob et al., 2019, 
van der Pluijm et al., 2019, Hamilton et al., 2019). Additional in vitro studies (Agrawal et al., 
2017, Dhingra et al., 2017, Ross et al., 2018a) have reported mutations in the chloroquine 
resistance transporter gene (pfcrt) that confer variable degrees of piperaquine resistance. 
Following these reports, more recent genetic studies (Hamilton et al., 2019) have identified 
an increased frequency of previously reported (Agrawal et al., 2017, Ross et al., 2018a) and 
novel mutations in PfCRT that have arisen on an amplified PM2-3 background that 
significantly associate with decreased piperaquine susceptibility. However, before these 
PfCRT mutations were prevalent, piperaquine treatment failures and parasites with decreased 
in vitro piperaquine susceptibility were present on PfCRT backgrounds lacking these 
mutations (Amato et al., 2017) (Chapter 2, Table 2.1). Consequently, many questions 
remain in the pursuit to discover the genetic determinants of piperaquine resistance. 
 
At the time this thesis commenced, a genome-wide association study (GWAS) (Amato et al., 
2017) of 297 parasite isolates exposed to DHA-PPQ identified SNPs that strongly associate 
with reduced PPQ susceptibility in vitro and DHA-PPQ failures in patients detailed in Table 
4.1. The top most significant nonsynonymous SNPs are located on chromosome 13 in a 
putative exonuclease (exo-E415G) and a mitochondrial carrier protein (mcp-N252D) (Table 
4.1). Unlike the above-mentioned markers of piperaquine resistance, no in vitro work has 









Table 4. 1 Top GWAS candidate SNPs associated with increased piperaquine IC50 
values 
 
Table 4.1, adapted from Amato et al. 2017 (Amato et al., 2017), displays the top ten GWAS candidate 
SNPs associated with increased piperaquine IC50 values in order of increasing p-value. Each gene is 
listed with: chromosome number (chr.); nucleotide position (position); gene ID and description; type 
of SNP: nonsynonymous (N) or synonymous (S); the amino acid difference (alteration); and p-value. 
 
The nonsynonymous SNP in the putative exonuclease protein, PF3D7_1362500, encodes a 
glutamic acid (E) to glycine (G) substitution at position 415 and the prevalence of this SNP 
has increased along with the PM2-3 amplification in Cambodia from the time period of 2012-
2015 (Figure 4.1) (Amaratunga et al., 2019). Though sparse information is known about this 
protein in P. falciparum, the putative exonuclease contains domains with sequence similarity 
to 3’- 5’ exonucleases from other organisms including both prokaryotes and eukaryotes 
(PlasmoDB; NCBI BLAST). However, sufficient data is currently not available for 
generating a proposed model for the domain structures of the putative exonuclease, 
PF3D7_1362500.  
 
As implied by their name, exonucleases are enzymes that cleave nucleotides from DNA at 
the 3’ or 5’ ends by hydrolyzing the phosphodiester bonds between nucleic acids (Shevelev 
and Hübscher, 2002, Lovett, 2011). This is a common feature of some polymerases that have 
“exo activity” or proofreading activity and is distinguished from endonuclease activity 
because exonucleases excise from the end of the DNA chain as opposed to internally (Lovett, 
2011). Prior research has shown that 3’-5’ exonuclease activity is also needed in double-
stranded break repair and in non-homologous end joining (NHEJ) showing a role for 
exonucleases not only in DNA replication but also in distinct repair processes (Shevelev and 










Figure 4. 1. Prevalence of the PM2-3 copy number amplification and exo-E415G SNP in three 
provinces in Cambodia from 2012-2015. (Adapted from Amaratunga et al. (Amaratunga et al., 
2019) with PM2-3 CNV data obtained from Chapter 3.) 
 
This study hypothesized that the P. falciparum putative exonuclease plays a 3’- 5’ 
proofreading role during DNA replication and perhaps even DNA repair. It is uncertain what 
role, if any, the exo-E415G SNP plays in piperaquine-resistant P. falciparum, however one 
possibility is that the SNP affects the proofreading or repair ability of the putative protein, 
leading to significant differences (increases or decreases) in the overall mutations in the 
parasite, which might aid in the resistant phenotype. Studies by Lee and Fidock (2016) 
examined mutator rates of Cambodian isolates with mutations in repair genes in comparison 
to reference laboratory strains without mutations and showed only a mild increase in overall 
mutations in Cambodian isolates possessing the mutant repair genes (Lee and Fidock, 2016). 
The role of the exo-E415G SNP could thus be directly related to survival or fill a milder, 
indirect role in resistance via fitness or compensatory measures. This thesis therefore hopes 
to provide insight into the role the exo-E415G SNP plays in the parasite response to 
piperaquine. 
 
Similar to the exonuclease, little is currently known about the putative mitochondrial carrier 
protein (MCP). The nonsynonymous SNP in the putative MCP, PF3D7_1368700, encodes an 
asparagine (N) to aspartic acid (D) substitution at position 252 (mcp-N252D). Mitochondria 
are vital organelles in all eukaryotic organisms, serving key roles in metabolism, apoptosis, 







proteins that mediate transport of molecules across the mitochondrial membranes. MCPs thus 
enable mitochondrial activities and connect processes in the cytosol with those in the 
mitochondrial matrix (Wohlrab, 2009). MCPs are nuclearly encoded and contain inner 
targeting signals that direct them to the inner mitochondrial membrane, where MCPs 
transport molecules such as adenosine triphosphate (ATP) or protons (H+) to establish 
membrane gradients (Kunji, 2004). Sequence analysis of the PF3D7_1368700 putative MCP 
using PlasmoDB and BLAST, shows that this molecule shares amino acid sequence 
similarity with other MCPs, specifically with the yeast ADP/ATP carriers, Aac2p and Aac3p 
(Ruprecht et al., 2014). Conserved motifs for MCPs consist of a PX(D/E)XX(K/R) motif 
(Ferramosca and Zara, 2013, Robinson and Kunji, 2006, Kunji, 2004), called the carrier 
signature and sequence analysis by this study suggests the motif is present in the 
PF3D7_1368700 MCP as PGDTVR. Similar to the putative exonuclease protein, not enough 
information is available to generate a model for the domain structures of the MCP, 
PF3D7_1368700. 
 
Antimalarial drug resistance in P. falciparum has long been associated with genetic variation 
in malaria transporters (PfCRT, PfMDR1, PfMDR2) (Ecker et al., 2012, Eastman et al., 
2011, Kirk, 2001, Sauvage et al., 2009) but no studies have yet reported a role for the 
putative MCP PF3D7_1368700 in resistance. However, studies by Cowell et al. (Cowell et 
al., 2018) have identified mutations in another mitochondrial protein on chromosome 1, 
PF3D7_0108400, after in vitro drug selection experiments with several different compounds. 
Due to the significant correlation of DHA-PPQ failures and the presence of this mcp-N252D 
SNP, I decided to test if the putative MCP, PF3D7_1368700, could also have a functional 
role in facilitating piperaquine resistance. It should be stated that like the exo-E415G SNP, it 
is possible the mcp-N252D SNP could have a modest role in resistance and instead serve a 
compensatory role in modulating parasite fitness. It is also entirely plausible that both SNPs 
are unrelated to piperaquine resistance. Furthermore, the putative proteins could behave very 
differently in P. falciparum when compared to the homologous proteins in other organisms 
from which they inherited their putative names due to sequence similarities. Thus, further 
genetic studies are imperative to shed light on these questions and postulations. 
 
The goal of this study is to evaluate the potential role of the resistance-associated SNPs, exo-
E415G and mcp-N252D, in susceptibility to piperaquine. To examine these genetic 
associations, I used CRISPR-Cas9-based genome editing to dissect out the potential 







Southeast Asian lab-adapted line Dd2 and in piperaquine-sensitive and resistant Cambodian 
isolates that contain the wildtype and mutant SNPs, respectively. I then examined if there 
were any phenotypic differences in the transgenic parasites by analyzing the drug 
susceptibility profiles of each edited line in response to piperaquine and other commonly 
used antimalarial drugs.  
 
4.1.3 Objectives 
Investigate the role of the putative exonuclease (PF3D7_1362500) and mitochondrial carrier 
protein (PF3D7_1368700) single nucleotide polymorphisms (SNPs) in piperaquine resistance 
(1) Investigate whether the exonuclease nonsynonymous SNP on chromosome 13, exo-
E415G SNP, confers piperaquine resistance and characterize any additional 
phenotypes 
a. Use CRISPR-Cas9 to insert the exo-E415G SNP into the lab strain, Dd2 and 
Cambodian field isolates 
b. Characterize the exo-E415G SNP in phenotypic assays 
(2) Evaluate the role of the putative mitochondrial carrier protein (PF3D7_1368700) 
nonsynonymous SNP on chromosome 13, mcp-N252D, in piperaquine resistance 
a. Use CRISPR-Cas9 to insert the mcp-N252D SNP into the lab strain, Dd2 and 
Cambodian field isolates 
b. Characterize the mcp-N252D SNP in phenotypic assays 
 
4.2 Materials and methods 
4.2.1  CRISPR-Cas9 mediated genome editing: two-plasmid system 
Initial attempts at CRISPR-Cas9-based gene editing (Jiang and Doudna, 2017, Sander and 
Joung, 2014) of the exonuclease SNPs were made using a two-plasmid system (Figure 4.2). 
All plasmids were designed and generously provided by Dr. Marcus Lee.  
 
4.2.1.1 Exonuclease exo-415 SNP editing plasmids 
For the exonuclease exo-415 wildtype (E) and mutant (G) SNP two-plasmid editing system, 
one plasmid (Figure 4.2A, plasmid one) contained the gRNA and Cas9 (pDC2-cam-Cas9-
U6-hdhfr, 11.9 kb) and the second plasmid (plasmid two) contained a 1 kb donor region with 
either the exo-E415 wild-type SNP or with the exo-G415 mutant SNP (pDC2-cam-egfp-BSD-
attP, 5.602 kb) (Figure 4.2B, plasmid two). Briefly, identification of an appropriate gRNA 
was performed using the online resources at Benchling (benchling.com) and Cas-OFFinder 







by the NGG motif, located near the SNP at the amino acid position 415 in the exonuclease 
gene, PF3D7_1362500, near the SNP location at amino acid position 415 followed by NGG. 
The Cas9 endonuclease encoded by plasmid one (Figure 4.2A) is from Streptococcus 
pyogenes which recognizes and will create a double stranded DNA break at the protospacer 
adjacent motif (PAM) sequence, 5’-NGG-3’ (Anders et al., 2014). The exonuclease donor 
sequence in the donor plasmid (plasmid two) (Figure 4.2B) was synthesized to include 
several synonymous SNPs at the gRNA recognition site (Table 4.2, lowercase letters) to 
prevent Cas9 from cleaving the plasmid and the edited genome. It should also be noted that 
for the exo-415 guide, the SNP of interest (415) is located within the gRNA sequence. For 
the wildtype codon, the sequence “GAG” encodes a glutamic acid (E) at position 415 (Table 
4.2, in bold), for the mutation, the sequence, “GgG” encodes the mutant glycine (G) (Table 
4.2, in bold).  
 
Table 4. 2 gRNA sequences in the donor plasmids for the exo-415 and mcp-252 
CRISPR-Cas9 plasmids 
Gene SNP position Guide RNA (5' - 3') in donor template 
exonuclease, E415 415 AAGAGGAAGTgAACAAcCAc 
exonuclease, G415 415 AAGgGGAAGTgAACAAcCAc 
mitochondrial carrier protein 252 CGATATTTTATTGATGCtTC 
 
4.2.1.2 Two-plasmid system: cloning of the gRNA and donor plasmids 
To clone the gRNA into plasmid one, pDC2-cam-Cas9-U6-hdhfr, two complementary 
primers including the specific gRNA sequence and overhangs for ligation into the BbsI site 
were generated (Figure 2A). The pDC2-cam-Cas9-U6-hdhfr plasmid was digested with BbsI 
followed by dephosphorylation of the vector using an alkaline phosphatase (NEB). At the 
same time, the complementary guide oligos were resuspended to 100 µM in water and 
phosphorylated in 10 µL total using: 1 µL of each oligo, 1 µL 10X ligation buffer (NEB) and 
0.5 µL T4 polynucleotide kinase (NEB), and 6.5 µL water. Guide oligos were then incubated 
in a thermocycler for 30 minutes at 37°C, followed by denaturation at 94°C for 5 minutes, 
then annealing in decreasing steps of 5°C every 5 minutes to 25°C. After annealing, the 
oligos were ligated into the BbsI digested pDC2-cam-Cas9-U6-hdhfr vector. A 1:200 dilution 
of the oligo mix was made and 1 µL of oligos was added to 1 µL of digested plasmid (50 ng), 
1 µL 10x ligase buffer (NEB) and 1 µL T4 ligase (NEB) in water up to 10 µL total. The 
ligation mix was incubated for 10 minutes at room temperature then transformed into XL10 
gold competent cells (section 2.8.1) and plated on LB-ampicillin plates. Donor regions were 







similar procedure using the enzymes AatII and EcoRI to digest the plasmid at the donor site. 
Following confirmation of the correct insertion of the guide and donor sequences, the 




Figure 4. 2. Two-plasmid system for CRISPR-Cas9 editing of the exonuclease SNP. A.) Plasmid 
one: the pDC2-cam-Cas9-U6-hdhfr plasmid with Cas9 expression cassettes. The gRNA cloning site is 
flanked by BbsI digestion sites (labeled)  B.) Plasmid two: the pDC2-cam-egfp-BSD-attP donor 
plasmid containing the homology region (HR) and the desired exonuclease SNP for editing parasites 
to either the wild-type (E) or mutant (G) exonuclease SNP on Chromosome 13. The donor cloning 
site outside of the homology region (gold) includes EcoRI and AatII digestion sites. 
 
4.2.2  CRISPR-Cas9 mediated genome editing: single plasmid system 
The pDC2-cam-coCas9-U6-hdhfr single plasmid editing system (Figure 4.3) designed by Dr. 
Marcus Lee was also used in this study. In this vector, Cas9 has been codon optimized for 
expression in P. falciparum, and in addition to the gRNA cassette, contains cloning sites for 
insertion of the donor region (Figure 4.3). This enabled the pDC2-cam-coCas9-U6-hdhfr 
plasmid (~11 kb, depending on donor size) to be used as a backbone for generating both the 
exo-E415G and mcp-N252D editing plasmids, both of which were also generated by Dr. 
Marcus Lee for use in this study. The procedure for inserting both the gRNA and donor sites 
was similar to the methods described above in section 4.2.1.2. The gRNA sequences used for 
the exo-415 single plasmid system were the same gRNAs used for the two-plasmid system 
and listed in Table 4.2.  
 
The mcp-252 editing plasmids for the mitochondrial carrier protein, PF3D7_1368700, were 







Selection of gRNA (Table 4.2) and molecular cloning of the donor and gRNA regions into 
the vector plasmids was performed as described for the exo-415 plasmids. The gRNA 
sequence in the donor region (Figure 4.3) was modified to introduce a synonymous SNP 
(Table 4.2, lowercase letters) to prevent Cas9 from cutting the plasmid and the edited region 
in the genome. The SNP was located 87 bp from the gRNA site and the mutant N252D 
plasmid changes the wildtype “AAT” (N) sequence to the mutant “gAT” codon (D), whereas 
the silent N-252N plasmid maintains the wildtype (N) sequence. 
 
 
Figure 4. 3. All-in-one pDC2-cam-coCas9-U6-hdhfr plasmid. Schematic of the all-in-one pDC2-
cam-coCas9-U6-hdhfr plasmid (~11 kb) design for CRISPR-Cas9 editing contains codon optimized 
Cas9 for expression in P. falciparum, and includes the cloning sites for inserting the donor (using 
EcoRI and AatII) and gRNA (using BbsI).  
 
4.2.3  Transfection of CRISPR-Cas9 exo-415 and mcp-252 plasmids 
The plasmids were transfected into field isolates and Dd2 parasites (Chapter 2, Table 1) 
following the protocols detailed in Chapter 2, sections 2.3.1-2.3.2. Both pre-loaded red blood 
cells (RBCs) and ring stage transfections were performed. As mentioned in Chapter 2, the 
pre-loaded RBC transfection method was preferred for field isolates because it does not 
involve direct electroporation of the parasites and as a result, is likely to be less harsh to these 
parasites. Ring stage transfections were always performed for the laboratory strain, Dd2, but 
were also attempted with field isolates. Both the PPQ-sensitive and resistant isolates 
(Chapter 2, Table 1) were transfected with the plasmids containing the SNP they already 
contain (i.e. only introducing the silent gRNA site mutations) to serve as an editing control, 








For the two-plasmid system (Figure 4.2), both the gRNA/Cas9 plasmid and donor plasmid 
were transfected at the same time using 50 µg of each plasmid. The pDC2-cam-Cas9-U6-
hdhfr contains a human dihydrofolate resistance gene (hdhfr) so transfectants were selected 
with 2 nM WR99210, a DHFR inhibitor. The pDC2-cam-egfp-BSD-attP donor encodes a 
blasticidin (BSD) resistance gene and 2 µg/mL of blasticidin (BSD) was used to select for 
this plasmid (Figure 4.2). Drug selection was started on day 1 or 2 post-transfection 
depending on parasitemia on day 1 and parasites were maintained on drug for at least 8 days 
and up to 2 weeks following transfection.  
 
For the single plasmid system (Figure 4.3), the pDC2-cam-coCas9-U6-hdhfr transfectants 
were selected with 5-10 nM WR99210 on day 1 post-transfection and parasites were 
maintained with drug for 10-12 days. The Cambodian isolates have a moderate level of 
resistance to DHFR inhibitors, due to the quadruple pyrimethamine-resistance mutations in 
dhfr, so 5-10 nM WR99210 was used for the transfected parasites while 5 nM WR99210 was 
used for Dd2. 
 
To increase transfection efficiency in field isolates, some of the transfected isolates were 
cultured in parasite-conditioned media (Tables 4.4-4.5), consisting of complete media (CM) 
supplemented with drug (WR or BSD) and 25-50% of spent media from the specific parasite 
line (called conditioned media), prepared as described in section 2.4.  
 
4.2.4 Screening for integration of the exo- and mcp-SNPs in transfected parasites 
As soon as the parasites recrudesced after transfection, an aliquot of the culture was saved for 
genomic DNA extraction as described in section 2.5. The parasites were screened for 
integration of the exo-E415G and mcp-N252D SNPs using the primers listed in Table 4.3. 
PCR amplification and sequencing protocols were performed as described in sections 2.8.3-
2.8.4. At least one primer was designed outside of the donor homology region to ensure that 
the region amplified was from the genome and not the episomal donor plasmid (Figure 4.4). 
 
After initial screening, the parasites with confirmed edits were cloned by limiting dilution 
(section 2.4) and collected for sequencing (section 2.8.4) to confirm the genotype in each 
clone. Following confirmation, clones were cryopreserved (section 2.1.3; at least two vials 









Figure 4. 4. Primers for PCR screening of transfectants for integration of the desired locus on 
chromosome 13 (blue line) to capture the exo-415 or mcp-252 SNPs. The gold HR1 and HR2 
regions represent the homology regions surrounding the SNP included in the donor region. The 
forward (Fwd) primer includes the region with the SNP and the reverse (Rev) primer is outside of the 
donor homology region so that only regions integrated into the genome will be amplified. 
 





name Primer (5' - 3') sequence Description 
exo exo-415 two exo_fwd1 
CTGACCCCTTTATAGG
AATGTGC 
fwd inside donor 
region; for 
sequencing 
      exo_rev1 
CTTGGTTAAGTGGTCT
TATATTCCAGTTAGC 
rev flanking donor 
region 
            
mcp mcp-252 single p1580 
GATGACAAAACAAAG
TTACGCTTCC 
fwd flanking donor; 
for sequencing 
      p1581 
CTTAATAAATCTAATG
GATATGAGAGAG rev flanking donor 
 
4.2.4 Drug sensitivity assays  
 
Drug susceptibility profiles of the wildtype and mutant exo-415 and mcp-252 edited parasite 
lines were assessed according to the protocols detailed in Chapter 2 (section 2.6). Standard 
IC50 assays (section 2.6.2) were performed using piperaquine (PPQ) and other commonly 
used antimalarial drugs including: dihydroartemisinin (DHA), lumefantrine (LUM), 
chloroquine (CQ), and mefloquine (MQ). Piperaquine survival assays (PSAs) (section 2.6.3) 
were also performed on the wildtype and mutant edited exo-415 and mcp-252 parasite lines. 
All IC50 assays and PSAs were performed in duplicate and triplicate, respectively, with three 




4.3.1 CRISPR-Cas9 editing of the exonuclease-415 SNPs: low transfection efficiency 
in field isolates 
CRISPR-Cas9 gene editing of the exonuclease, exo-415 SNP, to the wildtype (E) and mutant 
(G) SNPs observed in piperaquine-sensitive (PPQ-S) and resistant (PPQ-R) isolates from 
Cambodia was attempted in culture-adapted Cambodian field isolates (Ch. 2, Table 2.1). All 







performed using pre-loaded RBCs. The two-plasmid was used at the commencement of this 
study because this system had been used successfully by the Lee Lab and many other labs for 
CRISPR-Cas9 editing (Ghorbal et al., 2014). During the course of this study, Dr. Marcus Lee 
designed the all-in-one CRISPR-Cas9 plasmid and due poor transfection efficiencies with the 
two-plasmid system, I switched to the single-plasmid system.  
 
Transfection efficiency for all isolates was low with only five transfections out of 158 total 
transfections recrudescing post-drug selection, two of which were cultured with parasite-
conditioned media (Table 4.4). Amplified PCR products from transfected parasites that 
recrudesced were screened for edits and sequencing data showed that none of these 
transfectants contained the desired edits (Figure 4.5). The parasite lines 033 and 056 are 
PPQ-S isolates that should have been edited to the mutant G amino acid codon (“GGG”) but 
they remained the wildtype (“GAG”). The parasite line 021 is a PPQ-R isolate that should 
have been edited to the wildtype E amino acid codon (“GAG”) but also remained unedited 
(“GGG”) (Figure 4.5). 
 
Table 4. 4 CRISPR-Cas9 transfections and outcomes of exo-415 SNP editing 
experiments in Cambodian field isolates 
 
Table 4.4 Details of the field isolate transfections with exo-415 SNP plasmids, categorized by parasite 
line (field isolate name), PPQ susceptibility status (sensitive or resistant), and the plasmid system 
used for CRISPR-Cas9 gene editing (two-plasmid or single-plasmid). The transfections are further 
sorted based on whether conditioned media was used (Y= yes N= no) with the number of 
transfections exposed to conditioned media indicated in parentheses. Recrudescent transfections are 
highlighted in yellow and are denoted with an asterisk (*) if the transfections that recrudesced were 








Figure 4. 5. Sequencing analysis of the exo-SNP field isolate transfections that recrudesced. The 
top exo, PF3D7_1362500 Ref is the wildtype reference sequence. The red box highlights the location 
of the codon 415 SNP in the reference and isolates. Parasite isolates 033 and 056 are PPQ-S exo-E415 
isolates that should have been edited to G415. Parasite isolate 021 is a PPQ-R exo-G415 isolate that 
should have been edited to the wildtype E415 SNP. Primers used to screen the exo-SNP two-plasmid 
transfectants are listed in Table 4.3. 
 
Due to the lack of editing success in Cambodian field isolates, the exo editing plasmids were 
transfected into the Southeast Asian lab strain, Dd2, in parallel by Dr. Manuela Carrasquilla. 
Both the wildtype (silent) and mutant (G) exo-415 SNPs were edited in the Dd2 parasite 
using the single-plasmid system (Figure 4.3). Dr. Carrasquilla confirmed the edits using PCR 
and sequencing (data not shown).  
 
4.3.2 CRISPR-Cas9 editing of the mitochondrial carrier protein-252 SNPs: low 
transfection efficiency in field isolates and successful editing in Dd2 parasites 
CRISPR-Cas9 gene editing of the mitochondrial carrier protein, mcp-252 SNP, yielding the 
wildtype N codon (AAT) or the mutant D codon (GAT), observed in PPQ-sensitive and 
resistant isolates respectively, was attempted in lab-adapted Cambodian field isolates (Ch. 2, 
Table 2.1) and the Dd2 parasite strain. Both pre-loaded RBC and ring stage transfections 
were performed and are detailed in Table 4.5. Similar to the exo-415 plasmid transfections, 
efficiency of field isolate transfections with the mcp-252 single plasmid was low with one 
field isolate out of 120 total transfections recrudescing (Table 4.5). The line 033-mcp-N252D 
transfectant that recrudesced (Table 4.5, Figure 4.6) was screened for edits and sequencing 
data showed that the SNP remained unedited although the silent mutation in the gRNA donor 








Transfection efficiency of the Dd2 strain was much higher with two of four total 
transfections recrudescing and one of the transfections containing the edited SNP (Table 
4.5). The two Dd2-mcp-N252D transfectants that recrudesced were screened for edits and the 
sequencing data showed that one of the transfections carried approximately 30% of the edited 
SNP in the bulk culture (Figure 4.7A). The culture was cloned by limiting dilution and clone 
H5 was shown to contain the edited SNP (Figure 4.7B). Clone D2 did not contain the mutant 
SNP and remained wildtype (N252) (Figure 4.7C) but did contain the edit of the silent 
mutation in the gRNA region (Table 4.2). Since this indicates that clone D2 was edited, I 
used this clone as the mcp-N252N silent editing control for subsequent phenotypic assays.  
 
Table 4. 5 CRISPR-Cas9 transfections and editing efficiency of the mcp-252 SNPs in 
Cambodian field isolates and Dd2 
 
Table 4.5 Details of the field isolate transfections with mcp-252 SNP editing plasmids categorized by 
parasite line (field isolate name), PPQ susceptibility status (sensitive or resistant), and the plasmid 
system used for CRISPR-Cas9 gene editing (single-plasmid), and the method for transfection, pre-
loaded RBCs (loaded) or directed electroporation (rings). The transfections are further sorted based 
on whether conditioned media was used (Y= yes; N= no) with the number of transfections exposed to 
conditioned media indicated in parentheses. Recrudescent transfections are highlighted in yellow and 











Figure 4. 6. Sequencing analysis of the mcp-SNP field isolate transfection post-recrudescence. 
A.) The Ref sequence is the wildtype reference sequence. The red box highlights the location of the 
mcp-252 codon in the reference and isolate. Parasite isolate 033 is a PPQ-S mcp-N252 isolate that 
should have been edited to D252 (“GAT”) but remains the wildtype N (“AAT”) sequence. B.) The 
mcp gRNA sequence (listed in Table 4.2 and located 87 bp from the SNP) showing a silent mutation 
(lowercase letter “a”) in the donor region. C.) Sequence analysis of the transfectant 033-mcp-N252D 
shows that the silent mutation in the gRNA is edited in the parasite compared to the wildtype mcp-















Figure 4. 7. Sequencing analysis of the Dd2-mcp-SNP transfections. A.) The top Ref sequence is 
the wildtype reference sequence. The chromatogram shows the region of the mcp-252 SNP in the 
reference and the two Dd2 transfections that recrudesced: Dd2-mcp1 and Dd2-mcp2. The Dd2-mcp1 
chromatogram shows a mixed peak (red box) around position 252, displaying both a wildtype “T” and 
a small blue peak on the chromatogram that is the mutant “C”. Chromatograms for both the forward 
p1580 (F) and reverse p1581 (R) primers are displayed. Dd2-mcp2 did not show mixed peaks or any 
signs of editing. B.) Sequence analysis of Dd2-mcp1-N252D clones. Dd2 clone H5 contains the 
edited SNP “G” (highlighted in the red box) and the other clones (D2, G3, G4, and F10) are unedited 
and remain the wildtype “A”. Note: the sequence in panel (B) is the reverse sequence of the sequence 
displayed in panel (A). In the sequence in panel (A), the edited nucleotide is a C and in the reverse 
sequence in panel (B), the edited nucleotide is a G. C.) Sequence analysis of Dd2 clones shows that 
although the mutant D SNP is not edited in every clone, the silent mutation in the gRNA site is edited 
in all Dd2-mcp1 clones. Clone Dd2-D2 was used as the silent-edited wildtype line for all drug assays. 
Primers used to screen the mcp-SNP transfectants are listed in Table 4.3.  
 
4.3.3 Drug susceptibility profiles of the edited exonuclease and mitochondrial 
carrier protein SNPs in Dd2-edited parasite lines 
 
4.3.3.1 The exo-E415G SNP does not alter parasite susceptibility to common 
antimalarial drugs 
The transgenic exo-E415G mutant and wildtype (silent exo-E415E) parasites were tested in 
72-hour survival assays to compare susceptibility to piperaquine (PPQ) and several other 
antimalarial drugs: chloroquine (CQ), dihydroartemisinin (DHA), mefloquine (MQ), and 
lumefantrine (LUM). MQ, LUM, and CQ were selected based on their structural similarity to 
piperaquine, as they are quinolone drugs, and DHA, MQ, and LUM are all currently 







antimalarial drugs showed that the exo-E415G mutant SNP had little to no effect on parasite 
susceptibility to the five drugs compared to the wildtype control (Figure 4.8). This was 
further supported by the IC50 values for each drug condition (Figure 4.8F).  
 
4.3.3.2 The mcp-N252D SNP does not alter parasite susceptibility to common 
antimalarial drugs 
The transgenic mcp-N252D mutant and wildtype (silent mcp-N252N) parasites were also 
tested in 72-hour survival assays to compare susceptibility to the same drugs as described for 
the exo-SNP lines: PPQ, CQ, DHA, MQ, and LUM. The dose response curves for all five 
antimalarial drugs showed that the mcp-N252D mutant SNP had little to no effect on parasite 
susceptibility to the five drugs compared to the wildtype control (Figure 4.9). This was 
further supported by the IC50 values for each drug condition (Figure 4.9F). 
 
4.3.3.3 The exo-E415G and mcp-N252D SNPs do not alter parasite survival in 
piperaquine survival assays  
I further assessed the phenotype of the transgenic exo-E415G and mcp-N252D parasites in 
piperaquine survival assays (PSAs). After 48 hour exposure to piperaquine and then a further 
incubation period of 24 hours (as described in section 2.6.3), little to no differences were 











Figure 4. 8. The exo-E415G SNP has no effect on IC50 values or susceptibility to PPQ and other 
commonly used antimalarial drugs. A.-E.) Dose-response curves for Dd2 edited parasites 
containing the mutant exo-E415G SNP (red) or the wildtype exo-E415E control (blue) exposed to: 
piperaquine (PPQ) (A), chloroquine (CQ) (B), mefloquine (MQ) (C), dihydroartemisinin (DHA) (D), 
and lumefantrine (LUM) (E). Error bars represent SD (n=3 biological replicates). F.) Table showing 
the average IC50 values for the mutant and wildtype (WT) exo-415 SNP transgenic Dd2 lines 
calculated using GraphPad Prism Version 8.0.2. G.) Mean IC50 values ± SD for each drug (PPQ, CQ, 
MQ, DHA, LUM) tested on the exo-E415G SNP (red) and the wildtype exo-E415E control (blue) 
lines. Significance was determined using Mann-Whitney U tests comparing the mutant and silent 
edited lines. n.s. indicates not significant (p>0.05). No significant differences were observed between 












Figure 4. 9. The mcp-N252D SNP has no effect on IC50 values or susceptibility to PPQ and 
other commonly used antimalarial drugs. A.-E.) Dose-response curves for Dd2 edited parasites 
containing the mutant mcp-N252D SNP (green) or the wildtype mcp-N252N control (black) exposed 
to: piperaquine (PPQ) (A), chloroquine (CQ) (B), mefloquine (MQ) (C), dihydroartemisinin (DHA) 
(D), and lumefantrine (LUM) (E). Error bars represent SD (n=3 biological replicates). F.) Table 
showing the average IC50 values for the mutant and wildtype (WT) mcp-252 SNP transgenic Dd2 
lines calculated using GraphPad Prism Version 8.0.2. G.) Mean IC50 values ± SD for each drug (PPQ, 
CQ, MQ, DHA, LUM) tested on the mcp-N252D SNP (green) and the wildtype mcp-N252N control 
(black) lines. Significance was determined using Mann-Whitney U tests comparing the mutant and 
silent edited lines. n.s. indicates not significant (p>0.05). No significant differences were observed 









Figure 4. 10. The Dd2 transgenic exo-E415G and mcp-N252D edited SNPs have no effect on 
parasite survival to PPQ in piperaquine survival assays (PSAs). PSAs comparing parasite 
susceptibility to piperaquine. Parasites were exposed to 200 nM PPQ for 48 hours and measured at 72 
hours. Error bars represent SD (for exo, n=3 biological replicates; for mcp, n=2). Significance was 
determined using Mann-Whitney U tests comparing PSA values for the mutant and silent edited lines 
for each SNP, exo-415 and mcp-252. n.s. indicates not significant (p>0.05).  
 
4.4 Discussion and future work 
The studies by Amato et al. and Witkowski et al. (2017) were the first reports to 
independently identify molecular markers of piperaquine resistance that associated with 
DHA-PPQ failures in patients and decreased PPQ susceptibility in vitro (Amato et al., 2017, 
Witkowski et al., 2017). The top two nonsynonymous SNPs (Table 4.1) discovered by the 
GWAS performed by Amato et al., but not reported by Witkowski et al., were in a putative 
exonuclease protein, PF3D7_13625000, and a mitochondrial carrier protein, 
PF3D7_1368700 (Amato et al., 2017). These findings laid the groundwork for this thesis, 
which aimed to characterize the potential functional roles of the exo-E415G and mcp-N252D 
SNPs in piperaquine resistance. In order to investigate the molecular mechanisms of 
piperaquine resistance and to validate these two molecular markers of resistance, the study 
began with the initial questions: do these genes play a causal or compensatory role, if any, in 









This study used parasites generated by CRISPR-Cas9 gene editing to elucidate phenotypic 
effects of the exo-E415G and mcp-N252D SNPs in response to piperaquine pressure. One of 
the main objectives was to insert the wildtype and mutant SNPs into both piperaquine-
resistant (PPQ-R) and PPQ-sensitive (PPQ-S) isolates to examine if reverting PPQ-R 
parasites to the wildtype SNP and changing the PPQ-S to the mutant SNP would alter 
susceptibility of the isolates to piperaquine. Though over a hundred transfections of culture-
adapted lines from various Cambodian field sites were attempted for both the exo- and mcp-
SNPs (Tables 4.4-4.5), only five exo-415 SNP transfectants from three different isolates 
recrudesced; but sequencing showed that none of the desired editing events occurred (Table 
4.4, Figure 4.5). For the mcp-252 transfections, one transfectant recrudesced, but sequencing 
showed only a silent mutation present in the donor region of the gRNA and no change in the 
desired SNP (Table 4.2, Figure 4.6). Though the gRNA selected for the mcp-252 editing 
plasmid was close to the mcp-252 SNP (87 bp downstream) and contained all features of a 
suitable gRNA candidate with no predicted off-target sites (Table 4.2), it is possible that it 
was too far from the region of the SNP to be edited. It should also be noted that the genomic 
sequences of the field isolates were compared to the reference sequences of Dd2 from which 
the gRNA sequences were designed to ensure there were no additional SNPs in the field 
isolates that may have interfered with the editing processes for both the exo and mcp genes. 
Transformation of the Dd2 strain, however, proved successful with both exo- and mcp-SNPs, 
raising the intriguing question of other possible differences that might account for the editing 
successes with Dd2 but not with the more recently lab-adapted Cambodian lines. 
 
Transfections in P. falciparum asexual stage parasites are notorious for their low efficiency 
(de Koning-Ward et al., 2000, Carvalho and Menard, 2005). Prior notable studies have 
shown that transfections in the rodent malaria parasite, P. berghei are much higher than P. 
falciparum, with efficiency rates of 10-2 to 10-3 (Janse et al., 2006) compared to 10-6 to 10-9 in 
P. falciparum. Further studies in P. knowlesi have demonstrated even higher success rates, 
reporting 30-40% transfection efficiency (Moon et al., 2013). Due to these known 
transfection obstacles in P. falciparum, this study attempted to increase chances of 
transfection success in field isolates by favoring pre-loaded RBC transfection methods, 
which are shown to be ~5-180 fold more efficient than direct parasite electroporation 
methods (Hasenkamp et al., 2012). Additionally, about half of field isolate transfections were 
supplemented with parasite-conditioned media (Tables 4.4-4.5) to try to reduce parasite 
stress and promote favorable growth conditions. Several transfectants cultured with 







as seen in the parasite transfection efficiency Tables 4.4-4.5, these additional procedures did 
not produce edited parasites. Further comparisons of transfection efficiency with conditioned 
media and without are therefore necessary to determine if the supplemented media has any 
effect on transfection success. Furthermore, parasite-conditioned media is widely used to 
promote conversion of asexual stage parasites to gametocytes (Williams, 1999), based on the 
findings from Carter and Miller (Carter and Miller, 1979) which showed that the 
environmental culture conditions affect gametocytogenesis. Since field isolates already have 
a higher proportion of gametocytes and greater likelihood of parasites to commit to sexual 
stages than lab reference strains, it is possible that rather than promoting parasite growth, the 
conditioned media used in the field isolate transfections maintained stress in cultures that 
were already stressed, post-electroporation. However, conditioned media was only used for 
28% of the exo transfections and 18% of the mcp (Tables 4.4-4.5) field isolate transfections, 
so this would not explain why the other transfections did not recrudesce. Continued 
optimization of transfection efficiency in P. falciparum in general, and especially in lab-
adapted field isolates, is required. 
 
Successful editing of the lab strain, Dd2, with the single-plasmid system for both the exo and 
mcp SNPs was achieved (Figures 4.- 4). This indicates that the single-plasmid systems for 
the exo- and mcp- were able to produce the desired edits in P. falciparum. Since the two-
plasmid editing system for the exo-SNP was not attempted in Dd2, it is unclear if the low 
editing success was due to the plasmids or the low transfection efficiency in the field isolates. 
However, this cannot explain why the single-plasmid system for both the exo and mcp SNPs 
worked in Dd2 but not in the field isolates. As mentioned, the Dd2-exo-415 mutant and silent 
edited (wildtype) parasites were obtained from Dr. Carrasquilla and no data on transfection 
efficiency are available for those lines. However, for the Dd2-mcp-252 mutant and silent 
parasites, two out of two total Dd2 transfections (100% transfection efficiency) recrudesced 
with one of the transfections (50% editing success) carrying the desired N252D mutation. For 
the silent editing plasmid, mcp-N252N, 0 of 2 transfections recrudesced and further 
transfections of this plasmid in Dd2 were not performed because field isolate transfections 
were prioritized. As mentioned in section 4.3.2, one of the clones, Clone D2, transfected with 
the mutant mcp-N252D plasmid did not contain the mutant SNP and remained wildtype 
(N252) but did contain the edit of the silent mutation that was in the mcp-252 editing donor 
plasmid in the gRNA region (Table 4.2; Figure 4.7). Since this indicates that clone D2 was 








Analysis of the drug susceptibility profile of the Dd2 transgenic parasites revealed that 
neither the exo-E415G nor mcp-N252D SNPs altered susceptibility to PPQ based on IC50 
survival assays and PSAs (Figures 4.8-4.10). My findings indicate that the mutations 
observed in the exonuclease and mitochondrial carrier protein are not the primary genetic 
determinants of PPQ resistance, suggesting, in line with other studies, that mutations 
elsewhere in the P. falciparum genome are responsible for resistance. The Dd2-edited exo-
415 and mcp-252 lines also showed no difference in susceptibility to other quinolone drugs, 
CQ and MQ, and additional antimalarial drugs, DHA and LUM in 72 hour IC50 survival 
assays (Figures 4.8-4.9). Based on these results, this study further indicates that the exo-
E415G and mcp-N252D SNPs do have a causal role in resistance to several commonly used 
antimalarial drugs. It remains possible that the SNPs may affect parasite fitness. Drug 
resistance mutations are often accompanied by fitness costs (Rosenthal, 2013), so the exo-
E415G and mcp-N252D SNPs could serve in these roles. Further studies would be required to 
compare fitness between the wildtype and mutant SNP transgenic parasites. 
 
It must be noted that Dd2 is lab strain that has been cultivated for many years in vitro and 
although it comes from a Southeast Asian lineage, it is genetically different from the more 
recently adapted field isolates from Cambodia used in this study (Mackinnon et al., 2009). 
The phenotypic effects of SNPs observed in the exo and mcp genes could be dependent on 
the genetic background of the Cambodian isolates. Therefore continued efforts to edit field 
isolates with both the exo- and mcp-SNP plasmids is necessary. If editing of the Cambodian 
isolates continues to prove difficult, it could also be interesting to further genetically modify 
Dd2-transgenic parasites obtained by this study. For example, the PM2-2A-PM3 episomal 
plasmid generated by this study in Chapter 3 could be transfected into the Dd2 parasites to 
evaluate if increase PM2-3 copy numbers are needed for the exo- and or mcp- SNPs to have a 
measurable phenotypic effect. Or perhaps a mutant kelch13 background is necessary for the 
effects to be observed.  
 
Although Amato et al. performed stringent tests in their GWAS analysis to ensure the signal 
on chromosome 13 was not due to confounding or batch effects (Amato et al., 2017), it is still 
possible that the exo-E415G and mcp-N252D SNPs are associated with piperaquine 
resistance because of linkage to other functional mutations in the Cambodian isolates, such as 
the PM2-3 CNV (Amato et al., 2017). Further studies of Cambodian parasites may shed light 







Though outside the scope of this study, it would be very interesting to examine the functions 
of both the exonuclease and mitochondrial carrier proteins in P. falciparum.  
Aside from preliminary transcriptomics and sequencing work, it is also important to 
acknowledge that no studies have confirmed or refuted whether the putative exonuclease 
protein and mitochondrial carrier protein in P. falciparum are actually homologous to the 
proteins to which they share sequence similarity. Therefore, future studies into the 
exonuclease and mitochondrial carrier protein, including localization, should help to evaluate 
their potential roles in drug resistance and in the biology of the malaria parasite. 
 
In order to fully understand the causes of drug resistance and inform drug development and 
treatment strategies, it is necessary to complement genetic studies with functional assays. 
This study has enabled the possibility of examining whether genetic changes observed in 
patient isolates can also be investigated and observed in in vitro settings. This study 
successfully edited a molecular marker of piperaquine resistance, an mcp-N252D SNP, in 
Dd2 parasites. Additionally, this work assessed the phenotypes of the resistance-associated 
exo-E415G and mcp-N252D SNPs in response to piperaquine and other commonly used 
antimalarial drugs. The results from this study of transgenic Dd2 parasites indicates that the 
exo-E415G and mcp-N252D SNPs are not genetic determinants of piperaquine resistance and 
likely do not play a significant role in piperaquine resistance. Though future work is needed, 
this study provides novel insight into the roles of these genetic markers in piperaquine 



























Chapter 5: Discovery of molecular markers of piperaquine 
resistance by in vitro drug-pressure of a 
hypermutator Plasmodium falciparum line 
 
5.1 Declaration of work 
The hypermutator parasite line used in this study was generated by Dr. Krittikorn 
Kumpornsin. All bioinformatic analyses were performed by Dr. Frank Schwach. Both Drs. 
Kumpornsin and Schwach are cited in the relevant sections of this chapter for their 
invaluable contributions to this work. 
 
5.1.1 Significance and purpose of study 
The current frontline treatments for Plasmodium falciparum malaria, artemisinin 
combination therapies (ACTs), are designed to increase treatment efficacy and prevent the 
development of drug resistance. These therapies combine potent, short-acting artemisinin 
derivatives with partner drugs with different mechanisms of action and longer half-lives to 
clear any remaining parasites. However, the development of artemisinin resistance in 
Southeast Asia has placed increased pressure on partner drugs. Continued treatment failures 
of the ACT dihydroartemisinin-piperaquine (DHA-PPQ) have prompted multiple reverse 
genetic studies that have identified several candidate molecular markers of piperaquine 
resistance (Amato et al., 2017, Witkowski et al., 2017, Hamilton et al., 2019). Further 
studies, including work in this doctoral thesis, have performed functional analyses to assess 
the phenotypic relevance of these genetic markers (Ross et al., 2018a, Loesbanluechai et al., 
2019, Bopp et al., 2018) (Chapters 3-4). With limited drug alternatives available, it is 
imperative to have diverse approaches to study the malaria parasite biology and the 
molecular mechanisms through which drug resistance can emerge. In comparison to reverse 
genetics approaches, forward genetics methods in P. falciparum have been largely hindered 
due to the slow spontaneous mutation rates of P. falciparum (Bopp et al., 2013). Recent 
elegant studies in the rodent malaria parasite, Plasmodium berghei (Honma et al., 2014, 
Honma et al., 2016) have designed “hypermutator” parasites that are able to rapidly develop 
mutations which can be used to obtain resistant phenotypes for drug-pressured lines. Studies 
by Kumpornsin et al. (in preparation) used this work as a model to generate a hypermutator 
parasite line in P. falciparum. The purpose of this thesis study was to use a forward genetics 







piperaquine-resistant parasites in a feasible experimental timespan by utilizing a 
hypermutator P. falciparum parasite line. Through whole genome sequencing (WGS) 
analyses of these piperaquine-resistant parasites this study identifies several gene candidates 
that have already been reported to play a role in piperaquine resistance and resistance to other 
antimalarial compounds. This study also identifies multiple new gene candidates that may 
play a causal role in piperaquine resistance. These include mutations never identified before 
in transmembrane domain (TMD) 10 of PfCRT, a domain that is thought to have a critical 
role in the homo-dimer structure of the trans-membrane channel (Summers et al., 2012). By 
combining forward genetics tools with the reverse genetics approaches detailed in the 
previous chapters, this study aims to combine functional and genomic approaches to further 
drive the quest to uncover the mechanism of piperaquine resistance. 
 
5.1.2 Introduction 
The ability of the malaria parasite, Plasmodium falciparum, to develop resistance to nearly 
all approved treatments remains a severe challenge for disease prevention and elimination 
efforts. For almost two decades, ACTs have been the standard treatment for P. falciparum 
malaria because they maximize therapeutic efficacy by combining two drugs with different 
mechanisms of action while also reducing the potential for resistance to develop (World 
Health Organization, 2018, World Health Organization, 2015, World Health Organization, 
2001, Arrow, 2004). The ACT dihydroartemisinin-piperaquine (DHA-PPQ) combines the 
fast-acting artemisinin compound with a half-life of approximately one hour with a partner 
drug with a half-life of around 23 days (Hoglund et al., 2017, Batty et al., 1998). The inherent 
contradiction in this combination is that the mismatched pharmacokinetic profiles of the 
drugs means that any recrudescent parasite or new infection is exposed to suboptimal levels 
of piperaquine monotherapy. With the failures of two different ACTs in Southeast Asia, 
artesunate-mefloquine (AS-MQ) in 2004 (Denis et al., 2006) and most recently, DHA-PPQ 
(Leang et al., 2013, Saunders et al., 2014, Spring et al., 2015, Amaratunga et al., 2016), the 
question is no longer if resistance will develop, but when and how? To inform and improve 
treatment methods, it is essential to understand the mechanisms through which malaria 
parasites can respond and adapt to the diverse pressures in their environment.  
 
Similar to many other diseases, antimalarial drug resistance can be caused by a plethora of 
complex environmental and molecular interactions. Thus, multiple approaches may be 
needed to identify mechanisms of resistance. Both reverse (target-based) and forward 







resistance (Mitchison, 1994, Schenone et al., 2013). In previous chapters of this thesis 
(Chapters 3-4), I made use of genetic information provided by genome wide association 
studies (GWAS) to examine potential genetic determinants of piperaquine resistance. In 
addition to these reverse genetics approaches, I also employed a forward genetics approach to 
complement these studies in P. falciparum by using a “hypermutator” parasite line to select 
for a piperaquine-resistant phenotype. Combining forward and reverse genetics has the 
potential to provide insight into both the mechanism of resistance and the potential 
mechanism of action of piperaquine. 
 
In many eukaryotic organisms, forward genetics studies are hindered by the slow occurrence 
of spontaneous mutations. The estimated mutation rate of human cells is 1 x 10-8 per base 
pair (bp) per generation (Genomes Project et al., 2010). In P. falciparum, the mutation rate of 
asexual in vitro cultures is approximately 1.0–9.7 × 10−9 per bp per generation (Bopp et al., 
2013). For the parasite, this slow mutation rate is desirable as it reduces the potential for 
deleterious mutations that may negatively affect survival. However, for the researcher 
performing in vitro drug-selection experiments—where obtaining a phenotype of interest is 
the primary goal—the ability to generate mutations rapidly under selective pressure is 
advantageous.  
 
The low spontaneous mutation rate in eukaryotes is largely due to the proofreading functions 
of the high fidelity replication and repair enzymes, DNA polymerases (Shevelev and 
Hübscher, 2002). There are four nuclear DNA polymerases in eukaryotic cells, a, b, d, and e. 
Both DNA polymerases d and e have 3’à5’ exonuclease activity and these proofreading 
domains are highly conserved amongst prokaryotes and eukaryotes (Hubscher et al., 2002, 
Shevelev and Hübscher, 2002, Swan et al., 2009). Studies in yeast have shown that disruption 
of the exonuclease domain of polymerase d has a strong effect on proofreading ability, 
causing a “hypermutator” phenotype characterized by at least a 10-100-fold increase in 
spontaneous mutations (Morrison and Sugino, 1994, Fortune et al., 2005). Interestingly, the 
proofreading domain of polymerase d is also highly conserved in Plasmodium (Ridley et al., 
1991). Recent studies in P. berghei, the causative agent of rodent malaria, have mutated two 
highly conserved residues in polymerase d (D311A and E313A) to obtain a hypermutator 
parasite line with 86 to 90-fold higher mutation rates than the wildtype parasite (Honma et 








Modelled after the novel studies with hypermutator P. berghei parasite lines, Kumpornsin et 
al. (in preparation) generated a mutant P. falciparum polymerase d parasite line by mutating 
the two conserved residues (D308A and E310A) in the exonuclease domain reported to affect 
proofreading ability (Morrison and Sugino, 1994, Honma et al., 2014, Honma et al., 2016). 
Based on the similarity of the P. falciparum polymerase d to its homologues in other 
eukaryotes (Ridley et al., 1991), it is hypothesized that mutations of the conserved 
exonuclease domain will also have a profound effect on mutation rates, as was observed in P. 
berghei (Honma et al., 2014, Honma et al., 2016). Though measurements of the spontaneous 
mutation rate of the P. falciparum polymerase d mutant compared to the wildtype parasite are 
in progress, preliminary data by Dr. Kumpornsin indicated that the mutant parasite line had a 
higher propensity to yield drug resistance, observations that stimulated my use of this line for 
drug-pressure experiments with piperaquine.  
 
Hypermutator lines can rapidly generate mutations under various environmental conditions, 
which can be useful in determining if certain conditions produce measurable phenotypes. The 
use of hypermutator lines enable forward genetics approaches to gather data in more feasible 
experimental timelines. Such lines also enable the possibility of examining whether genetic 
changes observed in vivo can be observed in in vitro settings. As discussed in the previous 
chapters, multiple independent studies (Agrawal et al., 2017, Ross et al., 2018a, van der 
Pluijm et al., 2019, Hamilton et al., 2019) have reported a role for mutations in the 
chloroquine resistance transporter (PfCRT) in the piperaquine-resistant phenotype. Early in 
vitro drug-pressure studies by Eastman et al. found a SNP in pfcrt (encoding a C101F 
mutation) and an amplification event upstream of the pfmdr1 gene on chromosome 5 as well 
as a deamplification of pfmdr1 (also on chromosome 5) to be associated with piperaquine-
resistant parasites (Eastman et al., 2011), though the same mutations have not been identified 
in field isolates, to date. Recent studies by Agrawal et al., van der Pluijm et al., and Hamilton 
et al. have identified pfcrt SNPs in patient isolates from Southeast Asia that strongly 
associated with DHA-PPQ failures in patients (Hamilton et al., 2019, van der Pluijm et al., 
2019, Agrawal et al., 2017). Ross et al. have used genetic editing techniques to demonstrate a 
role for several of these pfcrt SNPs in piperaquine resistance in vitro (Ross et al., 2018a). The 
ability to gather multiple lines of evidence for the role of various genes in resistant 
phenotypes greatly aids in surveillance of drug resistance. Such extensive confirmation also 








As mentioned in Chapter 4, piperaquine treatment failures and reduced PPQ susceptibility in 
vitro was observed in patient isolates lacking the more recently reported mutations, for 
example the recently prevalent PfCRT T93S mutation (Hamilton et al., 2019) (Chapter 2, 
Table 2.1) (Amaratunga et al., 2016, Amato et al., 2017, Witkowski et al., 2017). However, 
most of the isolates used by our study from 2012-2013 (Amaratunga et al., 2016) contained at 
least one PfCRT mutation (H97Y, M343L, and one isolate with no PfCRT mutations) 
(Chapter 2, Table 2.1), though the GWAS study by Amato et al. did not find an association 
of mutations in PfCRT and the piperaquine resistant phenotype (Amato et al., 2017, 
Witkowski et al., 2017). The role of the other molecular markers of piperaquine resistance 
(PM2-3 copy number amplification) in the resistant-phenotype also remains unclear. It is 
therefore necessary to combine forward and reverse genetic approaches to gain further 
insight into the mechanisms of piperaquine resistance. 
 
The aim of this study was to elucidate the genetic determinants of piperaquine resistance by 
using in vitro drug selection methods. I used a hypermutator P. falciparum line to select for 
piperaquine-resistant parasites. Through WGS analyses of these piperaquine-resistant 
parasites, this study identifies nonsynonymous SNPs in multiple gene candidates that have 
not been previously linked to piperaquine resistance, including the formate-nitrite transporter 
(FNT), the multidrug resistance protein 1 (pfmdr1), and the multidrug resistance-associated 
protein 2 (mrp2). The study also identifies mutations in PfCRT, including an A366T 
mutation that is present in a piperaquine-resistant isolate used in this study (Chapter 2, 
Table 2.1) (Amaratunga et al., 2016). Additionally, this study identifies a pfcrt SNP resulting 
in a point mutation at position G353C, which is at the same position as a G353V mutation 
observed in field isolates and reported to demonstrate a piperaquine-resistant phenotype in 
vitro (Ross et al., 2018a). By combining these forward genetics tools with the reverse 
genetics approaches detailed in the previous chapters, this study aims to combine functional 


















Use a hypermutator P. falciparum line to select for a piperaquine-resistant phenotype in vitro 
(1) Examine the phenotype of piperaquine-pressured parasites in comparison to the 
parental hypermutator line 
(2) Use whole genome sequencing analysis to compare genetic differences between the 
parental hypermutator parasites and the piperaquine-pressured parasites 
a. Identify potential gene candidates that may play a role in the piperaquine-
resistant phenotype 
 
5.2 Materials and methods 
5.2.1 Hypermutator parasites: P. falciparum Dd2-polymerase 𝛿 mutants 
All experiments were performed with a hypermutator P. falciparum line generated by Dr. 
Krittikorn Kumpornsin (manuscript in preparation). The generation of this hypermutator was 
based on studies in Saccharomyces cerevisiae (yeast) and P. berghei that have shown that 
mutation of the conserved aspartic acid (D) and glutamic acid (E) residues in the exonuclease 
domain of DNA polymerase 𝛿 (Figure 5.1) significantly disrupts proofreading ability, 
causing a hypermutator phenotype (Morrison and Sugino, 1994, Fortune et al., 2005, Ridley 
et al., 1991, Honma et al., 2014, Honma et al., 2016).  
 
To obtain a hypermutator P. falciparum line, Kumpornsin et al. used CRISPR-Cas9 gene 
editing to mutate two conserved residues (D308A and E310A, Figure 5.1) in the 
proofreading domain of DNA polymerase 𝛿 (PF3D7_1017000) in the laboratory line, Dd2. 
After confirmation of the desired edits in a clonal population of Dd2-polymerase 𝛿 D308A-
E310A parasites, Dr. Kumpornsin kindly provided the line to be used in this study, referred 
to as “Dd2-hypermutator.” Any description of a “parental line” in this study refers to the 
Dd2-hypermutator without drug-pressure. 
 
 
Figure 5. 1. Alignment of the DNA polymerase 𝛿 amino acid sequence highlighting the 
conserved residues in the 3’à 5’exonuclease domain. Yeast (S. cerevisiae), human (H. sapiens), P. 
berghei, and P. falciparum all share the aspartic acid (D) and glutamic acid (E) residues in DNA 
polymerase 𝛿 exonuclease active site. The alignment was generated using the CLUSTAL O (1.2.4) 








5.2.2 Experimental design for selection of piperaquine resistant Dd2-hypermutator 
parasites: IC50 assays and selection procedures 
Previous work has selected for PPQ-resistant parasites using a clone of the Dd2 parasite line 
(Eastman et al., 2011). Eastman et al. pressured the parasite with 47 nM and 140 nM PPQ 
based on the peak plasma levels of PPQ following a low-fat or high-fat meal, respectively 
(Ashley et al., 2004, Sim et al., 2005, Tarning et al., 2005). They observed that no parasites 
recrudesced after 80 days of continuous 140 nM PPQ-pressure but did observe one flask (of 
triplicate flasks) that recrudesced under 47 nM PPQ-pressure at day 54 (Eastman et al., 
2011).  
 
Based on this prior work, my study was designed to avoid a PPQ concentration that would be 
too high to obtain recrudescent parasites. In order to tip the drug-selection balance in our 
favor, I decided to base the PPQ concentration on the standard PPQ IC50 values of the Dd2-
hypermutator line. IC50 assays were performed as previously described (Chapter 2, section 
2.6.2) to assess the PPQ half maximal inhibitory concentration for the Dd2-hypermutator line 
in comparison to the Dd2 wildtype line (Dd2). Significance was determined using Mann-
Whitney U tests comparing the IC50 values of wildtype Dd2 with the Dd2-hypermutator line 
and no significant differences were observed between the IC50 values for the two lines 
(p>0.05) (Figure 5.2). As seen in Figure 5.2B, the PPQ IC50 values were between 16 nM-20 
nM for both Dd2 and the Dd2-hypermutator line. I therefore decided to start PPQ-pressure at 
various increments of the lower of the two IC50 values, 16 nM. 
 
Two PPQ-selection attempts were made during the course of this study. The initial selection 
attempt was set up with 5 x 108 parasites per flask (in triplicate) at 3xPPQ IC50 (48 nM) in 50 
mL. As mentioned above, since spontaneous mutation rates of P. falciparum are quite low, in 
the second selection attempt, we increased the number of parasites to 1 x 109 parasites per 
flask (in triplicate) at 2xPPQ IC50 (32 nM) in 100 mL. Parasites were grown as described 
previously (Chapter 2, section 2.1.1) in complete media (CM) supplemented with the 
desired concentration of PPQ at 3% hematocrit. During the first week of drug pressure, 
media was changed daily and fresh red blood cells (RBCs) were added as needed for cutting 
the flasks, since the parasitemia was quite high and piperaquine clearance of parasites took 
several days. Parasitemia was maintained below 8% and preferably maintained around 3% 
until the parasites cleared (no parasites were observed by smear). Continuous drug pressure 








To account for spontaneous mutations that could be generated in the PPQ-pressured lines that 
are the result of the hypermutator line and not PPQ-pressure, the Dd2-hypermutator line was 
maintained in continuous culture for the duration of all experiments and was never pressured 





Figure 5. 2. Determination of PPQ concentration to use for selection of PPQ-resistant Dd2-
polymerase δ mutant parasites. A.) Dose-response curve for Dd2 (wildtype) and Dd2-polymerase δ 
mutant (Dd2-hypermutator) parasites after exposure to PPQ. Error bars represent SD (n=2 biological 
replicates). B.) Table showing the average IC50 values for Dd2 and the Dd2-polymerase 𝛿 mutant 
calculated using GraphPad Prism Version 8.0.2. Significance was determined using Mann-Whitney U 
tests comparing the IC50 values of wildtype Dd2 with the Dd2-hypermutator line. No significant 
differences were observed between the two lines (p>0.05). 
 
5.2.3 Preparation of PPQ-pressured parasites for whole genome sequencing 
analysis: cloning and genomic DNA extraction 
Any parasites that recrudesced following PPQ-selection were expanded and the lines were 
cloned by limiting dilution (Chapter 2, section 2.4). Genomic DNA (gDNA) from the bulk 
cultures and the clones was extracted as described previously and all lines were 
cryopreserved (Chapter 2, sections 2.1.3 and 2.5). The control parental parasite line (Dd2-
hypermutator parent) at the start of the experiment was also sent for sequencing analysis. The 
DNA concentration and quality were measured using a Qubit 2.0 Fluorometer (Thermo 
Fisher Scientific). DNA from the bulk PPQ-pressured cultures, clones, and the two parental 
controls was sent for WGS analysis at the Wellcome Sanger Institute.  
 
5.2.4 Whole genome sequencing analysis 
All WGS analyses were performed by Dr. Frank Schwach. Illumina sequence reads were 
mapped to P. falciparum genome version 3.1 using the Burrows-Wheeler Aligner (Li and 
Durbin, 2009) and the Picard toolkit. Local realignment by assembly as well as variant data 







recommendations for the GATK toolkit (DePristo et al., 2011), and the MalariaGEN project 
(https://www.malariagen.net/). Known P. falciparum variants were obtained from the 
MalariaGEN project. The SNPeff software (Cingolani et al., 2012) was used to annotate 
functional implications of variants and variants that did not have an impact on a protein 
product were filtered out. In addition, a minimum coverage of 30 reads was required for the 
final set of high quality variants. Variants that were observed in the parental line were 
disregarded in order to exclude differences between Dd2 and the 3D7 reference genome. 
Variants in known highly variable gene families were also excluded from further 
analysis. The Dd2-hypermutator parental line was used as the reference sequence for 
identifying variations present in the PPQ-pressured parasite lines.   
 
5.3 Results 
5.3.1 Selection of piperaquine-resistant Dd2-hypermutator parasites 
Two PPQ-selection experiments using the Dd2-hypermutator line were performed as outlined 
in Figures 5.3-5.4. The first selection experiment (Exp. 1, Figure 5.3), was started at 3xPPQ 
IC50 and when parasitemia was still high on day 4, the parasites were brought up to 60 nM 
PPQ and then to 90 nM on day 6. By day 9 the parasites were starting to clear and no 
parasites were visible by microscopy on day 12. On day 22, the cultures were split and one 
set of flasks was maintained at 90 nM PPQ and the other set was taken off drug. No 
recrudescent parasites were observed after 65 days (Figure 5.3). We hypothesized that the 
lack of recrudescence was due to the number of starting parasites or the rapid ramping up of 
the concentration of PPQ.  
 
 
Figure 5. 3. Initial attempt (experiment 1) for selection of piperaquine (PPQ)-resistant Dd2-







The second selection experiment (Exp. 2) was set up with a higher number of parasites and a 
lower concentration of PPQ (Figure 5.4). As seen in Figure 5.4, the parasites were still 
surviving well on 2xPPQ IC50 on day 6, so the flasks were split to 50 mL and one set was 
maintained at 2xPPQ IC50 and the other set was brought up to 3xPPQ IC50 (called 3x-day 6). 
On day 9, the 2xPPQ IC50 parasites were still not clearing, so they were also brought to 
3xPPQ IC50 (called 3x-day 9). On day 13, there were no visible parasites by microscopy in 
any flasks but flasks were maintained and checked every 2-3 days for parasites (Figure 5.4). 
On day 21, recrudescence was observed in a 3x-day 9 flask (PPQ#1) (Figure 5.4). On day 
~24 all flasks were taken off drug pressure including the PPQ#1 flask for which 
recrudescence was already observed. On day ~45, another 3x-day 9 flask (PPQ#2) 
recrudesced and on day 59 a 3x-day 6 flask recrudesced. The remaining flasks with no 
observed parasites were maintained in CM until days 65-70, but no parasites were observed. 
 
 
Figure 5. 4. Second attempt (experiment 2) for selection of piperaquine (PPQ)-resistant Dd2-








Of the three parasite lines that came up on PPQ-pressure (PPQ#1-3), PPQ#1 and PPQ#3 were 
cloned and a total of 23 clones from PPQ-pressured parasites and all three bulk cultures 
(PPQ#1-3), were whole genome sequenced. As described by Honma et al., the clones were 
also referred to as “PPQ-pressured lines” since presumably, these isogenic clones would also 
acquire mutations while in continuous culture (Honma et al., 2014). 
 
5.3.2 Phenotypic characterization of the piperaquine-pressured Dd2-polymerase δ 
mutant parasites 
5.3.2.1 IC50 survival assays of piperaquine-pressured Dd2-polymerase δ mutant 
parasites  
In order to determine if there were any phenotypic differences between the PPQ-pressured 
lines (PPQ#1-#3) and the parental Dd2-hypermutator line, IC50 assays were performed to 
compare PPQ susceptibility (Figure 5.5). The dose-response curves show differences in 
susceptibility of the PPQ-pressured lines compared to the parental line. The parental line has 
an IC50 similar to the value observed at the beginning of the drug-selection experiments, as 
expected (Figure 5.2) while the PPQ-pressured lines have IC50 values that are shifted 
approximately 6-fold or more (Figure 5.5). Due to time constraints, IC50 assays were only 
performed on the bulk PPQ-pressured lines, but analysis of the cloned PPQ-pressured lines is 
forthcoming. Also due to time constraints, determination of the optimal concentration of PPQ 
that results in complete death of the PPQ-pressured lines (PPQ#1-#3) is ongoing, therefore 
the dose response curves shown in Figure 5.5 are only intended to show the relative 
differences between the parental hypermutator line and the PPQ-pressured lines. As can be 
seen in Figure 5.5, without complete killing of the PPQ-pressured lines, the dose-response 
curves do not plateau and thus accurate IC50 values cannot be calculated and statistical 













Figure 5. 5. Comparison of PPQ susceptibility between the parental Dd2-polymerase δ 
hypermutator parasite and the PPQ-pressured lines. A.) Estimated dose-response curve of Dd2-
hypermutator (parent) line and PPQ-pressured lines (PPQ#1-#3). Error bars represent SD (n=2 
technical replicates). B.) Table showing the estimated average IC50 values for Dd2-hypermutator 
parent and PPQ-pressured lines. IC50 values were calculated using GraphPad Prism Version 8.0.2. 
The concentration of PPQ was not high enough to result in complete killing of the three PPQ-
pressured lines (PPQ#1-#3) so the dose-response curves and IC50 values shown here are only 
estimates used to show the relative differences between the lines. Accurate IC50 values and statistical 
significance cannot be determined from the data currently available, but continued assays with the 
PPQ-pressured lines are in progress. 
 
5.3.2.2 Morphological differences between the PPQ-pressured parasites and the 
parental hypermutator line 
Further analysis of the PPQ-pressured lines also indicated a starkly different morphological 
phenotype. Figure 5.6 shows Giemsa stained microscopy slides (Chapter 2, section 2.1.2) 
for both the Dd2-hypermutator parent and a PPQ-pressured line (Figure 5.6). As seen in the 
parental images, the parasites have the normal morphology of a mixed, asynchronous culture, 
with early ring stages and later trophozoites and schizonts (Figure 5.6A). In the PPQ-
pressured parasite line, the late stage trophozoites and schizonts strikingly show large, 
distended digestive vacuoles (Figure 5.6B). This phenotype is noted in the presence and 
absence of drug, and the pictures included in Figure 5.6 are from a parasite that had been off 
PPQ-pressure for at least two weeks. The parasites have not been synchronized and ongoing 










Figure 5. 6. Morphological difference between the parental Dd2-polymerase δ hypermutator 
parasite and a PPQ-pressured line. A.) Dd2-polymerase δ hypermutator parental line B.) PPQ-
pressured line showing large digestive vacuoles in the absence of PPQ. Slides were viewed with a 
light microscope using a 100X immersion field. Pictures were taken with a Leica EC4 Digital 
Microscope camera.  
 
5.3.3 Whole genome sequencing analysis and genetic characterization of the PPQ-
pressured Dd2-hypermutator parasites 
Whole genome sequencing was performed for the parental Dd2-hypermutator line, the bulk 
PPQ-pressured cultures (Figure 5.4), and the cloned PPQ-pressured lines (23 total clones) 
obtained from bulk cultures “PPQ#1” and “PPQ#3” Two controls were sequenced (section 
5.2.3), the Dd2-hypermutator line at the beginning for the experiment and the same parent 
line at the end of the experiment at the time the clones and bulk cultures were collected for 
sequencing. Preliminary alignments mapped the PPQ-pressured lines to the parental line at 
the start of the experiment as the reference.  
 
Initial analyses of the 23 PPQ-pressured lines in comparison to the Dd2-hypermutator parent 
have revealed multiple non-synonymous SNPs in genes previously reported to play a role in 
antimalarial drug resistance (Table 5.1): pfcrt, pfmdr1, formate-nitrite transporter (FNT), 
and multidrug resistance-associated protein 2 (Figure 5.7). The study identified pfcrt SNPs 
that resulted in the following mutations: N295T, G353C, A366T, D377Y, and T380S. The 
PfCRT A366 and G353 residues have been previously implicated in piperaquine resistance 
(Ross et al., 2018a). SNPs were found in other genes but due to time constraints, the study 
was specifically interested in looking at SNPs in transporter genes. Additionally, the SNPs 
listed in Table 5.1 are not present in each clone and vary by line. Future work dissecting out 
the various mutations in each clone and analyzing the full read-out of SNPs from the WGS 








The WGS analyses also identified a PfMDR1-N86I mutation in the PPQ-pressured lines 
(Figure 5.7) which is the same residue of a N86Y natural variant previously reported by 
multiple studies to affect susceptibility to various antimalarial drugs (Veiga et al., 2016b, 
Sisowath et al., 2005, Duraisingh and Cowman, 2005). SNPs were also discovered in two 
genes coding for transporters that have been implicated in antimalarial drug resistance, FNT-
A224T and FNT-S17F (Hapuarachchi et al., 2017) and pfmrp2-D1028Y  (Cowell et al., 2018, 
Veiga et al., 2014). 
 
Table 5. 1 Non-synonymous SNPs discovered in the PPQ-pressured Dd2-hypermutator 
lines 
 
Table 5.1. Representation of several non-synonymous SNPs discovered in the PPQ-pressured Dd2-
hypermutator lines. The SNPs in each of the 23 clones were different and this table shows a general 
subset of genes with the SNPs discovered in each. Further analysis of the WGS data is planned for 
assessing and comparing the genotypes of all clones. All genes included in this table have previously 
been reported to be involved in antimalarial drug resistance. Each gene is listed with: chromosome 
number (chr.); nucleotide position (position); gene ID and description; type and the amino acid 
difference (alteration). The last column includes if the SNP has been previously reported in field 
isolates. 
 
5.4 Discussion and future work 
The purpose of this study was to employ a forward genetics approach to gain further insight 
into the mechanisms of piperaquine resistance. This study has utilized a P. falciparum 
hypermutator line to select for a piperaquine-resistant phenotype in vitro. I was able to 
generate piperaquine-resistant parasites in a feasible experimental timespan with the first 
parasites demonstrating a PPQ-resistant phenotype by day 21 (Figure 5.4). The other two 
PPQ-resistant lines recrudesced within two months from the start of the experiment (days 40 
and 59, Figure 5.4). The use of the hypermutator P. falciparum polymerase 𝛿 mutant parasite 
appears to have greatly reduced the amount of time it took to generate parasites with a 
resistant phenotype. Though studies directly comparing the unedited Dd2 line (wildtype 
polymerase 𝛿) (Figure 5.2) to the Dd2-hypermutator under PPQ pressure would be able to 
confirm if this suggestion holds in practice. Previous work by Eastman et al. pressured a Dd2 







flasks) after 54 days (Eastman et al., 2011). This is likely due to the slow spontaneous 
mutation rate of P. falciparum (Bopp et al., 2013) and the concentration of PPQ used. As 
shown through the studies of Oduola et al. in obtaining a mefloquine resistant P. falciparum 
line, generation of a mutant parasite can require continuous culture for over a year, 
depending on the drug and protocol used (Oduola et al., 1988a). Drug selection experiments 
often entail a bit of trial and error, based on what seems most appropriate for the particular 
parasite line and the specific drug of interest. However, hypermutator lines may tip the 
balance in favor of selecting a resistant-phenotype.  
 
WGS of the piperaquine-resistant lines obtained through these experiments have identified 
nonsynonymous SNPs in gene candidates that have previously been reported to play a role in 
antimalarial drug resistance (Table 5.1), including SNPs in the transporter genes: 
chloroquine resistance transporter (pfcrt PF3D7_0709000), multidrug resistance protein 1 
(pfmdr1, PF3D7_0523000, formate-nitrite transporter (FNT, PF3D7_0316600), and 
multidrug resistance-associated protein 2 (mrp2, PF3D7_1229100).  
 
Recent studies have discovered SNPs in pfcrt that confer piperaquine resistance in vitro and 
strongly associate with DHA-PPQ failures in patients (Agrawal et al., 2017, Ross et al., 
2018a, van der Pluijm et al., 2019, Hamilton et al., 2019). Interestingly, two of the pfcrt 
SNPs discovered by this study, pfcrt A366T and pfcrt G353C have been observed in field 
isolates and associated with PPQ-resistance in vitro. The pfcrt A366T SNP discovered in our 
WGS analysis is present in a PPQ-resistant field isolate from Pursat, Cambodia that has been 
used by this study (Chapter 2, Table 2.1) and has been reported in Cambodian isolates by 
other studies (Ross et al., 2018a). The pfcrt G353C SNP from our study results in a point 
mutation at residue G353, which has previously been found to harbor a G353V mutation in 
field isolates. Gene editing of the pfcrt G353V SNP was shown to confer PPQ-resistance in 
vitro (Ross et al., 2018a). Further work by Ross et al. edited several other pfcrt SNPs present 
in field isolates, H97Y, F145I, M343L, into Dd2 parasites and found that the gene-edited 
pfcrt mutations alone could confer PPQ-resistance in vitro, though a fitness cost was noted 
for all SNPs but the PfCRT M343L variant (Ross et al., 2018a).  
 
As noted in Figure 5.6, I observed large, distended digestive vacuoles in the PPQ-pressured 
lines. Ross et al. also reported this phenotype in their pfcrt-edited parasites, including the 
G353V edited line (Ross et al., 2018a). Previous studies by Pulcini et al. have also reported 







C101F or L272F mutations (Pulcini et al., 2015). Intriguingly, the light microscopy images 
published by Ross et al. and Pulcini et al. display striking similarity to the images shown in 
this thesis, pictured in Figure 5.6 (Pulcini et al., 2015, Ross et al., 2018a). It is acknowledged 
that the parasites shown in Figure 5.6 are asynchronous and the parental and PPQ-resistant 
lines are not showing the same stage parasites. However, this preliminary indication of a 
distinct morphological phenotype will guide future work to demonstrate this vacuole 
phenotype in synchronised parasites. Intriguingly, Ross et al. noted that the distended 
vacuole phenotype was not observed in the field isolates containing these mutations (Ross et 
al., 2018a). PPQ-resistant isolates may have compensated for this effect through other genetic 
pathways and that the observed phenotype may be dependent on the genetic background of 
the parasite. Future work planned by this study will examine if the plasmepsin 2-3 (PM2-3) 
copy number amplification has any effect on the PPQ-pressured hypermutator lines. We plan 
to transfect the PPQ-pressured lines with the PM2-3 overexpression plasmid generated in 
Chapter 3. This will enable us to see if the PM2-3 amplification, and consequent increase in 
abundance of these vacuolar proteases, has any effect on the PPQ-resistant phenotype and 
will enable us to see if this amplification may reduce the distended vacuole phenotype. 
 
The other transporters with nonsynonymous SNPs discovered by this study: PfMDR, FNT, 
and PfMRP2 have all previously been shown to play a role in antimalarial drug resistance 
and could have a role in PPQ-resistance. The N86Y mutation in PfMDR1 is associated with 
chloroquine and amodiaquine resistance, but reported to increase susceptibility to 
lumefantrine, mefloquine, and dihydroartemisinin and moderately to piperaquine (Veiga et 
al., 2016b). Recent drug-pressure experiments used to screen new compounds with 
antiplasmodial activity found mutations in the lactate/H+ transporter, FNT, specifically FNT-
G107S, to reduce susceptibility to two of these novel, structurally similar compounds, 
MMV007839 and MMV000972 (Hapuarachchi et al., 2017). The study by Hapuarachchi et 
al. (Hapuarachchi et al., 2017) is the first to report compounds that target FNT, which is 
located on the parasite cell membrane and functions to remove lactic acid, a waste product 
from glycolysis (Marchetti et al., 2015, Wu et al., 2015). Prior work assessing mrp2 
polymorphisms reported a high frequency of SNPs within the gene as well as microindels, 
which have been shown to reduce parasite susceptibility to quinolone drugs (Veiga et al., 
2014, Mok et al., 2014). It is not clear what role these SNPs could play in PPQ resistance, but 








The intriguing results of selection pressure experiments and WGS analyses have clearly 
demonstrated the need for future studies. Continued examination of the WGS data is in 
progress. Importantly, analysis of copy number variations (CNVs) is ongoing. It will be 
interesting to learn if any CNVs are present in the PM2-3 genes or any other genes. In most 
PPQ-resistant isolates observed to date, the parasites have a single copy of pfmdr1 (Amato et 
al., 2017, Witkowski et al., 2017). The Dd2 wildtype parasite has two copies of pfmdr1 and 
presumably the Dd2 polymerase 𝛿 hypermutator line used by this study has two copies of 
pfmdr1. However, it is important to check if the increased copy numbers have been retained 
in the PPQ-resistant lines. Studies have hypothesized that PfMDR1 could facilitate PPQ entry 
into the digestive vacuole (Witkowski et al., 2017), which could explain the presence of 
single pfmdr1 copy numbers in field isolates from regions where DHA-PPQ has been used. 
Other in vitro studies have reported a deamplification on chromosome 5 in the region with 
pfmdr1 after exposure to piperaquine (Eastman et al., 2011), thus there is precedence for 
further investigation of the role of PfMDR1 in the PPQ-resistant phenotype. 
 
Further analysis of the WGS data will also enable us to determine which gene candidates to 
target for further study. CRISPR-Cas9 gene editing can be used to evaluate non-synonymous 
SNPs. It is also necessary to compare growth rates of the parasites and conduct competition 
assays to determine if there are any fitness effects of the acquired mutations. Cross-resistance 
studies with different antimalarial drugs will also provide vital insight into the 
characterization of the PPQ-pressured lines. 
 
It is imperative to discuss that there are inherent caveats when using hypermutator parasites. 
The ability of the parasite to develop mutations more rapidly would mean that drug-pressured 
parasites may also rapidly acquire mutations that have nothing to do with the drug pressure. 
This can add unnecessary noise when trying to filter out the genetic variants that play a 
causal role in the resistant phenotype. It is also possible that while cloning to obtain isogenic 
parasites, the parasites are acquiring further mutations that have nothing to do with the 
resistance observed. However, this can be controlled for by performing multiple independent 
drug-pressure selections. I have performed the piperaquine pressure experiments in triplicate 
flasks, thus hits obtained across multiple independent selections adds confidence that the 
variations identified are due to drug pressure, and are not random. We have also included a 
control in this study to assuage, not solve, these limitations. The parental-hypermutator line 
from the start of the experiment was maintained in culture for as long as the other drug-







line at the start of the experiment, we also sequenced this parental line that was grown for the 
duration of the experiment. As mentioned, due to time constraints, we have only been able to 
compare the PPQ-pressured lines to the parental line from the start of the experiment. 
However, comparison of both parental lines parental-start and parental-end will be 
performed. When we are able to compare the parental-start and parental-end genotypes, we 
will be able to estimate the spontaneous mutation rate of the parasite and this information can 
provide insight into how long the PPQ-pressured cloned lines can be kept in continuous 
culture. We will also be able to compare mutation rates of the PPQ-pressured lines. This 
information can inform future drug selection experiments.  
 
Through the use of a hypermutator line, this study provides new insights into the PPQ-
resistant phenotype while providing experimental evidence that supports previously reported 
markers of PPQ resistance. This study may also serve as a proof-of-concept study for using a 
hypermutator line for in vitro drug selection. Though the data presented here is preliminary, 
it offers promising potential and clearly defines future work needed in the quest to 



































Chapter 6: What’s next on the resistance front? Conclusions, 
reflections, and future work 
 
Antimalarial drug resistance came into the spotlight with the first documented reports of 
chloroquine resistance in the 1950s-1960s (Harinasuta et al., 1965, Payne, 1987, Talisuna et 
al., 2004, Wellems and Plowe, 2001). Since then, drug resistance has impeded malaria 
prevention, control, and elimination efforts—with no signs of leaving the world’s stage. The 
most recent development in this saga is the failure of dihydroartemisinin-piperaquine (DHA-
PPQ), one of the recommended frontline artemisinin combination therapies (ACT) in 
Southeast Asia (SEA) (World Health Organization, 2018, van der Pluijm et al., 2019). By 
combining functional molecular approaches with genomic studies, this dissertation has 
investigated the molecular mechanisms of piperaquine resistance in P. falciparum malaria.  
 
In the first research chapter (chapter 3), I developed copy number assays for detecting the 
plasmepsin 2 and plasmepsin 3 (PM2-3) copy number variation (CNV) associated with 
piperaquine resistance using genomic DNA from patient blood or dried blood spots. In order 
to mitigate the effects and spread of resistance, it is critical to have reliable methods to detect 
and monitor potential markers of drug resistance. The breakpoint PCR and qPCR-based 
assays for determining PM2-3 copy numbers developed by this study are robust, timely, and 
cost-efficient methods for measuring PM2-3 copy numbers in comparison to whole genome 
sequencing (WGS) techniques. Additionally, these assays can be performed in the field as 
long as a PCR or qPCR machine is present. While these new methods have many advantages, 
one limitation of the breakpoint PCR is its specificity for the predominant PM2-3 breakpoints 
observed in Cambodian isolates (Amaratunga et al., 2016, Amato et al., 2017). The PCR 
primers designed for the breakpoint PCR would fail if used for samples with a different 
breakpoint. Cambodian isolates that have different PM2-3 breakpoints were reported by 
Witkowski et al. (Witkowski et al., 2017) in 2017, and additional analyses of the PM2-3 
breakpoints in isolates from 2017 to the present day have not been reported. Further research 
will be needed to determine if the PM2-3 breakpoints have remained the same or if they have 
changed in the last couple of years.  
 
It will also be important to track if the PM2-3 amplification will persist in parasite 
populations as the frontline treatments shift from DHA-PPQ to artesunate-mefloquine (AS-







isolates from SEA have increased PM2-3 copies and single pfmdr1 copies. As AS-MQ is 
reintroduced in the region, samples should be monitored for increased copies of pfmdr1, 
which was found to be the molecular marker and mechanism of mefloquine resistance (Price 
et al., 2004). Since piperaquine is a component of the TACT regimens, it is possible that the 
PM2-3 amplification will remain or that copies may increase, as seen in samples from 2014-
2015 with increased numbers of parasites with three PM2-3 copies (Jacob et al., 2019). 
However, the role this amplification plays in antimalarial drug resistance remains to be 
elucidated. Will the pfmdr1 copy number increase in the presence of increased PM2-3 copy 
numbers? Can parasites become resistant to both mefloquine and piperaquine? Would the 
genetic alterations cause fitness disadvantages? Continued surveillance of parasite 
populations for these markers is necessary and it is crucial to understand what functional role 
(if any) the PM2-3 CNV serves. 
 
Although the PM2-3 CNV is currently used as a molecular marker of piperaquine resistance, 
it has yet to be validated as a causal genetic determinant of piperaquine resistance. Initial 
attempts by this dissertation to evaluate the functional role of the PM2-3 amplification have 
found that overexpression of PM2-only in a Cambodian field isolate (163-KH3-005) does not 
have any effect on parasite response to piperaquine. This study has also synthesized a PM2-
2A-PM3 plasmid for overexpressing stoichiometric amounts of PM2-3 in transfected 
parasites to more closely mimic the CNV observed in the field. I confirmed that the plasmid 
was transfected into a piperaquine-sensitive field isolate from Cambodia (163-KH3-005) and 
Dd2, but similar to the PM2-only transfectants, it is necessary to confirm RNA and protein 
levels in the transfected parasites compared to the parent lines. Once overexpression of both 
the PM2 and PM3 genes is confirmed, I will be able to perform functional assays on these 
parasites to determine if the PM2-3 amplification results in increased survival or plays a 
more compensatory role in fitness. One drawback of this study was the lack of successful 
transfections in isolates with kelch13 (K13) mutations, one of the molecular markers of 
artemisinin resistance. Piperaquine resistance emerged on an artemisinin-tolerant 
background, thus it is hypothesized that the presence of K13 mutations or other molecular 
markers of artemisinin resistance and/or piperaquine resistance (PfCRT mutations) may be 
needed for the PM2-3 amplification to demonstrate its role in parasite survival. Future work 
will be able to use the PM2-2A-PM3 plasmid generated by this study to transfect isolates 









The importance of examining the role of the PM2-3 amplification in piperaquine resistance 
has been further demonstrated by recent studies by Leroy et al. (Leroy et al., 2019) that have 
detected increased PM2 copies in Burkina Faso and Uganda (>30% of samples in both 
countries) and in Mozambique and Gabon (12.5% and 11.3%, respectively). This was one of 
the first studies to report increased PM2-3 copy numbers in Africa, but several earlier reports 
also reported low levels of increased PM2 copy numbers in Mozambique (1.1% of isolates) 
(Gupta et al., 2018) and Mali (10.8% of isolates) (Inoue et al., 2018).  
 
The discovery of increased PM2 copy numbers in African countries suggests that this marker 
of piperaquine resistance may be the same across endemic countries, which supports a 
functional role for the variation. In the context of chloroquine, resistance independently 
emerged due to mutations in PfCRT throughout malaria endemic areas where the drug was 
used. It is possible that the PM2-3 CNV will be found in other regions where piperaquine has 
been used as a partner drug. It is also possible that due to the different genetic backgrounds 
of parasites in South America, Africa, and other malaria endemic regions, mechanisms of 
piperaquine resistance will involve different genetic pathways, if resistance occurs. The 
environment that P. falciparum evolves in is very different throughout endemic regions that 
have various climates, Anopheles species, other Plasmodium species, insecticides, 
antimalarial drug use/history, transmission rates, and many other conditions. With so many 
different factors it is possible that piperaquine resistance may emerge differently in different 
areas. It is thus necessary to not only monitor for known markers of resistance, but to 
continue surveillance for other genetic markers of resistance throughout endemic regions.  
 
In chapter 4, I evaluated the functional relevance of two additional candidate markers of 
piperaquine resistance: a putative exonuclease protein SNP, PF3D7_1362500 (exo-E415G), 
and a putative mitochondrial carrier protein SNP, PF3D7_1368700 (mcp-N252D). Although 
these non-synonymous SNPs were identified in a GWAS by Amato et al. (Amato et al., 
2017) as the top signals associated with decreased piperaquine susceptibility in vivo, this 
dissertation found no difference in the responses of wildtype and mutant transgenic Dd2 
parasites responses to piperaquine. This suggests the exo-415 and mcp-252 candidates are not 
causal determinants of piperaquine resistance. As discussed for the PM2-3 overexpression 
plasmids, it is necessary to examine if the exo-E415G and mcp-N252D SNPs have any effect 
in the presence of other molecular markers of piperaquine resistance (PfCRT mutations or the 








Low transfection efficiency of field isolates in chapters 3 and 4 are limitations of these 
studies. Though multiple field isolates, different conditions, and different plasmids were 
tested, these variations did not have an effect on transfection efficiency. In future studies, it 
will be essential to survey more culture-adapted field isolates to test which isolates tolerate 
growth at very low parasitemia (as would be expected after transfection while on drug 
pressure and during cloning by limiting dilution). Another alternative would be to supress 
conversion of asexual parasites to gametocytes by use of the lipid compound, 
lysophosphatidylcholine or LysoPC. Studies in P. falciparum have found that a reduction in 
LysoPC triggers an environmental cue that causes asexual parasites to differentiate to 
gametocytes (Brancucci et al., 2017). This pathway could be used as a method  to increase 
transfection efficiency by supplementing transfected cultures with LysoPC to prevent 
unwanted conversion of the parasites to gametocytes during the stress of transfection. Such 
modifications will be tested in future transfection attempts. 
   
In chapter 5, I used a hypermutator P. falciparum parasite line to generate piperaquine-
resistant parasites in a feasible experimental timeline of six months rather than years. The use 
of the hypermutator line allowed this dissertation to complement the reverse genetics studies 
in chapters 3 and 4 with a forward genetics approach. Rather than starting with candidate 
gene markers of resistance and performing functional studies to assess their potential role in 
resistance, I selected for a piperaquine-resistant phenotype in vitro. Initial WGS analyses of 
the piperaquine-pressured parasites identified mutations in PfCRT and PfMDR1, among 
others. As discussed, this is of particular relevance as mutations in PfCRT have been reported 
to confer piperaquine resistance in vitro (Eastman et al., 2011, Ross et al., 2018a, Dhingra et 
al., 2017) and are increasingly prevalent in field isolates. The WGS analysis is ongoing and 
additional gene candidates and variations present in the piperaquine-pressured parasites will 
be examined. It has not been determined if these parasites have any copy number variations, 
including the PM2-3 CNV, but these parasites do not have mutations in the genes encoding 
the putative exonuclease (PF3D7_1362500) or mitochondrial carrier protein 
(PF3D7_1368700). Analysis of the WGS data will shape the course of continued studies with 
these parasite lines (competition assays, growth assays, gene-editing, and more). 
 
Currently, DHA-PPQ treatment failures have been confined to SEA. If such treatment 
failures were to occur in African countries where malaria transmission is high, it would have 
devastating effects on the ability to cure malaria-infected patients. With only five 







understand how drug resistance develops. Additionally, the partner drugs in use today are 
believed to have the same site of action in the digestive vacuole, so resistance to one drug 
could promote resistance to another. An understanding of the mechanism of resistance to 
antimalarial drugs will provide knowledge that can be used to prolong the lifespan of the 
limited drugs that are currently available. This should be prioritized, for the same drugs 
continued to be recycled and rotated in the face of treatment failures (AS-MQ to DHA-PPQ 
back to AS-MQ).  
 
Advanced understanding of the mechanisms of drug resistance informs the development of 
new drugs. Recent studies have used knowledge of antimalarial drug resistance to select for 
new compounds that specifically select against known antimalarial drug resistance alleles 
(Lukens et al., 2014, Ross et al., 2018b). New antimalarial drugs are also being discovered 
through large high-throughput screens that select for compounds based on anti-Plasmodial 
properties and not on structural similarity to quinine or chloroquine, as done in the past 
(Fidock et al., 2004, Cowell et al., 2018). These studies also prioritize drugs that can target 
different stages of the parasite lifecycle (liver stage, sexual stage, and asexual stage), which 
will be the best way to fight malaria going forward. Drug discovery, development, and 
regulation takes time, however, several organizations in recent years have been created to 
discover and develop new antimalarial drugs. One example is the product development 
partnership (PDP), Medicines for Malaria Venture. Such organizations combine basic 
science, pharmaceutical industries, economic assets and more—multidisciplinary 
approaches—with the same purpose of discovering and producing new antimalarial drugs. 
 
Before the World Summit on Malaria in April 2018, Bill Gates (who committed another $1 
billion dollars to the fight against malaria in 2018 through the Bill & Melinda Gates 
Foundation) said that there is no standing idle with malaria. “If we stand still, the insecticides 
we use stop working, the drugs stop working because the parasite itself evolves around that, 
so this is a game where you are either falling behind or getting ahead (BBC, 2018).” Malaria 
eradication is possible. Understanding how resistance develops is one facet of the problem 
that will aid in defeating the disease, and this doctoral dissertation has shed light on drug 
resistance to one commonly used antimalarial drug. In the battle against malaria, there must 
be new innovations from all sides. Basic science can provide much insight through 
understanding parasite and mosquito biology and through the development of new drugs and 
vaccines. In addition to this, there must be innovative solutions to the social, economic, 







Through these combined efforts, the slogan “eradication within a generation (Feachem et al., 
2019)” could come to fruition. To stay in the game, the path to elimination and eradication 
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